ESG REPORT 2022
Biocon 5.0
Patients
People
Environment
Social
Governance
Transform
Action

Transform
Action
Biocon’s problem-solving spirit has led it 
to harness the transformational power of 
biotechnology-led innovation to improve 
the health and well-being of humanity. Over 
the past four decades, we have leveraged 
our 
knowledge 
of 
modern 
molecular  
biotechnology to engineer organisms with 
beneficial traits, thus enabling new solutions 
to the challenges of disease.
From our origins as a pioneering biotechnology enterprise, we inculcated a research-driven 
strategy to introduce eco-friendly, enzyme-based solutions in industrial processing. 
Our innovation-led healthcare solutions that provide affordable access to patients who 
battle cancer, diabetes, and autoimmune diseases, are propelled by a clear sense of 
business purpose and responsibility.

Environmental, Social and Governance (ESG) is at the core of our business purpose and 
responsibility. By serving patients, protecting the environment, and promoting business 
integrity, we are taking ‘sustainable action’ every day, reinforcing our commitment to 
building an equitable and viable future.
We are putting new, research-driven insights into action to develop cost-effective 
therapeutic products that address unmet patient needs and reduce health inequities.
We are leading the transformation of patient ecosystems in collaboration with partners 
and disruptive operating models.
We are unleashing the power of technology to improve the quality of performance, 
increase efficiency and enable the highest levels of quality compliance.
We are building a diverse, equitable, and inclusive workplace through affirmative action, 
from recruitment to career and leadership development. 
We are transitioning to renewable energy, reducing our carbon footprint, conserving 
natural resources, and safeguarding ecological diversity to ensure long-term environmental 
sustainability.
We are building resilient solutions that enable and empower disadvantaged communities 
to live better, every day.
We are implementing globally benchmarked standards of governance to create trust with 
patients, employees, customers, shareholders, and society.
It is transformation in action.
The challenges facing humanity remain significant. The past two-years have been a stark 
reminder of our fragility as a species. In the face of a deadly viral pandemic, climate 
disruption and economic standstill, embracing ESG is now, more than ever, imperative for 
a responsible corporate citizen like Biocon.
We are committed to taking bold and transformative action for the planet, people, and 
prosperity.

About the Report
Report overview
As a company committed to achieving sustainable growth 
with positive social and environmental impacts, it is with 
immense pride that we present Biocon’s first ESG Report 
in FY22. The purpose of this report is to share our value 
creation journey with all our stakeholders and provide 
insights into the non-financial performance of Biocon. 
Through this report, our aim is to uphold the values 
of accountability, responsibility and transparency that 
resonate across everything that we do.
Reporting standards
This report has been prepared in accordance with the 
Global Reporting Initiative (GRI) Universal Standards and 
the Securities Exchange Board of India’s (SEBI) Business 
Responsibility 
and 
Sustainability 
Reporting 
(BRSR) 
guidelines and attempts to provide a holistic overview of 
our ESG management practices and performance.
Reporting scope and boundary
The FY22 ESG Report includes disclosures on the 
non-financial performance of Biocon Limited and Biocon 
Biologics Limited, excluding Syngene International, for the 
period 1st April 2021 to 31st March 2022. The reporting 
boundary further extends to include discussions on 
sustainability factors that impact the company’s ability to 
create long-term value.
Responsibility statement  
We believe that this Report offers a balanced view of our 
ESG performance and our efforts to make a difference to 
all our stakeholders.
The Board of Directors confirms that the content of this 
report has been developed under the guidance of the 
senior leadership and the support of the various business 
functions.
| ESG Report 2022
4

Contents
02	 TransformAction
06	 Our Transformative Story
10	 Statements from the Leadership
20	 Transformational Progress in Action
24	 Transforming Patient Lives
30	 Governance in Action
40	 Partnership in Action
46	 Transforming the Workplace
To view or download our 
online reports, please log on 
to biocon.com
58	 Responsible Action Towards  
	
Environment
66	 Transforming our Communities
72	 ESG Scorecard
81	 GRI Standards Index
89	 BRSR Index
Biocon Limited
TransformAction | 
5

Our Transformative Story
Biocon was set up in 1978, as a joint venture with an 
Irish biotech company to manufacture bio-enzymes 
for the brewing industry for its partner’s global 
customers. Beginning with a modest investment of 
` 10,000 and operating out of a garage in Bengaluru, 
Biocon has steadily evolved over the years, from being 
an entrepreneurial enzymes enterprise, to a globally 
recognized, innovation-led biopharmaceuticals company.
Vision 
To enhance global healthcare through innovative and affordable biopharmaceuticals 
for patients, partners and healthcare systems across the globe
Mission
Values
Over the years, Biocon has periodically re-invented its 
business model to usher in transformational change. 
Driven by a strong belief that the pharmaceutical industry 
has a humanitarian responsibility to enable access to 
essential drugs for patients and to do so with the power of 
innovation, Biocon has focused on building a new model 
of innovation that adds the condition of affordability to 
ensure accessibility. 
To be an 
integrated 
biotechnology 
enterprise 
of global 
distinction
Management of research and business partnerships
Internationally benchmarked quality and regulatory systems
New medical insight through disease specific clinical research
Human resource development through training, mentoring and empowering
Intellectual asset creation through discovery, research, and development
Customer relationship through outstanding products and services
State-of-the-art manufacturing capabilities
Collaboration, teamwork, and mutual respect
Quality through compliance and best practices
Performance-driven work culture
Integrity and ethical behaviour
Value creation through innovation and differentiation
| ESG Report 2022
6

Biocon is a differentiated player in the global 
pharmaceutical space 
$1.1 
billion
Generated 
revenues of
in FY221
50+
cGMP approvals from 
International regulatory 
agencies
1,060
registered trademarks1
14,750+
employees1
1,300
patents granted1
120+
countries1
1Includes Syngene
Generics
When we entered the biopharmaceutical sector in the 
early 2000s, we made the strategic choice of leveraging 
our core competence in fermentation sciences to produce 
small molecule Active Pharmaceutical Ingredients (APIs). 
As a result of this focus, we were able to command a 
significant market share for our portfolio of APIs, initially 
comprising of statins and later, increasingly dominated by 
immunosuppressants and other specialty small molecules. 
For over 20 years, our global portfolio of APIs has catered 
to over 700 pharma companies, with an impeccable 
track record of quality, safety, and reliability. To capture a 
larger portion of the value chain in the Generics business, 
which was a key anchor of Biocon’s initial success in 
biopharmaceuticals, we forward integrated into complex 
formulations such as injectables and oral solids that 
incorporated our differentiated APIs. We have successfully 
commercialized several generic formulations under our 
own label in the U.S. and are gradually expanding our 
reach to other geographies.
We have built a pipeline of niche, difficult-to-make 
formulations with high barriers to entry. This, coupled 
with our excellence in execution, will enable us to help 
address the needs of patients, partners, and healthcare 
systems worldwide. 
Biosimilars
To address the global challenges associated with 
non-communicable diseases (NCD), Biocon rapidly moved 
up the pharmaceutical value chain from small molecules 
to recombinant proteins and antibodies in the early 
2000s. We enabled competition for expensive innovator 
biologics through our biosimilars for diabetes and cancer. 
We invested in cutting-edge Research and Development 
(R&D) 
and 
commercial 
scale 
globally 
compliant 
manufacturing 
facilities 
across 
diverse 
technology 
platforms spanning insulins, monoclonal antibodies, and 
conjugated recombinant proteins. 
Biocon Limited
TransformAction | 
7

Biocon Biologics, which is an independent subsidiary of 
Biocon, is leveraging cutting-edge science, advanced R&D 
capabilities, innovative tech platforms and global-scale 
manufacturing capacities to develop and manufacture 
high-quality biosimilars for a global patient population. 
We established global credibility as a serious biosimilars 
player through several ground-breaking achievements, 
starting with the Indian approval for the world’s first 
bTrastuzumab in 2014 and the Japanese approval for 
bGlargine in 2016. We were the first in the world to 
obtain U.S. approvals for bTrastuzumab in 2017 and 
bPegfilgrastim in 2018. 
Our biosimilar monoclonal antibodies and therapeutic 
proteins are significantly impacting cancer care worldwide. 
Our portfolio of affordable recombinant human insulin 
and insulin analogs are benefiting millions of people 
with diabetes globally. In FY22, we touched 5.3 million 
patients’ lives worldwide through our biosimilars portfolio 
for diabetes, oncology, and immunology.  
Our investments in building global scale manufacturing 
have led us to be among the world’s Top 15 
bio-manufacturing companies. We are one of the leading 
insulin producers worldwide and have global scale 
antibodies manufacturing capacities as well.
To make a greater impact on global health, Biocon Biologics 
executed two strategic transactions in FY22. This included 
acquisition of Viatris’ global biosimilars business will create 
a fully, vertically integrated world-leading biosimilars 
company with direct commercial presence in developed 
and key emerging markets. The strategic alliance with 
Serum Institute Life Sciences provide Biocon Biologics 
an ‘asset light’ by accelerating entry into vaccines. 
These strategic developments will create a business 
that will not only be able to expand our reach, but also 
transform patients’ lives by delivering affordable access 
to innovative and inclusive healthcare solutions, thereby 
addressing the issue of health inequity.
Novel Biologics
Biocon’s ground-breaking work in novel biologics has 
enabled the company to address unmet requirements 
for the treatment of cancer and autoimmune ailments. 
Our current portfolio includes molecules that we are 
developing in-house, as well as, those that are driven by 
external collaborations. 
We are proud to be pioneers in the development and 
launch of BIOMAb-EGFR (Nimotuzumab), India’s first 
indigenously manufactured novel monoclonal antibody for 
the treatment of head and neck cancer. Furthermore, we 
developed and launched ALZUMAb (Itolizumab), the 
world’s first novel anti-CD6 monoclonal antibody, for 
psoriasis and other indicators. Our proven capabilities in 
discovery, process, and product development, translational 
and clinical sciences, maximize the overall probability of 
our success.
In the next few years, we are expecting results from 
studies involving our novel assets.
Bicara Therapeutics, an associate of Biocon based in 
Boston, U.S., is developing a pipeline of bifunctional 
antibodies 
that 
exploit 
the 
recent 
advances 
in 
immuno-oncology. Bicara enables access to the thriving 
innovation ecosystem in the U.S. which accelerates our 
development of cutting-edge therapies for cancer. We are 
confident that synergies between the scientific teams in 
Boston and Bengaluru will pioneer rapid and cost-effective 
breakthrough innovation.
Research Services
Started in the early 1990s, Syngene was India’s first 
Contract Research Organization (CRO), set up with 
the aim of catering to the R&D needs of the global 
pharmaceutical industry. Syngene’s emergence as India’s 
leading contract development and manufacturing 
company (CDMO) triggered its successful public listing 
in 2015. Today, Syngene is well-positioned with its 
capabilities and infrastructure to leverage the strong 
market demand for the development and manufacturing 
of drugs. The company is moving beyond a traditional 
service outsourcing model toward true end-to-end 
collaborations, accelerating innovation for its clients 
across the drug R&D continuum. It is building expertise 
in immuno-oncology, CAR-T, mRNA, and small interfering 
RNA (siRNA) platforms for researching next-generation 
therapies.
| ESG Report 2022
8

Biocon Limited
TransformAction | 
9

Statements from the Leadership
Transformative Action for Sustainable Outcomes
Chairperson’s Statement
Kiran Mazumdar-Shaw, 
Executive Chairperson 
Biocon and Biocon Biologics
Innovation that delivers affordable 
access to life-saving therapeutics 
for patients worldwide is at the 
core of our business ambition. Our 
philosophy of ensuring health equity 
resonates with our Environmental, 
Social, and Governance or ESG 
aspirations. In a world where ESG is 
increasingly becoming a “biomarker” 
of business purpose, Biocon has 
adopted practices to demonstrate 
conscious capitalism, environmental 
stewardship, talent diversity, and 
equitable 
governance 
within 
its 
stakeholder ecosystem.
In FY22, Biocon made strategic moves 
to further its purpose of catalyzing 
transformative change to address 
health inequities across the world. 
We charted new growth paths and 
made a mega acquisition, fostered 
alliances, and made multiple new 
investments.
| ESG Report 2022
10

Transformative Investments
Our landmark decision to acquire the global biosimilars 
business of our long-term partner, Viatris, will enable full 
vertical integration across the biosimilars value chain from 
‘lab to market’ and take us closer to patients, payors, and 
healthcare providers in developed and emerging markets. 
Our quest to impact global healthcare steered us towards 
a strategic expansion into adjacencies such as vaccines. 
In FY22, Biocon Biologics entered an alliance with India’s 
largest vaccine maker, Serum Institute to join the effort of 
addressing the inequitable access to vaccines.
Mission Insulin for Health Equity
As we commemorate 100 years of the discovery of  
Insulin, we are positioning ourselves to build global 
leadership through unlocking equitable access to 
insulin and meeting varied patient needs through our 
comprehensive portfolio.
We are proud of the historic approval we received for the 
world’s first interchangeable biosimilar in the US. In FY22, 
the launch of our interchangeable Glargine is in line with 
our aspiration to provide our biosimilar to ‘one-in-five’ 
insulin-dependent people with diabetes, globally. 
Saving Lives During the Pandemic
At the height of the pandemic, we were able to realize 
the potential of bio-therapeutics in the fight against 
Covid-19 induced cytokine storm. Our repurposed novel 
biologic ALZUMAb-L (Itolizumab) benefited over 40,000 
COVID-19 patients so far.
Practicing Environmental Empathy 
As a company, we believe that health equity is embedded 
in restoring ecological balance. This belief has driven us 
continuously to identify opportunities to increase the 
share of renewables in our energy mix, improve energy 
efficiency, innovate to drive productivity across our value 
chain, implement the principles of a circular economy, 
and adopt digital solutions that minimize inefficiencies.
Through usage of solar and wind energy, the share of 
‘green power’ in total energy purchased across Biocon and 
Biocon Biologics India rose to 58% in FY22. We achieved 
117,697* tonnes of carbon dioxide equivalent (tCO2) 
reductions in the year as a result of our green power 
initiatives and the use of clean fuel (natural gas) for steam 
generation. 
We recorded 680,000 liters of incremental water savings 
per day from water conservation initiatives across the 
global manufacturing operations of Biocon and Biocon 
Biologics.
Working Towards Gender Equity
As a woman entrepreneur, I have inculcated a strong sense 
of purpose and commitment to diversity, inclusion, and 
social equity at Biocon. This is reflected in our aspiration 
to get to a 50:50 gender ratio by 2030. To achieve this 
target, we are refining our policies and increasing career 
opportunities for women through initiatives that include 
management and leadership development programs.
We were certified by Great Place to Work® India as a 
Workplace with Inclusive Practices, acknowledging our 
investment in our people and our inclusive culture. 
Digital transformation: A key strategic initiative  
ESG is foundational for Biocon’s digital transformation 
initiative. We are making significant investments to 
transform the Biocon Group into a data and digital-led 
global biopharmaceuticals organization. These initiatives 
are enhancing quality and compliance while augmenting 
productivity through enhanced operational excellence. 
They 
are 
also 
enabling 
data 
integrity 
through 
technology-led data transparency. Digitalization, we 
firmly believe, can build higher standards of governance 
and build greater levels of trust with all stakeholders. 
* BL + BBL (Excluding Malaysia)
Biocon Limited
TransformAction | 11

Building Hallmarks of Trust and Reliability 
At Biocon, we believe in building trust with patients, 
customers, shareholders, and society is the anchor for 
long-term success. 
We are evolving and expanding our sustainability reporting 
and have captured our environmental management, 
social impact, and corporate governance practices in our 
first GRI-aligned ESG Report.
Keeping with our focus on ESG issues, we are taking 
transformative action to ensure sustainable performance 
across operational, financial, environmental, social, 
governance and humanitarian facets of our enterprise. 
Corporate philanthropy in action
Biocon’s corporate philanthropy aims to build resilient 
and innovative solutions that enable and empower 
disadvantaged communities to live better. In FY22, 
the Biocon Foundation implemented several initiatives 
targeted at increasing access to healthcare for underserved 
communities, improving the nutritional standing of 
school-age children, promoting science & technology, 
and sponsoring urban afforestation initiatives.
Biocon Academy is the outcome of our endeavor to build a 
talent ecosystem for biotech-related skills in India. We have 
trained over 850 students over the last eight years, by 
augmenting their industry readiness and providing them 
with value added employment opportunities in the Indian 
life sciences sector. 
Embracing ESG to drive the next phase of 
transformative action
Our business purpose is deeply intertwined with ESG. 
By protecting the environment, serving patients globally, 
and promoting business integrity, we are reinforcing 
our commitment to building a sustainable future. 
Our recent entry in the Dow Jones Sustainability Index 
(DJSI) Emerging Markets Index, where we achieved a 93rd 
percentile position with a Total Sustainability Score of 45, 
is a testimony to our responsible and sustainable business 
practices.
Kiran Mazumdar-Shaw
Executive Chairperson 
Biocon and Biocon Biologics
ESG is foundational for Biocon’s digital transformation 
initiative. We are making significant investments to 
transform the Biocon Group into a data and digital-led 
global biopharmaceuticals organization.
| ESG Report 2022
12

Q&A with Siddharth Mittal,  
Managing Director and CEO, Biocon Limited
How is the Indian landscape evolving from the 
perspective of industry in achieving UN Sustainable 
Development Goals?
Companies have started realizing that sustainability is 
a serious business driver. They now understand that 
profitability and growth depend upon how effectively 
they are able to meet the expectations of different 
stakeholders, who are more aware and concerned about 
sustainability than ever before. Employees, for example, 
want their work to have a purpose that goes beyond a 
narrow professional definition. They want to be part of 
a company that believes in being socially responsible. 
Investors are now recognizing this reality and are asking 
questions about a business’ sustainability strategies. 
Customers, too, are looking at a company’s track record 
on sustainability and social commitment before making 
their purchasing decisions.
An article published by McKinsey and Co stated, “We 
looked at companies on the New York Stock Exchange 
and Nasdaq that had strong ESG records at the start of 
the pandemic, both when markets started to collapse and 
from March 2021 onward when the markets began to 
recover. In both of those periods, companies with better 
ESG records outperformed those with low records.”
Not surprisingly, sustainability is now a critical part of 
business strategy that is driven at the Board level in several 
companies, including Biocon. This is aided and propelled 
by increasing regulatory momentum as well. For example, 
SEBIs Business Responsibility and Sustainability Reporting 
framework will help create a level playing field to 
ensure transparency, consistency, and comparability in 
non-financial disclosures.
At the 26th UN Climate Change Conference, also referred 
to as COP26, India has committed to achieve Net Zero 
emissions by 2070 and declared that 50 percent of our 
electricity production will be from renewable sources 
within the next decade. These commitments are sure 
to translate into policy action to incentivize and support 
businesses that decrease their carbon footprint.
As a company, we believe in truly exploiting the 
opportunity to invest in innovation and R&D. With this, 
our purpose of promoting good health and well-being 
as well as reducing inequalities in access to necessary 
healthcare across spectrums is met.
Sustainability is Integral to Business Strategy
Biocon Limited
TransformAction | 13

What are the objectives and targets of your 
sustainability efforts in Biocon?
Making ESG commitments and stating a purpose is 
easy. However, these become meaningless without 
transformative action. One has to have a clear ESG 
strategy, based on which  a coherent program can be 
created, comprising specific action points and clearly 
defined, realistic goals.
Sustainability is integral to Biocon’s business strategy as 
well as necessary for fostering long-term investment, 
financial stability, and business continuity.
Environment – We have sharpened our focus on climate 
action to understand, assess, and manage climate-related 
risks. We have adopted circular economy principles 
to reduce water usage and improve the efficiency of 
resource utilization. Our target is to ultimately transform 
our operations and make them net water positive, or at 
the very least, water neutral. Environmental responsibility 
is also embedded in our supply chain management 
practices.
Social – Social responsibility is intrinsic to our corporate 
policies and work culture. Being an equal opportunity 
employer, we believe strongly in the power of diversity, 
equity, and inclusivity. Our people policies and practices 
foster a culture of mutual trust and respect. Additionally, 
our actions are aimed at delivering positive societal and 
environmental outcomes and building intrinsic value in 
the community that we are a part of. We regard these as 
part of our business goals.
Governance – We have established high standards of 
governance to build an environment of trust, transparency 
and accountability. To drive a top-down approach for 
ESG integration, our Corporate Social Responsibility 
Committee at the Board level was reconstituted to 
‘Corporate Social Responsibility and Environment, Social, 
and Governance Committee’ with the primary objective 
of providing oversight, direction and monitoring our ESG 
strategy and initiatives, as well as to direct initiatives 
to embed integrated thinking within Biocon’s culture. 
Additionally, at Biocon Limited and  Biocon Biologics, the 
Board formed an Environment, Social and Governance 
Committee to drive positive impacts across the entity.
Can you provide an overview of what Biocon 
achieved during FY22 in terms of ensuring 
stakeholder equity?
The past two years were very challenging for the world 
at large with the COVID-19 pandemic almost bringing 
the world economy to a standstill. Being in the pharma 
sector, our responsibility was multifold. We had to ensure 
that our patients continued to get our medicines, which 
they count upon to stay in good health. At the same 
time, we had to ensure the safety and well-being of 
our employees and their families, while also supporting 
the government and local authorities in their efforts to 
mitigate the pandemic’s impact.
However, amidst all this disruption, we never lost sight of 
our ESG goals and undertook several measures towards 
achieving them.
Last year, we conducted a detailed Materiality Assessment 
(MA) covering as many as 113 different stakeholders, both 
internal and external. The MA helped us identify the most 
material issues to be prioritized for creating long-term 
value and strategize resource allocation accordingly. 
Demonstrating 
transparency 
and 
inclusion, 
while 
prioritizing key focus areas for our growth, has enabled 
us to gain our stakeholders’ trust. I am delighted that 
the stakeholder priorities that emerged are aligned with 
Biocon’s business priorities. The details of the assessment 
can be perused later in this report. 
This year we published our first Tax Transparency Report, 
demonstrating our commitment to openness on tax 
matters. We also developed a Code of Conduct as a 
support program for our suppliers and partners that 
help them align their operations and practices with our 
ESG goals. This enables us to build synergies with our 
suppliers.
We have published our first standalone Human Rights 
Policy*, which details our approach to upholding human 
rights across our value chain, including our permanent 
and contractual employees, suppliers, consultants and 
our Board members.  
Embedding ethics and compliance in every aspect of our 
business has resulted in our CDP, DJSI CSA and EcoVadis 
scores improving significantly.
*Similar principles applicable to Biocon Biologics, currently embedded in its Code 
of Conduct, is being developed as an independent global policy document.
| ESG Report 2022
14

Our employees are our biggest asset and to facilitate 
our commitment towards transforming their career 
journeys, we have developed a competency framework 
which acts as the foundation for all our people processes, 
covering talent acquisition, performance evaluation, 
talent development, and succession planning. We have 
also launched initiatives to build a pervasive culture of 
excellence at Biocon and systematically incorporated 
tech-enabled tools into our processes to enhance 
efficiency, eliminate human error and ensure consistency 
of quality. Our digitization journey is ongoing and driven 
at the highest levels.
Can you provide an overview of what Biocon 
achieved during FY22 in terms of ensuring 
environmental equity?
We continue to build on the programs and initiatives 
undertaken over the last two years.
•	 With regard to energy purchased, we have reduced our 
non-renewable energy from 141,700-megawatt hour 
(MWh) to 137,200 MWh, and increased our renewable 
energy to110,000 MWh from 95,000 MWh.
•	 We invested ` 80 million in a new 600 kiloliters/day 
(KLD) capacity zero liquid discharge (ZLD) effluent 
treatment plant in Bengaluru. This will gain us 680,000 
liters of incremental water savings per day as 100  
percent of wastewater is recycled and reused back in 
the process or in utilities.
•	 We also sent over 5,500 tonnes of high-calorific waste 
for reuse as an auxiliary fuel to cement factories. 
Besides, as much as 60 percent of solid waste generated 
at our facilities is recycled.
•	 Approximately 58 percent of total electricity purchased 
for consumption at our India sites in FY22 was from 
green sources for BL & BBL Indian operations.
All of these transformative actions have helped us  
achieve reductions of over 102,000 tCO2 in FY21 and 
117,000 tCO2 in FY22.
Due to the need of a highly-skilled workforce, how 
do you focus on attracting and retaining talent and 
building their skills? Can you specify the efforts you 
are making to ensure diversity and inclusion?
The well-being of our employees is of paramount 
importance at Biocon, and we have in place several 
initiatives and programs to enable them to stay in good 
health, physically, mentally, and emotionally. We foster a 
sense of belonging and an ambience of mutual respect 
and positive collaborative spirit through several employee 
engagement initiatives that cover health and wellness 
and motivational sessions, to name a few.
We hired 2,806 individuals as full-time employees during 
FY22. We introduced several initiatives to enable our 
employees to learn, grow and develop their careers, such 
as departmental scorecards, career-pathing, competency 
frameworks, and digital learning programs to facilitate 
the development of individuals in multiple domains. 
In this vein, the total training hours for our employees 
stood at over 178,000. We invested a total of ` 27 million 
for employee learning and development in FY22.   
Biocon is an equal opportunity employer and abides 
by a policy of equal pay for equal work. Diversity and 
inclusion are intrinsic to our work culture and people. 
Our organization level diversity ratio grew from 10.5 
percent in FY 2020-21 to 12.3 percent in FY 2021-22
How would you sum up Biocon’s ESG journey in 
FY22?
The significant improvement in our scores in DJSI and 
CDP is a validation of the transformative actions being 
undertaken at Biocon to embed ESG within and beyond 
the organization. As an ongoing journey, this aspect of 
our business has been accorded the topmost priority and 
is overseen at the highest levels. Going forward, we see 
ourselves delivering even better results on the ESG front 
in the years to come.
Siddharth Mittal
Managing Director and Chief Executive Officer, Biocon Limited
Biocon Limited
TransformAction | 15

Q&A with Dr. Arun Chandavarkar, Managing 
Director, Biocon Biologics
How are you improving global patient equity 
through Biocon Biologics’ biosimilars business?
At Biocon Biologics, we strongly believe that healthcare 
must take many forms and should be accessible to all in a 
cost-effective way. Biologics have increasingly become the 
foundation of innovative therapies in modern medicine. 
Given the pipeline of therapies in clinical development, it 
is evident that biological therapies will continue to gain 
importance, if not dominate the market.  
Biosimilars, which are follow-on biologics typically  
launched after the innovator molecules lose patent 
protection, have already demonstrated their ability to 
broaden access to several life-saving therapies, thus 
enabling patient equity. Having entered this segment 
more than 15 years ago, Biocon is a frontrunner in 
biosimilars today. As an industry pioneer, Biocon was 
amongst the first wave of companies to address the 
global need for biosimilars. Biocon Biologics, which is an 
independent subsidiary of Biocon with its management 
team, is leveraging strong science, global scale and its 
long experience in biopharmaceuticals to develop and 
manufacture several high-quality biosimilars for treating 
various chronic conditions for global patient population. 
We have developed several monoclonal antibodies and 
therapeutic proteins, which are significantly impacting 
cancer care worldwide. Our portfolio of affordable 
recombinant human insulin and insulin analogs is 
benefiting millions of people with diabetes globally. 
In FY22, we touched 5.3 million patients’ lives worldwide 
through our biosimilars portfolio for diabetes, oncology, 
and immunology.  
Our expertise in product development and manufacturing 
has allowed us to build a pipeline of 20 biosimilar assets 
for the coming decade. We will continue to invest in R&D 
to develop quality biosimilars for high-value therapeutics, 
enabling wider patient access. 
How do you see Biocon Biologics contributing to the 
global fight against diabetes?
Diabetes is a worldwide NCD pandemic that affects 
nearly half a billion people. Unfortunately, ‘four out of 
five’ people with diabetes live in low- and middle-income 
countries (LMICs). Insulins help save the lives of millions of 
diabetes patients each year, yet millions are denied access 
to this life-saving therapy due to its prohibitive costs. 
Turning ESG Strategy into Action
| ESG Report 2022
16

Despite the capital-intensive nature of insulin production, 
Biocon Biologics has succeeded in expanding access to 
insulin therapy in India and key global markets by pursuing 
an innovation strategy that is rooted in affordability. 
We have built one of the largest insulin manufacturing 
capacities in the world, which we are using to shift the 
access paradigm for insulins, worldwide.
Biocon Biologics, through its proprietary Pichia pastoris 
platform, has been able to disrupt the insulins market 
globally. Our journey, which started with recombinant 
human insulin in India, has broadened to cover several 
global markets including the U.S. We have cumulatively 
supplied over 2.75 billion doses of recombinant human 
insulin to patients globally over the years.
Following the landmark commercialization of bGlargine 
in the U.S. in FY21, we marked another milestone by 
obtaining interchangeable designation from the U.S. 
FDA for our bGglargine in FY22.  We are the first in the 
world to obtain approval for an interchangeable biosimilar 
product in the U.S. The interchangeability approval, which 
allowed substitution of our product for the innovator 
at the pharmacy counter, demonstrated our scientific, 
quality, and regulatory capabilities. The interchangeability 
status is allowing us to offer people living with diabetes 
in the U.S. more treatment options, rationalize cost of 
therapy and generate savings for the overall healthcare 
system. Our insulins are widening the treatment options 
available to patients living with diabetes, as well as 
enabling local healthcare systems to realize substantial 
savings on diabetes care. With the aim of making insulins 
affordable and accessible to patients in LMICs, we have 
rolled out our ‘Mission 10 cents’ initiative to supply 
recombinant human insulin at less than 10 U.S. cents per 
day to governments in some countries.
With the EU approval of our bAspart, we now have a 
broad portfolio, comprising basal, mixed and rapid acting 
insulins to meet the varied needs of people with diabetes 
worldwide.
Biocon Biologics has been making large investments 
in expanding its manufacturing capacities. How do 
these investments dovetail with your sustainability 
objectives?
Biocon Biologics has taken a modular approach to capacity 
expansion. As we progress on our strong growth trajectory, 
we will continue to invest in upgrading our facilities with 
new age technology and capabilities to ensure that we 
meet our global sustainability goals. Our new 340,000- 
square feet, monoclonal antibodies manufacturing facility 
received an honorable mention at the 2021 Facility of 
the Year Award (FOYA) from the International Society 
for Pharmaceutical Engineering (ISPE). This facility has 
been designed to be energy-efficient with green building 
design features, thus reducing our carbon footprint.
Conducting our business in the most responsible 
manner has always been in our DNA since inception. 
We continuously undertake initiatives across our facilities 
to ensure minimal environmental impact. We have been 
increasing the share of renewable energy across our 
operations through onsite solar installations and the 
procurement of wind energy. Further, we have adopted 
other innovative technologies like energy efficient 
centrifugal air compressors, water chillers and motors, 
and rooftop solar panels to reduce energy consumption, 
thereby, offsetting 63 percent of our total greenhouse 
gas emissions across Biocon Limited and Biocon Biologics.
Bio-manufacturing being a water-intensive industry, we 
have implemented targeted interventions to ensure all 
our manufacturing operations in India are Zero Liquid 
Discharge (ZLD) facilities equipped with advanced 
engineering systems to treat and reuse wastewater and 
effluents.
Biocon Biologics has multiple partners across the 
globe, including developed and emerging markets. 
How do you ensure stakeholder equity? 
At Biocon Biologics, we believe synergistic collaborations 
can help us capitalize on each others strengths to 
deliver on our objective of enabling patient equity. 
Therefore, we have entered global partnerships for 
research, 
manufacturing, 
and 
commercialization. 
Our long-standing global partnership with Viatris 
has enabled us to achieve many firsts, setting new 
benchmarks for the global biosimilars industry. In FY22, 
we made a strategic decision to acquire the global 
biosimilars business of Viatris to create a fully integrated 
biosimilars business in Biocon Biologics. This deal provides 
several advantages, including expanded global footprint, 
direct-to-market access, strategic agility and operational 
efficiencies. Once concluded, this acquisition will enable 
us to expand patient access to biosimilars and reduce 
healthcare inequities worldwide.
Biocon Limited
TransformAction | 17

During FY22, we also entered into a strategic alliance 
with Serum Institute Life Sciences (SILS) for vaccines 
to make a meaningful impact in fighting infectious 
diseases. Vaccines and antibodies for infectious disease 
are a natural adjacency to Biocon Biologics’ existing 
capabilities in biologics for non-communicable diseases. 
Together with SILS, we believe we can address patients’ 
needs for vaccines for various infectious diseases, 
including COVID-19.
Our partnerships extend beyond our peers to include our 
vendors and consultants who have provided us with a 
continuous supply of raw materials, equipment as well 
as technical expertise when required. We are grateful for 
their efforts, which have enabled us to scale our operations 
and ensure business continuity, even in difficult times.
Our investor community has been vital in ensuring that 
we maintain a culture of transparency and accountability. 
We have received funding from four private equity 
investors and will be welcoming SILS and Viatris as 
shareholders post the completion of the two strategic 
deals, which I am sure will support us in building a 
world-class biosimilars company.
As a biopharma leader who has to deal with the 
shortage of high-quality talent, what are your key 
focus areas for talent management?
Biocon Biologics’ workplace culture has been built on a 
strong sense of purpose and values.
It is designed to foster a healthy, happy and safe work 
environment where employees can fulfill their career 
aspirations while contributing to the organizational goals. 
We continuously strive to build a culture of transparency, 
openness, and innovation where people can find solutions 
to address patients’ needs.
Biocon Biologics continues to make investments for 
people development, in learning & training, mentoring 
& empowering and enabling their career growth, thereby 
accentuating their contribution to the biopharma 
industry. We pride ourselves on our people-centric 
approach. Our concern for the health and well-being of 
our employees is evident through the various employee 
engagement initiatives, which have been recognized 
through several awards both nationally and internationally.
What is Biocon Biologics doing to ensure diversity, 
equity and inclusion especially with respect to 
gender parity?
Diversity and inclusion are at the core of our business 
strategy as we believe that everyone has unique strengths 
which can be leveraged to create a culture of innovation 
at Biocon Biologics. Over the years we have focused on 
diversity hiring and have a large pool of women scientists 
who have partnered our science-led innovation journey. 
We take pride in having a merit-based work culture and 
have ensured gender parity in terms of compensation and 
benefits for similar roles. In order to ensure that women 
are well-represented in every team, we run special 
leadership development programs for women to take up 
larger roles. 
Having already created a professional management 
team and an independent Board for Biocon 
Biologics, what additional measures are you taking 
to reinforce corporate governance in the entity?
The premise of carving out Biocon Biologics as an 
independent entity with its own professional management 
team and independent Board of Directors was not only 
to ensure undivided focus on the biosimilars business, 
but also ensure better governance. We have adopted 
globally benchmarked standards of governance to foster 
long-term investment, financial stability and business 
integrity, which enable sustained and equitable growth. 
Our ethical business practices have earned us a strong 
reputation and we continue to always uphold these 
through the highest level of compliance to our Code of 
Conduct and Ethics. We have put systems and processes 
in place at Biocon Biologics that support the anticipated 
growth in business while protecting the interests of our 
shareholders and other relevant stakeholders. In order to 
ensure consistent focus and drive our ESG strategy we have 
designed a robust multi-tiered governance framework at 
the Board, management and working group levels. As we 
bring global investors and new partners on board, we 
will uphold our firm commitment to ethics and values 
inherited from our parent company, Biocon Limited.
Dr. Arun Chandavarkar
Managing Director, Biocon Biologics
| ESG Report 2022
18

Biocon Limited
TransformAction | 19

Transformational 
Progress in Action
Our purpose, to champion change and make a meaningful and 
tangible difference in the lives of our patients and our people, 
forms the basis of all our business decisions. To deliver on our 
purpose, we are committed to a sustainable and equitable 
future with a strong focus on employee wellbeing, enabling 
development in the community and minimizing our impact on 
the environment.
| ESG Report 2022
20

A purpose-led approach translates into integrating ESG 
considerations in the design and execution phase of 
our business strategies. We have defined our vision 
and ambition towards ESG integration, supported by 
clear goals and commitments, and are transforming 
our business to better deliver shared value for our 
stakeholders. Our approach to ESG pivots around building 
trust, accountability, and transparency to drive long-term 
value, minimize risk and seize emerging opportunities. 
Transformational Action on ESG
While the formal integration of ESG into our business 
model has been a recent development, its core ethos 
and principles have always been a part of our business 
decisions. We believe in doing business the right way and 
over the years we have implemented a robust framework 
of policies and processes that enable us to be responsible 
corporate citizens.
The emergence of ESG standards and frameworks 
coupled with rapidly evolving regulations have provided 
an impetus at Biocon to better understand and formulate 
our business strategy to deliver a positive impact for our 
stakeholders. The journey of recognizing ESG principles 
as a key, standalone criterion for business decisions 
underwent several steps:
•	 Conducted an ESG diagnostic: We started our ESG 
journey by conducting a detailed assessment to review 
and benchmark our existing policies and processes, 
identifying opportunities and strategies to build a more 
sustainable company. The outcomes of the exercise 
established a baseline and provided insights into 
opportunities for further improvement, which became 
integral considerations to our ESG roadmap for FY22 
and beyond.
•	 Assessed materiality: The ESG landscape is dynamic 
and ever evolving. In order to understand changing 
stakeholder expectations and capture their perspective 
on ESG priorities for our business, we conducted a 
detailed materiality assessment, wherein we engaged 
with over 110 internal and external stakeholders through 
online survey questionnaires, and personal interviews. 
The results of the assessment provided us with a priority 
list of ESG topics that are relevant to the long-term value 
creation potential of the company. These ESG topics 
helped us develop our ESG focus areas over the next two 
to three years.
•	 Institutionalizing ESG into our governance 
structure: We recognize that in order to truly integrate 
ESG into our business model, we need to identify ESG 
stewards within the organization and assign roles 
and responsibilities for implementing and monitoring 
our progress along the ESG transition. To provide 
adequate oversight and accountability on ESG, we 
have instituted the ‘Corporate Social Responsibility and 
Environment, Social and Governance Committee’ and 
the ‘Environment, Social and Governance Committee’ 
at Biocon Limited and Biocon Biologics Limited, 
respectively. The Committees report directly to the 
Board and drive a top-down approach towards ESG 
integration.
•	 Developing an ESG roadmap: We also recognize 
that embedding ESG into everything we do is a gradual 
process. Accordingly, we have developed a pathway 
towards greater ESG adoption by developing detailed 
actions plans and business-function level roadmaps. 
The roadmap sets out clear goals to achieve our 
sustainable development ambitions and will be tracked 
based on clearly defined metrics under our established 
governance process.
•	 Managing supply chain ESG risks: We hold our 
partners and suppliers accountable to the same set of 
expectations on ESG as we hold ourselves. While we 
do have defined processes for supplier assessments, we 
developed a ‘Supplier Code of Conduct’, a standalone 
charter which outlines expectations from third parties, 
vendors and suppliers towards fair treatment, ethical 
behavior and safe and sustainable business practices.  
•	 We are publishing our first ESG Report for FY22 in 
accordance with the Global Reporting Initiative (GRI) 
Universal Standards to enhance transparency on 
non-financial performance. This report will also be our 
first step to integrate SEBI’s BRSR guidelines for ESG 
reporting ahead of its prescribed statutory adoption in 
FY23
•	 Tax Transparency Report for FY22: In lieu of 
the recent developments related to stakeholder 
expectations demanding greater tax transparency, 
we have developed and published a comprehensive 
tax Policy, and we are also publishing our first ever 
‘Tax Transparency Report’. The purpose of the Report 
is to provide an overview of our tax strategy, our 
Biocon Limited
TransformAction | 21

governance, control and risk management framework 
and our contributions to the exchequer. The publicly 
available Tax Transparency Report is intended to 
improve transparency and build a deeper sense of trust 
in our stakeholders regarding the management of tax 
in our company.  
•	 Human Rights Policy*: Demonstrative of our 
values, this year we strengthened our commitment 
to free and fair practices by formulating our Human 
Rights Policy*. This is in alignment with the ten-tier 
principles of the UN Global Compact and the Universal 
Declaration of Human Rights (UDHR). This policy is 
aligned with Biocon’s Code of Conduct and Supplier 
Code of Conduct and imbibes the spirit of protecting 
human rights in our operations and across the value 
chain. The Policy confirms our commitment to equal 
opportunity, non-discrimination, health and safety, 
free employment, fair wage and benefits, data privacy, 
corporate social responsibility, etc. The Human Rights 
Policy* applies to all employees of Biocon Limited 
and its subsidiaries (excluding Biocon Biologics, 
Syngene and their subsidiaries), including business 
partners, contractual employees, trainees, volunteers, 
consultants, and members of the Board of Directors. 
We intend to conduct appropriate training for various 
stakeholders to ensure that they understand and share 
the same commitment towards this end.
•	 Improving our ESG ratings and scores: We featured 
for the first time on the DJSI Emerging Markets Index 
in 2021, with a total sustainability score of 45 as 
against the industry average of 18, thereby achieving 
a 93rd percentile position. We have also secured ‘B’ in 
the Carbon Disclosure Project (CDP) for both Climate 
Change & Water Security demonstrating disclosure, 
awareness and management of climate change and 
water related issues in our business, which is higher 
than the global average of the biotech and pharma 
sectors. We were awarded a Bronze Medal by EcoVadis 
in FY22 for our ESG performance.
Our ESG Highlights
We have continued to improve our ESG initiatives to 
ensure that the impact of our actions leads to positive 
change. This is evidenced by our key highlights for FY21 
and FY22, detailed below:
•	 Biocon Biologics’ proposed acquisition of partner 
Viatris’ biosimilars business is a transformational deal 
that will accelerate our mission of making biosimilars 
affordable, available and accessible to a larger global 
patient pool.
•	 Biocon Biologics has entered into an alliance with 
Serum Institute Life Sciences (SILS) to join the effort of 
addressing the inequitable access to vaccines.
•	 The landmark approval of interchangeable bGlargine, 
co-developed with Viatris, will allow Biocon Biologics 
to improve accessibility, availability and adoption of 
biosimilars in the U.S. for the benefit of patients and 
the overall healthcare system.
Governance in Action
•	 Robust 
and 
globally 
benchmarked 
corporate 
governance policies
•	 Published our first Tax Policy and, voluntary ‘Tax 
Transparency Report’ FY22 
•	 Biocon Limited published a standalone Human Rights 
policy*
•	 Published our Supplier Code of Conduct which 
integrates ESG expectations such as Zero tolerance for 
child labor
•	 All employees trained in Adverse Event Reporting 
•	 Continued 
digitization 
initiatives 
to 
strengthen 
the Quality Management System and Learning 
Management
Transforming Patient Lives
•	 R&D Spend - ` 5,950 Million (FY22), 10% of total 
revenue**
•	 Doses of rh-Insulin supplied to people with diabetes 
globally since 2004 - ~2.75 billion
•	 Patients benefitted through our biosimilars in FY22 
- 5.3 million
**BL and BBL
*Similar principles applicable to Biocon Biologics, currently embedded in its Code 
of Conduct, is being developed as an independent global policy document.
| ESG Report 2022
22

Responsible Action Towards Environment4
•	 Energy consumed - 511,354 MWh
•	 Water consumed - 1.71 million m3
•	 Green Energy Purchased - 58 percent for BL & BBL 
Indian operations
•	 Total GHG offset - 117,697 tCO2
•	 ISO 14001 (Environmental Management Systems 
certified
Transforming the Workplace
•	 The number of women in the permanent workforce 
stood at 1,531 in FY22 while it was 1,354 in FY21.
•	 13 percent increase in women who constitute the 
permanent workforce in FY22 as compared to FY21 
•	 ` 12.8 million invested in activities such as annual 
health check-ups, employee engagement initiatives, 
and RT-PCR testing for our employees at Biocon 
Limited, India
•	 The total hours of training in FY22 stood at 178,264. 
The average training hours per full-time employee 
for FY22 stood at 19.9. Furthermore, the average 
amount spent per full-time employee on training and 
development stood at ` 3,033 in FY22 
•	 ISO 
45001 
(Occupational 
Health 
and 
Safety 
Management Systems) certified
Transforming our Communities
•	 ` 113 million (BL and BBL) in Corporate Social 
Responsibility (CSR) spending in FY22
•	 Investment in Hebbagodi Lake Rejuvenation Project 
since inception is more than ` 82 million, with  
` 5 million invested in FY22 
•	 120+ students graduated from Biocon Academy in 
FY22 with 100 percent placement across leading 
pharma, biotech, and life sciences companies
•	 ~71,000 patient visits at the Biocon Foundation-run 
eLAJ smart clinics in FY22 
4FY22
Top 15
Companies from India on 
Dow Jones Sustainability 
Emerging Markets Index 
in the 2021 Corporate 
Sustainability Assessment
Among
C to B
in 2021
Carbon Disclosure Project 
(CDP) rating on Climate 
Change and Water Security 
improved from
18 to 45
in 2021
Dow Jones 
Sustainability Index 
(DJSI) score improved 
from
this year, compared to 
last reporting year
35 to 52
Ecovadis assessment 
score increased from 
ESG highlights:
Biocon Limited
TransformAction | 23

Transforming 
Patient Lives
We discover, develop, and deliver affordable medicines that 
help transform patient lives. Their health and wellbeing are 
our top priority. Our products have also helped enhance the 
healthcare process in developing countries, furthering our goal 
of achieving health equity for all.
| ESG Report 2022
24

Our global portfolio in APIs has grown 
significantly 
catering 
to 
~500 
pharma 
companies in 100+ countries, including the 
U.S., Europe and large emerging markets. 
Strengthening capacity and capabilities in API 
manufacturing  
We are close to completing the commissioning of our 
greenfield, fermentation-based immunosuppressant API 
manufacturing facility in Visakhapatnam, Andhra Pradesh. 
This is our first facility to be enabled with Industry 4.0. 
transformative technologies and will add much-needed 
capacities to serve our customers’ demands. We are also 
investing in synthetic, potent, and peptides API manufacturing 
in addition to injectables in alignment with our strategic 
priorities. Apart from manufacturing capacity and capability 
expansion, we strengthened our R&D capabilities as well 
through an improved organizational structure.
Global health today is characterized by deeply entrenched 
inequities in access to quality healthcare. Availability and 
accessibility of essential and life-saving medicines are a 
prerequisite to guarantee healthy lives and social security 
for the majority of the world’s population. Our commitment 
is to deliver medicines to a vast proportion of people 
and ensure better patient outcomes. Over the past 20 
years, Biocon has leveraged India’s value advantage of 
scientific talent and advanced manufacturing to deliver 
scale, speed, and quality that enabled affordable access 
to complex therapies for chronic conditions. Through our 
portfolio of generics, biosimilars and novel biologics we 
have strengthened our value proposition to reflect our 
four strategic pillars: accessibility, affordability, availability, 
and assurance. 
Generics
Biocon is focused on delivering high-quality and efficacious 
small molecule generic APIs and formulations across the 
globe. The cost savings offered by generic drugs position 
them as affordable alternatives to innovator drugs. 
They reduce the burden of healthcare costs for patients, 
providers and healthcare systems. If more prescribers 
substituted generics for brand-name drugs, healthcare 
spending could reduce substantially, especially for those 
in the middle to low-income brackets. 
With a track record of excellence for over 20 years, our APIs 
find application in high-quality drugs that treat oncology, 
cardiology, CNS, neurology, orthopedic, pulmonology, 
gastroenterology, 
nephrology, 
ophthalmology, 
and 
endocrinology conditions. 
During the fiscal year, we filed 34 DMFs globally, including 
5 in the U.S. We also received approvals for 16 DMFs in 
various geographies across the U.S., Europe, and most of 
the world (MoW).
This 
year 
began 
with 
two 
new 
formulation  
product launches – Labetalol Hydrochloride tablets and 
Esomeprazole Magnesium Delayed-Release capsules. 
Labetalol is used to treat high blood pressure and 
helps in the prevention of cardiovascular complications 
such as heart attack and stroke, while Esomeprazole 
Magnesium, a proton pump inhibitor, is indicated for 
the treatment of gastroesophageal reflux diseases. 
This was followed by a key launch of our vertically 
integrated complex formulation, Everolimus tablets in 
October 2021. Everolimus is a prescription medication 
that is used to treat certain types of cancers and tumors. 
Further, we secured product approvals for Mycophenolic 
Acid, which is indicated for the prophylaxis of organ 
rejection, Posaconazole, an anti-fungal drug, as well as 
Dorzolamide, an ophthalmic product. Before the close of 
the fiscal, we were able to commercialize the latter two 
products.
We continue to expand our portfolio and our regional 
presence while also building in-house manufacturing 
capabilities to support  future growth.
Biocon Limited
TransformAction | 25

Biosimilars
Biocon operates its biosimilar business through its 
subsidiary Biocon Biologics Limited (BBL). We develop 
high-quality, affordable biosimilars that can expand access 
to cutting-edge therapeutics for patients globally at our 
R&D sites in Bengaluru and Chennai (India). These are 
manufactured at scale for both developed and emerging 
markets in Bengaluru (India) and Johor (Malaysia). 
Our products are marketed globally through a hybrid 
commercial model, wherein we have direct commercial 
presence in a few countries and in others, we leverage 
partners such as Viatris to expand patient reach.
FY22 was a transformational year for Biocon Biologics. 
It marked several watershed events, both strategic and 
operational, which have set the stage for us to better 
deliver on our commitment to serve patients and enhance 
global healthcare.
Accelerating our vision of widening access to 
biosimilars
Earlier this year, we signed a definitive agreement to 
acquire the global biosimilars business of our long-term 
partner Viatris for USD 3.3 billion. This acquisition, upon 
closing, will accelerate our strategy to create a fully, 
vertically integrated company with direct commercial 
presence in the developed markets. This transaction is 
unique as it brings together the two companies’ teams, 
which have been collaborating on common projects, into 
a single, integrated organization driven by a common 
vision and mission of improving affordability and enabling 
greater access through lifesaving biosimilars.
Through this deal, we intend to integrate Viatris’ 
biosimilars commercial infrastructure globally. We will 
gain from Viatris’ experience on navigating the formulary 
positioning, contracting, front end sales, regulatory 
interface, and distribution in these markets.
As a vertically integrated enterprise, we will be able to 
drive efficiencies in the system with quicker decision 
making, improved market insights and common focus 
across functions. This deal gives us better strategic agility 
to improve overall cost of supply chain, capital allocation 
and distribution, among others.
Expanding into adjacent therapies 
Whilst we have been primarily focused on bio-therapeutics 
for non-communicable disease to deliver on our vision of 
affordable, innovative and inclusive healthcare solutions, 
we recognize that a strong presence in communicable 
disease is an essential element to have a holistic impact 
on patient lives.
The rapid increase in the frequency of viral outbreaks such 
as Dengue, Zika, Ebola and more recently COVID-19, has 
had a devastating impact on human life. Through our 
Covid-care portfolio, anchored by Alzumab-L (our novel 
antibody Itolizumab), we were able to realize the potential 
of bio-therapeutics in the fight against infectious diseases.
Biocon’s more than 20 years of investments in biologics 
provides a strong foundation to contribute further to this 
fight, leading to our strategic expansion into adjacencies 
such as vaccines and antibodies.
Biocon Biologics entered in a partnership with Serum 
Institute Life Sciences (SILS) in September 2021 for supply 
of about 100 million annual doses of vaccines per annum. 
The vaccines alliance with SILS strengthens Biocon 
Biologics’ presence in infectious diseases, enabling it to 
further its offering to patients.
Gradually, we aim to establish a vaccine R&D division to 
support the strategic alliance in developing both vaccines 
and biologics for communicable diseases, adding to our 
portfolio of life saving patient therapies.
Biocon also entered into a partnership with Adagio 
Therapeutics for manufacturing and commercializing a 
novel COVID-19 antibody therapy, ADG20 in India and 
select emerging markets.
Aiming to make a difference with 
first-ever interchangeable biosimilar 
Insulin Glargine in U.S. 
In July 2021, our biosimilar Insulin Glargine received historic 
U.S. approval as the first interchangeable biosimilar under the 
351(k) regulatory pathways. Our partner Viatris launched this 
first-ever interchangeable biosimilar Glargine in the U.S. in 
November 2021, thus providing a more affordable option for 
the millions of Americans living with diabetes. 
| ESG Report 2022
26

Novel Biologics
Our novel molecule, Itolizumab, is currently being 
developed for indications such as acute graft-versus-host 
disease (aGVHD) and systemic lupus erythematosus (SLE) 
or lupus nephritis (LN) by our U.S.-based partner Equillium 
for the U.S., Canada, Australia and New Zealand.
Itolizumab has been at the forefront of our fight against 
COVID-19 in India, after we repurposed it for the 
prevention and treatment of cytokine release syndrome 
(CRS) in moderate to severe acute respiratory distress 
syndrome (ARDS) patients due to COVID-19. In FY22, we 
completed our Phase IV study of Itolizumab to treat CRS 
in moderate to severe ARDS patients. 
In July 2021, the European Medicines Agency’s 
Committee for Orphan Medicinal Products granted an 
orphan medicinal product designation to Itolizumab for 
the treatment of both acute and chronic GVHD. This was 
a milestone for us as we intend to develop this drug for 
patients in Europe upon regulatory approval.
Our actions during the pandemic
The unprecedented events of the past two years are 
reflective of the unique challenges the world is facing. 
And the actions undertaken by our employees and 
partners are a testament to our ability to mitigate 
such challenges. Powered by a culture of innovation, 
Biocon and its subsidiaries ensured that we fulfilled our 
commitment of providing access to life-saving medicines 
during COVID-19. Our top priority remained to protect 
human lives in a public health crisis and encourage all 
our employees to relentlessly contribute towards ensuring 
stability in our operations.
As the COVID-19 pandemic swept through India, Biocon 
responded to the need of the hour and repurposed its 
novel biologic, ALZUMAb (Itolizumab) a first-in-class, 
anti-CD6 IgG1 monoclonal antibody. Itolizumab was used 
to treat cytokine release syndrome (CRS) in COVID-19 
patients experiencing moderate to severe acute respiratory 
distress syndrome (ARDS). ALZUMAb-L benefited over 
30,000 COVID-19 patients in FY22.
We offered a comprehensive portfolio of products for 
treating COVID-19 patients at different stages of the 
This is a matter of great pride for the country and for all of us at 
Biocon Biologics. We believe this interchangeable designation 
is a game-changing development, as it will allow pharmacy-
level substitution of the reference product by our biosimilar 
Insulin Glargine. It will maximize access to an important 
therapy, regardless of financial circumstances, insurance, or 
channel.
Already, our interchangeable product has been included in 
the National Formularies of two leading Pharmacy Benefit 
Managers (PBM) in the U.S., Express Scripts and Prime 
Therapeutics, which together have a reach of over 60 million 
members. The product will also be offered through the 
Walgreens Prescription Savings Club, saving members up 
to 80 percent off the cash price of comparable long-acting 
insulins purchased at Walgreens.
We believe our biosimilar Insulin Glargine has the potential 
to bring significant cost savings for patients, employers and 
PBMs, making insulin-based therapy affordable for a large 
number of people with diabetes in the U.S. 
Enabling affordable access to 
quality insulins  
In April 2022, the Ministry of Health (MoH), Malaysia awarded 
a three-year contract to Biocon Biologics for its recombinant 
human insulin brand Insugen®. As a result, our Insugen 
formulations will be available to patients at all MoH hospitals, 
district health offices and health clinics. This will further 
expand affordable access to 400,000 patients with diabetes 
and support the government in its journey towards equitable 
access to diabetes care.
Since our entry into Malaysia in 2011, the prices of human 
insulin have dropped by over 20 percent and insulinization has 
improved by 30 percent. Being the only insulin manufacturer in 
Malaysia, we play a transformative role in insulin self-sufficiency, 
enabling our mission towards increasing health equity.
We have designed a special program, ‘Mission 10 cents’, 
to offer our rh-Insulin to governments in Low- and Middle-
Income Countries for less than 10 U.S. cents a day. We have 
signed pacts to enable access to rh-Insulin in the Philippines 
and Tanzania. Through this initiative, Biocon Biologics focuses 
on implementing a continuum of care model encompassing a 
diabetes patient’s journey from awareness to early diagnosis 
and treatment.
Biocon Limited
TransformAction | 27

disease spectrum, including RemWin (Remdesivir) and 
ARAFLU (Favipiravir) for mild to moderate patients, 
ALZUMAb-L for moderate to severe patients and CytoSorb 
for critical patients.
Our actions to combat the pandemic went beyond 
supplying therapies for treating COVID-19. We set up 
the necessary infrastructure required to provide proper 
COVID care. During the reporting period, we undertook 
the responsibility of augmenting the COVID-19 care 
infrastructure at the Anekal General Hospital and 
supported the State Government in its pandemic 
response efforts across over 20 Primary Health Centers 
in Karnataka. With resources being diverted towards 
pandemic 
management, 
our 
health 
interventions 
addressed the need for prevention, screening and control 
of common NCDs such as hypertension, diabetes and 
common cancer.
In FY21, we had established a reverse transcription–
polymerase chain reaction (RT-PCR) testing facility which 
is approved by NABL and ICMR and adheres to the BSL-2 
criteria. Over 100,000 samples have been tested at this 
facility over the past two years.
In FY22, we implemented a COVID-19 vaccination drive 
covering several thousand eligible individuals, including 
senior citizens, people with co-morbidities and differently 
abled individuals which was organised by the Biocon 
Foundation.
| ESG Report 2022
28

Biocon Limited
TransformAction | 29

Governance 
in Action
At Biocon, we live our values by demonstrating the highest 
levels of ethics, compliance, and governance. By further 
integrating ESG within our governance and risk management 
framework, we are expanding our field of view, assessing 
risks holistically, implementing comprehensive controls and 
identifying new opportunities to deliver transformative 
outcomes to all stakeholders.
| ESG Report 2022
30

We implemented globally benchmarked standards of 
governance to build trust with patients, customers, 
shareholders and society. With the aim to develop 
a culture of the best management practices and 
compliances, sound corporate governance rests on the 
pillars of integrity, transparency, accountability, and the 
highest standards of business ethics. 
The commitment to adopt effective corporate governance 
practices in all the spheres of working, has always been 
an imperative factor in the decision-making process, 
providing immense value addition and a competitive 
advantage.
Our continued success is driven by the trust, commitment 
and faith, our stakeholders have in our brand. To ensure 
this, we have built a highly experienced executive 
leadership team, professional management teams and 
independent Boards for all our businesses, which enables 
efficient governance across the Group.
Our Board of Directors are fully committed to enhance 
and retain investor confidence while creating a culture of 
transparency. We established a multi-tiered governance 
structure with defined roles and responsibilities for every 
constituent to align with our management philosophy. 
As a company, we believe in going beyond the 
requirements of the legal framework and hence, while 
we adhere to all applicable regulatory requirements, we 
also adopt global best practices in corporate governance. 
Board oversight
The Board of Directors provides oversight and comprises a 
diverse and multidisciplinary group of knowledgeable and 
experienced professionals. Their objective is to ensure our 
success by collectively driving and directing management 
actions and reviewing overall performance, ensuring that 
stakeholder expectations are surpassed. Their guidance 
provides strategic insights to steer the company in the 
right direction and their expertise and counsel in areas 
of risk, control and compliance helps us maintain the 
highest standards of corporate governance and enhance 
shared value. 
Board diversity
As a leading biopharmaceutical company, we take pride in 
our commitment to embed diversity and inclusion across 
all levels of the organization. A diverse Board enables us 
to obtain different perspectives that positively transform 
our decision-making process. We have formulated a 
‘Board Diversity Policy’ that creates a clear path to more 
inclusive and collective corporate governance. It sets 
out an approach to have diversity in terms of thought, 
experience, knowledge, perspective and gender in the 
Board.
We believe that a diverse Board enables the following 
positive outcomes:
•	 Enhance the quality of decision making and ensure 
holistic tracking of business performance. 
•	 Encourage diversity of perspectives, thereby fueling 
creativity and innovation. 
•	 Supplement and enhance the skills, knowledge, and 
experience of the Board.
•	 Ensure effective corporate governance.
Composition and engagement 
At Biocon Limited, the Board consists of nine directors, 
two executive directors, two non-executive directors, and 
five independent directors. We have two women on our 
Board.
The classification of the Board according to various 
categories are as follows:
Independent
Non-Executive
Executive
56%
22%
22%
Biocon Limited
TransformAction | 31

Our commitment to a diverse and equitable workplace 
extends to Biocon Biologics Limited which is a material 
unlisted subsidiary of Biocon Limited and has a 
well-established Board of Directors. At Biocon Biologics 
Limited, the Board of Directors consists of eight directors, 
with two being women and majority of them being 
independent directors. 
All Board members at Biocon are encouraged to meet 
and interact with the management at timely intervals. 
We ensure that the members of the Board receive invites 
to key management meetings to consider their advice 
and insights for strategic guidance.
Board Membership Criteria and Selection 
Process
At Biocon, the Nomination and Remuneration Committee 
(NRC) follows a disciplined process to identify and evaluate 
Board Evaluation
A key function of the Board is to manage, monitor, and 
review the Board evaluation framework. The evaluation 
criteria for the performance of the Chairperson, Board, 
Committees and executive/non-executive/ independent 
directors have been laid down by the NRC as well as 
the Board. This is undertaken through peer evaluation, 
excluding the evaluation of the director. 
Additionally, to ensure transparency and objectivity, the 
Board Evaluation is conducted by an external agency, 
at least once in three years. In FY21, this exercise was 
conducted by Egon Zehnder, a global management 
a candidate Board membership under Section 178 of the 
Companies Act and SEBI Regulations. 
The NRC assesses the composition and diversity of the 
Board to ensure the appropriate elements of skills, 
experience, independence and knowledge for continued 
effectiveness. In this case, diversity encompasses plurality 
in perspective, experience, education, background, 
ethnicity, nationality, age, gender and other personal 
attributes. These attributes may extend to professional 
experience, 
functional 
expertise, 
educational 
and 
professional background.
The Independent Directors annually provide a certificate 
of Independence, in accordance with the applicable laws, 
which is recorded by the Board. All Board members are 
encouraged to meet and interact with the management 
and are also invited to key meetings to provide strategic 
guidance as well as advice.
The NRC selects suitable candidates based 
on defined attributes and expertise
After thorough screening, the NRC 
recommends desired candidates to the Board
The Board recommends the appointment 
of the director to the shareholders
The proposal is placed before the 
shareholders for their approval
Men
Women
78%
22%
Promoter
Non-Promoter
78%
22%
| ESG Report 2022
32

consulting and search firm. In FY22, this activity was 
conducted through the deployment of self-evaluation 
questionnaires and focused on the following aspects:
•	 Board dynamics and other aspects of Board effectiveness
•	 Board Composition, quality, and culture
•	 Board meetings & procedures
•	 Execution & performance of specific duties
•	 Board & Management relations
•	 Succession planning
•	 Committee effectiveness
•	 Evaluation of Chairperson, Executive & Non-Executive 
Directors.
The outcomes of this evaluation were discussed 
at the Board of Directors meeting and appropriate 
recommendations for implementation were provided. 
Key expertise and attributes of the Board of 
Directors
In compliance with the SEBI Listing Regulations, the 
Board has identified the following competencies which 
are fundamental for the effective functioning of the 
Company. These are taken into consideration by the NRC 
while recommending the appointment of any candidate 
to the Board of the Company.
Committees of the Board
Biocon Limited and Biocon Biologics Limited have 
constituted various committees to focus on specific areas 
and make informed decisions within their authority. 
Each of these committees meet periodically, along with 
members of the management team, to deliberate over 
applicable matters and monitor the same.  Each committee 
has its own charter which outlines the scope, roles, and 
responsibilities. Decisions taken or recommendations 
made by the committee are placed before the Board for 
approval. Each committee has the authority to engage 
outside experts, advisors or counsel, to the extent 
considered appropriate, to assist them in their functioning. 
The committees call for various details from the senior 
officers or function heads, which are presented by them 
for review, discussion, and deliberation. 
Given the emerging importance of ESG, the Board of 
Directors of Biocon Limited has incorporated oversight 
for ESG related activities under the ambit of its Corporate 
Social Responsibility Committee, which has been 
reconstituted as the ‘Corporate Social Responsibility and 
Environmental, Social and Governance Committee’. 
The ESG key roles of the Committee comprise of:
•	 Embedding CSR & ESG into the business 
•	 Developing action plans 
•	 Mobilizing resources and expertise for the initiatives 
•	 Building capacities for CSR & ESG at all levels 
•	 Involving employees to volunteer for CSR & ESG related  
activities 
•	 Engaging stakeholders on a regular basis 
•	 Building partnerships for scale 
•	 Making strategic grants to support worthwhile 
projects/programs 
•	 Being transparent, consistent, and fair in communication 
•	 Carrying out periodic reviews and reporting 
•	 Ensuring continuous compliance with statutory 
requirements 
BOARD EXPERTISE
Global Healthcare
Technology and Digital Perspective
Finance and Risk Management
General Management
Corporate Governance and Compliance
Research and Innovation
Scientific Knowledge
Biocon Limited
TransformAction | 33

The Committee consists of a minimum of 3 Directors, of 
which at least one is an Independent Director.
The Board of Biocon Biologics formally approved the 
constitution of an ‘Environment, Social and Governance 
Committee’. 
The 
Nomination 
and 
Remuneration 
Committee has assigned an Independent Director to be 
the Committee Chairperson and appointed four Board 
Directors as its members.
FAMILIARIZATION PROGRAM FOR 
INDEPENDENT DIRECTORS - FY22
In FY22, the members of the Board were regularly updated 
with the relevant regulatory and policy changes as well as 
the workings of the Company and its operations under 
each business function by the Senior Management Team. In 
addition to this, the business function heads also presented 
their respective performance and future strategy to the Board.
The Board is also responsible for conducting strategy meetings 
periodically to review the long-term plans and growth of the 
Company. 
The familiarization program for the Independent Directors are 
also a part of the quarterly board meetings of the Company. 
This year, our Independent Directors spent approximately 
148.25 hours in the programs cumulatively
The Code of Conduct (CoC)
Our Code of Conduct (CoC) that came into effect in 
2009, is one of the most important ethics and compliance 
communications provided to our employees. It doesn’t 
just outline policies and acceptable behavior but also 
introduces our compliance program to cultivate a 
positive work culture and align all stakeholders with the 
expectations of the company. Our CoC is reviewed and 
amended periodically and was most recently revamped 
in FY21, with the vision to transform our CoC into an 
interactive document that helps create ‘buy-in’ and 
guide employees to the most helpful information such 
as illustrations, frequently asked situations, real life 
examples, situations and solutions. To understand the 
‘why’ behind the policies, training on the CoC is provided 
to all employees, including the new joiners who are 
subjected to a specific program on the same as a part of 
their onboarding process.
The Code of Conduct for Prevention of Insider 
Trading 
Biocon Limited has a “Code of Conduct for Prevention of 
Insider Trading” in place to implement and practice the 
principles of Corporate Governance based on fairness, 
transparency, integrity, honesty and accountability. 
The observance of the Code is a prerequisite to ensuring 
complete confidentiality of all “Unpublished Price Sensitive 
Information” and to build general investor confidence 
and stakeholder credibility. This policy is applicable to 
the employees/designated persons of all the subsidiaries, 
joint ventures and associates in India as well as our global 
counterparts.
In addition to this, the company has also adopted the 
“Code for Corporate Disclosure Practices for Prevention of 
Insider Trading” to ensure timely and adequate disclosure 
of Price Sensitive Information with special reference to 
analysts and institutional investors.
Supplier Code of Conduct (SCoC)
In FY 22, we have developed a Supplier-Centric Code of 
Conduct that outlines our core values and expectations 
from our business partners and suppliers. The ‘Supplier 
Code of Conduct’ covers suppliers, service providers, 
customers, distributors, wholesalers, resellers, and other 
business partners and forms the foundation to build a 
strong culture of collaboration and a strong sense of 
purpose. The SCoC outlines our partners’ expectations 
regarding business ethics, human rights, business 
practices, employee relations, health and safety and other 
topics related to sustainable and responsible business 
practices. It encourages our business partners to go 
beyond legal compliance, drawing upon internationally 
recognized standards.
Enhancing our ‘culture of ethics and compliance’ 
How can an organization support large numbers of 
employees across locations in doing the right thing when 
faced with an ethical dilemma?  
This thought led to the creation of a specific program 
with the primary objective to proliferate a network of 
fully trained ethics ambassadors throughout the business. 
| ESG Report 2022
34

The training sessions are designed, managed and 
conducted 100 percent by women leaders from different 
departments. 
Currently 700+ employees have been trained across all 
departments and geographies. who act as advocates for 
the ethics program and the values of the organization. 
They also help in communicating and disseminating 
information that promotes a culture of compliance and 
good governance.
The CoC is communicated to the employees in the form 
of a ‘Global Ethics and Compliance’ (GEC) policy designed 
to help foster a positive work culture which ensures 
necessary compliance and enables the employees to be 
aligned with our values of integrity and ethical conduct 
of business. 
We also use the following tools to train our employees 
on the policies within the CoC, including courses 
on anti-bribery and corruption, prevention of sexual 
harassment at the workplace and health and safety.
•	 Dedicated YouTube channel for micro-learning videos 
•	 On the go, QR code based training video to promote 
ethical behaviors
•	 Animated micro-learning videos covering all industry 
specific topics
•	 Interactive learning platform ‘Kahoot’ to conduct live 
training through gamification and data analytics for 
focused training needs 
Human Rights Policy*
As a pharmaceutical company, we recognize that health 
is a human right and ensuring access to medicines is 
vital. Beyond the core function of our company, we are 
committed to upholding human rights to the highest 
order. This includes taking action on issues pertaining to 
child labor and forced/compulsory labor, diversity, equal 
opportunity, and non-discrimination, wage, working 
hours, and benefits, and data privacy, among others.
This year, we formulated our Human Rights Policy*, which 
aims to prevent human rights violations by responding 
promptly with appropriate action. Our policy is further 
in alignment with global standards---this includes the 
ten-tier principles of the UN Global Compact (UNGC).
Biocon’s Human Rights Policy*, 2022
At Biocon, we endeavor to identify, prevent, and mitigate any 
human rights violations within the organization as articulated 
in our Code of Conduct. To further strengthen the process 
and demonstrate this commitment, Biocon Limited has 
published its Human Rights Policy* this year. While a detailed 
global policy on similar lines is currently under development at 
Biocon Biologics, the organisation continues to abide by the 
principles through the CoC.
Biocon Limited’s policy focuses on fostering an inclusive, safe, 
and open workplace. It is in line with the Code of Conduct 
which confirms our commitment to abide by all applicable 
laws relating to wage, benefit, safety, and Human Rights 
principles. The focus areas are as mentioned below:
•	 Child labor and forced/complusory labor
•	 Diversity, equal opportunity, and non-discrimination
•	 Environment, health and safety
•	 Wage, working hours, and benefits
•	 Data privacy
•	 Disciplinary measures 
•	 Corporate social responsibility
•	 Management systems
The Human Rights Policy* is a reflection of Biocon’s values. 
We advocate and practice five values with a Zero-Tolerance 
approach to violations. The guiding five values include 
integrity & ethical behavior, performance-driven work culture, 
value creation through innovation & differentiation, quality 
through compliance & best practices, and collaboration, 
teamwork & mutual respect.
*Similar principles applicable to Biocon Biologics, currently embedded in its Code 
of Conduct, is being developed as an independent global policy document.
Biocon Limited
TransformAction | 35

Ethics and integrity
The principles of integrity, transparency, accountability, 
and business ethics are embedded in our DNA. At Biocon, 
we expect adherence to the highest standards of ethical 
conduct. To continuously be in alignment with this 
vision, we have devised policies, procedures, controls, 
and have implemented global best practices in corporate 
governance and risk management.
Integrity and whistleblowing policy
Biocon’s Integrity Committee (IC) or Audit Committee (AC) 
governs the reporting and investigation of allegations of 
suspected unethical practices and enables the Board and 
employees to report their grievances. Biocon’s Integrity 
and Whistleblower Policy enables a person to report an 
unethical practice in an anonymous manner, without 
the fear of retribution. The responsibility of the IC is to 
assess the concerns raised by the whistleblower and 
initiate appropriate corrective action. A summary of key 
investigations is then collectively presented on a quarterly 
basis to the AC.
Transparency and accountability
Transparency and accountability are the values that 
reinforce our pursuit of good governance and fostering 
deep, long-standing trust with our stakeholders. 
Increasingly, 
businesses 
are 
facing 
scrutiny 
from 
stakeholders, including customers, investors, employees, 
and policymakers around ESG issues, driving the demand 
for disclosure, transparency and sustainable actions. 
At Biocon, ESG is very much part of our Boardroom 
conversations and we are committed to purposefully 
embracing ESG aspects in our strategy and everyday 
decision-making processes.
Considering the appropriate structures and reporting 
systems in place to foster disclosure, we have begun 
to engage with ESG rating organizations and investors 
to better understand their expectations and reflect 
their priorities in our business activities and disclosures. 
We are committed to demonstrating the highest levels 
of transparency and accountability through voluntary 
ESG disclosures over and above statutory reporting 
requirements.
Tax strategy
As one of the leading and pioneering healthcare providers, 
we have a responsibility towards maximizing value for our 
stakeholders and upliftment of our communities across 
the geographies where we operate. This responsibility 
also extends to meeting our stakeholders’ expectations 
on good tax governance. To promote trust and credibility 
in our tax practices, we have published our ‘Tax Policy’ 
and our first ever ‘Tax Transparency report’ for FY22. 
It highlights our practices to balance tax compliance 
with business activities while meeting societal, ethical, 
and sustainability-related expectations. The Report 
structure and content are aligned with global trends on 
tax transparency and with the GRI 207 standards on tax 
reporting.
Biocon’s Tax Transparency Report, 2022
With a focus on transparency in the tax realm, our first ever 
Tax Transparency Report, published in July 2022, is reflective 
of our efforts to promote better visibility on how we run our 
business. It elaborates on our commitment towards adoption 
of responsible tax principles and behavior to maintain high 
standards of integrity with respect to tax compliance and 
reporting, including:
•	 Complying with both the letter and spirit of tax laws and 
regulations in jurisdictions and countries we operate in, in 
a timely, efficient, and accurate manner.
•	 Adhering to global standards and regulations on transfer 
pricing, including but not limited to ensuring that all 
transactions undertaken with related third parties are in 
line with the OECD guidelines.
•	 Maintaining a strong control environment and tax risk 
framework to identify tax-related risks and uncertainties 
and evaluate how they can be addressed.
•	 Engagement with the tax authorities in fair, transparent 
and co-operative manner.
| ESG Report 2022
36

Importance to stakeholders
n = 113
Importance to business (Executive Leadership Team (ELT) + Board)
Includes Biocon Limited and Biocon Biologics Limited
Key to the materiality matrix
Ethical sales and 
marketing
Community 
engagement
Supply chain 
sustainability
Digitization
Safe & empowering 
workplace
Ethical governance
Product quality
Research & Development
Access & affordability
Environmental 
performance
Inclusion and diversity
Top priorities: The issues that fall under this category are critical 
to both our stakeholders and our business. An effective and 
externally visible management response to these issues is vital for 
long-term business success.
Key issues: These are medium to high priority issues which 
require an effective and externally visible management response 
for our end to address them.
Hidden value creators: Although not of high importance on our 
priority list, these issues are nonetheless important to our business. And 
it is our responsibility to educate our stakeholders on the relevance of 
these issues.
Hygiene factors: Issues that are regarded as high priority for our 
stakeholders but are considered as low priority for our business 
are categorised here. They require a balance response from our 
end, keeping both perspective in sight.
Monitoring issues: The last category addresses the issues that are 
of low importance to our stakeholders and also have limited impact 
on our business. Constant vigilance is required to ensure these 
issues do not become more prominent over time. 
The material issues for Biocon have been defined in line 
with the GRI guidelines and are linked with our value 
creation process. 
Materiality 
Assessment 
and 
Stakeholder 
Engagement 
At Biocon, we believe in placing the utmost importance 
on engaging with our stakeholders, appreciating their 
views and, where applicable, incorporating them within 
our business operations. We are committed to designing 
an effective ESG strategy that reflects and is responsive to 
their expectations. 
In FY22, we conducted a materiality assessment to identify 
key ESG topics for Biocon and Biocon Biologics. The  
process 
involved 
undertaking 
extensive 
secondary 
research 
on 
ESG 
within 
the 
biopharmaceutical 
industry and preparing an exhaustive list of 50 topics. 
Through understanding the macro business environment, 
sector specific trends and challenges, as well as 
benchmarking against peers, this list was condensed to 30 
of the most relevant issues with respect to the company’s 
operations. These issues were then categorized into 10 
themes, aligned with our strategic objectives.
The assessment was rolled out to diverse internal and 
external stakeholders who were asked to rate the 
importance of each topic on a five-point scale ranging 
from low to very high. Based on the responses received, 
the weighted average of each topic was calculated, 
arriving at a score to prioritize the 10 themes, which are 
presented in the graph aside. 
The responsibility of tax governance rests with our tax function, 
in consultation with our Chief Financial Officer (CFO). The 
Audit committee provides oversight and guidance on tax 
governance and the Risk Management Committee provides 
oversight and guidance on effective tax risk management 
respectively. Our Tax Policy has been recommended by the 
Audit Committee and approved by the Board of Directors.
The Tax Transparency Report is a voluntary initiative, published 
on our website to provide insights to all our stakeholders, 
including our patients, employees, shareholders, vendors, 
customers, government agencies, supply chain participants, 
etc., and enable wider discussions around our tax trends, tax 
legislation and tax transparency matters. 
Biocon Limited
TransformAction | 37

The Risk Management Committee, formed by the Board, 
reviews critical emerging or existing risks on a rotational 
basis every quarter while also monitoring the de-risking 
strategies and their implementation. This is in line with 
the risk management plan to measure effectiveness of 
mitigation actions defined against critical risks and their 
impact on overall risk exposure of the company. All the 
critical risk areas are covered at least once a year and the 
identified risks are re-evaluated annually by the company. 
During the year, as and when required, changes are 
made to the risk register, considering internal or external 
changes.	
Key risks identified
Due to the nature of the business, the global pharma 
industry is potentially exposed to inherent risks including 
product safety and quality issues, intellectual property 
tangles, regulatory delays and inappropriate marketing 
practices, which can lead to penalties, product recalls, 
brand/reputation loss, and revenue loss. These risks have 
been elaborated upon in our Annual Report.
Electronic medical records, cloud-based technologies, and 
data-sharing among industry stakeholders have increased 
the complexity of managing and ensuring the safety of 
information assets, particularly protecting patient health 
information and intellectual property. However, with 
digitization, we can control quality and operations, bring 
in flexibility and adaptability, and improve management 
effectiveness.
We have identified the primary risks which are 
material to the business. These include product quality, 
environmental performance, supply chain sustainability, 
safe & empowering workplace and ethical governance. 
For details on the impact of these to the business and 
our mitigation plan to address them, please refer to page 
number 93 – of this Report.
COVID-19 related risks
While the impact of the pandemic in FY22 was lower in 
comparison with the year before, the industry continued 
to witness risks related to supply chain and logistics 
bottlenecks, delays in the development programs 
including regulatory reviews or approvals, delays in 
completion of capex projects as well as workforce safety.
Risk management 
From being managed in silos to being recognized as 
highly interconnected and interdependent, the practice 
of risk management has shifted fundamentally. The new 
approach views all risks together, within a strategic 
framework and encourages transformational actions 
throughout the organization.
At Biocon, risk management is a structured, integrated, 
consistent, and continuous process across the entire 
organization for identifying, assessing, mitigating, and 
reporting on opportunities and threats in a timely manner 
and in alignment with our strategic objectives.
Our risk management process entails the following: 
•	 Risk identification and assessment
•	 Risk mitigation 
•	 Risk monitoring and reporting
These aspects are aligned with the daily operations of 
the company, thus ensuring that the management of 
risks is embedded within the processes and systems. 
With risk identification being the first step, we undertake 
the approach of ‘Treat, Terminate, Transfer and Take’ to 
manage and mitigate the risk, restricting the same to a 
tolerable level.
The risk monitoring and reporting provides assurance that 
the risks identified have been managed and all measures 
have been undertaken to ensure that the company does 
not face any negative consequences.
Risk governance
An enterprise-wide risk management framework (ERM) 
is implemented with an objective of timely identification 
of risks, assessment and evaluation of risks which are in 
line with the overall business objectives or strategies and 
defining adequate mitigation strategies. This year, risks 
associated or impacting the ESG priorities or objectives 
were also incorporated into the ERM, including mitigation 
measures for those risks identified. Our aim is to align 
our corporate strategy, risk processes and ESG, which 
will allow us to gain a complete view on the risks and 
opportunities which are applicable to us.
| ESG Report 2022
38

With a transition to the “new normal” and to emerge 
stronger after the pandemic, we put in place key mitigation 
actions to continue our operations and support business 
continuity plans. These included but were not limited to:
•	 Inventory buildup in case of supply chain disruptions
•	 Vaccination campaigns for workforce and their family 
members
•	 Virtual reviews by regulators
•	 Other 
safety 
precautions 
such 
as 
continuous 
temperature monitoring, remote working options, etc.
Internal controls                  	
At Biocon, we have established a strong internal control 
system, which comprises policies, guidelines and 
procedures adopted by us to ensure orderly and efficient 
business conduct including adherence to policies, asset 
safeguarding, fraud and error prevention and detection, 
accounting records accuracy and completeness, and the 
timely preparation and presentation of reliable financial 
information.
This internal control system aims to assure our operational 
effectiveness and efficiency, compliance with laws and 
regulations, asset safeguarding and reliability of financial 
and management reporting.
We are staffed by experienced, qualified professionals 
who play an important role in designing, implementing, 
maintaining, and monitoring the internal control 
environment.
An independent firm of chartered accountants performs 
periodic internal audits to provide a sensible assurance 
of internal control effectiveness and advises us on 
industry-wide best practices. Our Audit Committee, 
consisting of independent directors, reviews important 
issues raised by the internal and statutory auditors 
regularly and the status of rectification measures to ensure 
that risks are mitigated appropriately on a timely basis. 
Our Compliance Management System was reviewed by 
an independent third party in FY 22. No major deviations 
were identified and recommendations for improvement 
are being incorporated
Biocon Limited
TransformAction | 39

Partnership  
in Action
As the effects of the biggest health crisis in a century continue 
to be felt across the globe, in communities and within business, 
we are determined to honor our commitment to patients and 
partners through unified action and transformative measures. 
We believe that by ensuring consistent and targeted action, we 
effectively collaborate with partners, to improve and enhance 
access, affordability, and reach. This is further augmented by our 
integrated supply chain and strategic partnerships, both local and 
international, which drive efficiencies right from the procurement 
of raw materials to last-mile delivery of life saving drugs.
| ESG Report 2022
40

It has been two years since the start of the COVID-19 
pandemic, and while there has been relief in the form 
of widespread vaccination drives and a reduction in 
daily cases, business as usual continues to be disrupted, 
severely affecting supply chains and delivery logistics. 
Despite these challenges, we have worked closely with 
our partners and suppliers to deliver the global patient 
pool with our generic and biosimilar therapies. 
The unwavering sense of purpose of our people and 
partners to put ‘patients first’ ensured that we delivered 
on our promise of providing access to life-saving 
healthcare 
solutions 
during 
COVID-19, 
globally. 
Our generic formulations business in the US had zero 
back orders throughout the pandemic and we were able 
to act with efficiency and speed to ensure crucial supplies 
of much-needed APIs and formulations from India were 
distributed to over 70 countries. Our efforts to distribute 
medicines contributed towards countering medicine 
shortages during the pandemic.
For our biosimilars business, we have established a strong 
foothold in developed markets like the U.S., Canada, EU, 
and Australia through our long-standing partner Viatris. 
Biocon Biologics also has a wide commercial footprint 
across many Emerging Markets, where we have partnered 
with leading local pharma companies.  
Creating value together with our partners
We believe in forging strategic partnerships that expand 
our ability to create value and deliver quality products 
to patients across the globe. Through the widespread 
reach of our businesses, we are ensuring we lead from 
the front, ensuring we strengthen our value proposition 
of augmenting our four strategic pillars: accessibility, 
affordability, availability and assurance. 
In FY22, we ramped up our presence in emerging markets 
by signing 44 new partnerships across 50 countries for 
our biosimilar products, enabling us to expand our reach.
In FY22, we continued to forge impactful partnerships 
across our businesses:
•	 Biocon Biologics entering into a strategic alliance with 
Serum Institute Life Sciences to expand into vaccines.
•	 Biocon Biologics entering into a collaboration with 
the Research Society for the Study of Diabetes in India 
(RSSDI) to expand its insulins access program to address 
the needs of young people with Type 1 diabetes in 
India.
•	 Biocon Biologics partnering with US based Adagio 
Therapeutics for an exclusive license to manufacture 
and commercialize ADG20 in India and select emerging 
markets. ADG20 is a novel monoclonal antibody 
targeting the spike protein of SARS-CoV-2 and related 
coronaviruses.
•	 Strengthening an existing partnership by acquiring 
Viatris’ Biosimilars Assets for up to $ 3.335 billion 
to create a world leading fully integrated biosimilars 
enterprise.
Various partnerships and collaborations we 
have forged over the years*
*Represents select key partnerships
Biocon Limited
TransformAction | 41

Our acquisition of Viatris will 
transform our business and expand 
our reach:
Our belief in the strength of collaborations first led us to 
partner with Viatris (previously Mylan) in 2009 to co-develop 
a portfolio of biosimilar antibodies and recombinant proteins. 
We expanded this collaboration to include insulin analogs in 
2013. Over the years, we synergized our frontier science and 
robust manufacturing capabilities with Viatris’ regulatory and 
commercialization expertise to deliver affordable therapies 
to patients in both developed and emerging countries. As it 
stands, we have one of the most extensive biosimilars portfolio 
with seven biosimilars from our joint portfolio commercialized 
in global markets. 
In February 2022, Biocon Biologics announced that it would 
acquire Viatris’ Biosimilar Assets for $3.335 billion. This 
acquisition further builds on the strategic global partnership 
that we have forged with Viatris over a decade. Our symbiotic 
partnership which will mature further after the completion 
of this acquisition, will allow us to share risks, lower costs, 
maximize our efficiencies, expedite development, and expand 
our reach. As we integrate the two businesses, we will 
continue on our transformation journey under one umbrella, 
creating operational efficiencies and agility across value chain.
Partnering to address inequitable 
access to vaccines and biologics for 
infectious diseases
While Biocon Biologics continue to have a broad and robust 
pipeline of biosimilars that target NCDs, it has made strategic 
alliances to expand its presence in communicable diseases, 
through two key partnerships, one with Serum Institute Life 
Sciences (SILS) for vaccines and infectious disease antibodies, 
and the second with Adagio Therapeutics for a novel 
COVID antibody therapy. The Serum Institute Life Sciences 
strategic alliance provides Biocon Biologics an asset-light and 
accelerated entry into the vaccines segment. This alliance 
will complement the strengths and resources of the two 
leading players in vaccines and biologics, with the objective 
of addressing inequitable access both in emerging and 
developed markets for life saving vaccines and biologics.  SILS 
will get about 15 percent stake in BBL enabling us to work 
together to grow together. Thereby, through this alliance, 
both companies aim to make a significant impact on global 
healthcare.
Transformative partnership with Tabuk 
Pharmaceuticals to commercialize 
specialty generic drugs in the Middle East 
and North Africa (MENA)
In December 2021, we announced a partnership with Tabuk 
Pharmaceuticals Manufacturing Company, a subsidiary of 
Astra Industrial Group, to commercialise of specialty generic 
products in the  MENA region. As part of the agreement, 
Biocon will develop and manufacture the products, while 
Tabuk would commercialize them. 
The partnership with Tabuk ensures that we are synergizing 
with a leading pharmaceutical company who understands 
the MENA market and will enable us to register, import, and 
promote specialty generic medicines in Saudi Arabia and 
other Middle East countries, as they would hold marketing 
authorization of these products. Through this partnership 
Biocon is laying the foundation to expand into the MENA 
region, with a focus on markets like Saudi Arabia, UAE, 
Kuwait, Qatar, Oman and Iraq, Jordan, and Lebanon. Our 
plans to expand into this region further corroborate our 
commitment towards ensuring global availability of affordable 
and accessible medicines. 
| ESG Report 2022
42

Collaborating 
with 
suppliers 
to 
ensure 
continuous delivery of quality and value 
To ensure reliable supply of affordable therapies for 
patients and to make them accessible globally, we 
leverage strong partnerships with our supply chain 
and logistics partners. Such strategic partnerships help 
optimize cost, minimize resource consumption, and 
increase the affordability of our products. Our integrated 
supply chain ensures uninterrupted medicine availability 
to our customers, patients, partners, and healthcare 
systems globally. Continuous focus on cost effective and 
sustainable supply chain remains a key priority to increase 
access and affordability of the products to the patients. 
Whilst we utilize both air and sea modes for movement of 
our products, we are increasingly focusing on sea freight 
to create a positive impact on the environment.
Through the course of the pandemic, we strived to 
maintain business continuity, and this is something we 
are continuing to do via collective action from within the 
organization as well as outside. As a result, we are now 
well versed in weathering the toughest challenges and 
will continue to stand with our vendors and collectively 
navigate global disruptions. 
Responsible sourcing
For us, responsible sourcing is a key criterion towards 
ensuring patient, people, social, and environmental 
equity. As a result, we procure our raw materials from 
approved vendors, both local and international, and audit 
our critical suppliers periodically on business sustainability 
parameters. These parameters are closely aligned with 
global frameworks and standards to guarantee our 
products meet the requirements of all 120 countries 
where we supply the product.
We have made tremendous progress in moving away from 
an animal-origin to a recombinant supply base for some 
of our key products, including insulins. The sourcing team 
focuses on the use of non-petrochemicals based ‘green 
solvents’, which are environmentally friendly alternatives 
to petrochemical based solvents.
We strive for a high level of conformance towards 
environmental compliance for our critical vendors. 
By evaluating various business and quality performance 
indicators, we ensure seamless supply across all 
manufacturing plants. To encourage new ideas and 
implement sustainable practices across the supply chain, 
we organize periodic business sessions with suppliers and 
logistics service providers. 
E-Sourcing has been implemented for our top solvents 
to gain visibility in the market and procure raw materials 
at competitive rates. We are in the process of designing 
a vendor portal to increase transparency and evaluate 
vendor performance. This portal will also support Biocon’s 
paperless initiative through seamless real time SAP data 
integration, repository creation of vendor documentation 
and process simplification.
Effective alignment and action through our Supplier 
Code of Conduct
To guide our value chain partners on the behavioral and 
ethical standards we expect from them, we have developed 
a Supplier Code of Conduct in FY22. In alignment with 
our Code of Conduct, we have zero tolerance for child 
labor and have always ensured no children are employed 
in any of our operations. During the year, there were 
no reportable incidents of child labor from any of our 
vendors. 
Moreover, we are working towards ensuring ESG is 
integrated within supplier and vendor practices, and in 
this regard, we have developed and designed a detailed 
ESG training and development program. In FY22, we 
rolled out the program for our key value chain partners 
to guide them on applicable laws, regulations, policies, 
and procedures, as well as the behavioral and ethical 
standards we expect from them.
Biocon Limited
TransformAction | 43

Biocon’s Supplier Code of Conduct
At Biocon, we aim to adhere to the highest ethical standards 
by operating within a framework of principles, guidelines 
and policies aligned with ethical, social, and environmental 
responsibilities to deliver our brand purpose and promise. 
Consequently, we seek to partner with third parties, vendors 
and suppliers that are aligned with our values and are 
committed to operating ethically and responsibly. 
The Supplier Code of Conduct (SCoC) outlines our expectations 
and guidelines with respect to responsible sourcing and calls 
for third parties, vendors, and suppliers to commit to fair 
treatment and professional and ethical behavior along with 
safe, sustainable business practices.
Local Sourcing 
Biocon prefers to collaborate and develop small and 
medium enterprises (SMEs) around its area of operations 
to foster local economy. Local sourcing reduces carbon 
footprint from freight, increases local employment and 
builds trust amongst local communities. With the disruption  
in global healthcare delivery during the pandemic and the 
Suez Canal blockage highlighting the importance of local 
sourcing, we have further strengthened our local vendor 
base throughout our value chain. 
Transparency and Traceability
Biocon engages with an extensive network of suppliers 
worldwide to ensure supply chain resilience. Supply chain 
teams collaborate with stakeholders within and outside 
the organization to anticipate and respond to complex 
and interconnected risks that threaten the continuity of 
business operations. We focus on product safety and 
integrity throughout our logistics channels and implement 
measures to ensure traceability of our products, 
whilst strengthening compliance with Customs-Trade 
Partnership Against Terrorism (C-TPAT) and Drug Supply 
Chain Security Act (DSCSA).
Periodic Vendor Evaluation
Periodic Reviews are done to address any issues, based 
on metrics including OTIF (On-Time, In-Full Deliveries) 
and number of quality complaints. Third-party vendor 
evaluation is carried out by international agencies such as 
Dun & Bradstreet, as required.
Ethics &
business integrity
Health & safety
Labour &
human rights
Environmental 
compliance & 
sustainability
Quality
Management 
systems
THE CODE COMPRISES OF THE FOLLOWING ESG ASPECTS:
| ESG Report 2022
44

Biocon Limited
TransformAction | 45

Transforming  
the Workplace
At Biocon, we believe that organizational growth hinges on 
the continued development of our workforce. Our investments 
and strategy, therefore, aim to create a diverse, equitable, and 
inclusive workplace. Further, a performance driven work culture 
based on transparency, integrity, teamwork, and collaboration 
helps us drive innovation in our thinking. This enables us to 
co-create transformative solutions to real-world problems 
by ‘doing things differently’ and ‘doing different things’. 
Leveraging this ethos, through our practices and processes, we 
strive to develop the workforce of tomorrow.
| ESG Report 2022
46

Repurposing our hiring and onboarding
The company’s mission is to be an integrated biotechnology 
enterprise of global distinction7. To achieve this, we place 
emphasis on our human resource development, which 
starts with right hiring and effective onboarding. 
By recruiting the best talent, we actively seek to create 
future leaders, who can further our purpose of creating 
unparalleled impact. 
We lay equal emphasis on the expertise of potential hires 
and the alignment of their aspiration with our values. 
Our hiring philosophy is governed by transparency, 
visibility, and respect for diversity across all levels. It is 
imperative for us to onboard passionate individuals, who 
are determined to create transformational solutions 
for the healthcare industry. This is exemplified with our 
diversified Talent Acquisition strategies. In FY22, we 
accessed skilled talent through our targeted programs 
such as campus placements, and other hiring initiatives 
across geographies which includes attracting talent from 
Tier 2/Tier 3 cities. Our engagement framework with 
various campuses provides support to students through 
internship opportunities and multiple knowledge sharing 
platforms that bridges the gap between academics and 
industry know-how for the students. This approach 
enables the organization to deploy the young talent early 
on.
To ensure smooth navigation of our processes, technology 
has been kept at the forefront of our hiring strategy. 
Our approach leverages various Artificial Intelligence 
(AI) interventions to identify and attract talent from 
prestigious institutions in India. As an example, at Biocon 
Limited, the hiring efficiency increased through the 
integration of AI-based tools to match the Company’s 
requirements using talent acquisition metrics. The tool 
ensures effective tracking of timelines and quality of hires 
against such metrics. This led to the creation of talent 
acquisition scorecards that helped revamp our recruiting 
processes. We have leveraged technology for the entire 
pre-employment medical examination. Similarly, to enable 
data driven decision making on contractual workforce, 
a Dashboard has been operationalized which provides 
real-time 
insights 
into 
budget, 
demographics, 
cost-efficiency, and resource utilization of contractual 
workforce. 
At Biocon, we place emphasis on leveraging the internal 
talent pool and have revamped our processes to promote 
career growth and development. The job posting process 
allows filling vacant positions internally first, before 
expanding our search outside. The process is managed by 
our newly launched in-house career portal, MyCareer, that 
maps internal roles to employees based on aspirations, 
experience, skill, and competencies. This portal notifies 
the target population meeting the criteria for internally 
advertised jobs. Post this, the selected candidates undergo 
an in-depth interview as well as panel assessments.
Our hiring, onboarding and employee lifecycle processes 
have been linked with technology to reduce human 
dependency and create an efficient process. In FY22, we 
hired a total of 2,806 individuals as full-time employees. 
Of these, we hired 594 full-time female employees. 
For FY22, an increase of ~94 percent has been recorded 
for the number of full-time employees hired, as compared 
to FY21 levels.
7 http://covid19.biocon.com/our-vision-mission-values
Biocon Limited
TransformAction | 47

Strengthening performance management 
Our dynamic environment requires our employees to 
be adaptable, agile, and passionate problem-solvers. 
For this reason, performance management systems need 
to go beyond the traditional approach toward continuous 
feedback and evaluation of performance. 
During FY22, we strengthened our systems by introducing 
the ‘department scorecard’ — a process that supports 
individual business functions to identify, prioritize and 
track their strategic priorities in line with the organizational 
goals. The integration of goal alignment in the scorecards 
has resulted in proper measurement of performance 
and achievement across the organization. This leads to 
creation of a shared sense of ownership across levels in 
the organization through the goal cascading process. 
This goal setting then forms the basis of the promotion and 
career progression cycle and provides periodic monitoring 
of performance and progress against individual goals.
Furthermore, we have developed a robust technical and 
behavioral competency framework that is embedded in 
our performance management process. One of the key 
outcomes of our performance management process is to 
identify the key development areas for the employees and 
provide support for improvement through learning and 
development.
Identification of 
Strategic Priorities
Creation of Department 
Scorecards (Strategic imperatives 
and other initiatives)
Cascading of Organization 
Objectives to the Departments
Quarterly Tracking and Scoring
| ESG Report 2022
48

To remain relevant and up to date in technical skills, 
there has been a great emphasis on defining technical 
competencies required for each role within the 
organization. We collaborated with Mercer consulting to 
build a technical competency framework. This initiative 
has assisted in identifying technical competencies and 
proficiency levels for diverse roles across the business 
functions of the organization. This forms a core part of the 
overall talent and organizational development strategy. 
Transforming through learning 
To establish domain expertise and build functional 
capabilities, we have partnered with India’s prestigious 
educational institutes giving higher education opportunity 
to employees while they continue to work.
We strive to support the skill development of our people 
through meaningful interventions via Education, Exposure 
and Experiences Augmenting leadership capabilities and 
building a succession slate is one of the key focus areas 
for the organization.
At Biocon Biologics, to build future-ready leaders and 
accelerate career development, we have introduced a 
structured talent development program for the top talent 
which aims to develop internal talent and strengthen our 
succession pipeline for leadership roles. In partnership 
with the external parties, we have developed a bespoke 
program with blended learning experiences that include 
coaching, 
cross-functional 
projects, 
and 
external 
market orientation thus enabling individual and group 
learnings. Additionally, we also provide various learning 
and development programs to support the building of 
professional, digital, innovation and managerial skills for 
our employees. 
At Biocon Limited, senior leaders in the organization 
underwent a behavioral competency assessment program 
conducted by Saville and Holdsworth Limited (SHL). 
Subsequently, ~ 40 leaders from senior management 
are undergoing a 10-month development program in 
partnership with a global firm - Development Dimension 
International (DDI), which includes various master classes, 
group coaching, and learning projects.
 
For our middle management level, we identified a pool of 
140 employees who underwent assessments conducted 
by Basil Tree, a leading talent assessment and development 
firm. The assessments evaluated cognitive potential 
and abilities based on our competency framework. 
The outcomes of the evaluation were utilized to develop 
customized individual development plans. This will be 
followed by an 8–10-month development journey in 
partnership with an external facilitator. In addition, 
we implement various initiatives to nurture and build 
technical capabilities. A few noteworthy initiatives are 
mentioned below:
•	 Lean Six Sigma Training: In FY22, we conducted 
sessions in Bengaluru, training a cohort of our employees 
as Green Belts (GB). There are multiple green belt projects 
currently underway, anchored by trained GB employees.
•	 Data Analytics Program: This has been conducted 
for a group of our R&D scientists. The training is divided 
into two phases, focused on training the scientists on 
Senior Leadership  
Development Program 
The leadership development program aims to build future 
succession roles by developing a second line of leaders. The 
program constitutes a two phased approach, wherein:
•	 Phase one involved the participants undergoing extensive 
assessments conducted by SHL, an external talent and HR 
consultancy firm. The assessment results form the foundation 
for formulating individual development plans, in consultation 
with their respective managers/mentors.
•	 Phase two focuses on Biocon’s defined leadership 
competencies and identified learning needs. This will be an 
immersive 10-month blended learning format—leveraging 
online and offline tools. The program has been designed to 
be result-oriented, to ensure that leadership competency is 
built in a contextualized and customized manner. To ensure 
that competencies are built, business critical Action Learning 
Projects (ALP) are allocated to participants which are reviewed 
by the senior management. The key objective of phase two is 
to develop strategic ability, a mindset for collaboration, and 
team management skills for participants. 
Biocon Limited
TransformAction | 49

Embedding diversity and inclusion 
As a leading biopharmaceuticals company, we recognize 
that diversity and inclusion are the driving force for 
innovation, new ideas, and perspectives. Our diverse 
employee base reflects this recognition and are the carriers 
of our success.  As a result, we are investing in building the 
next cadre of empathetic and smart women leaders who 
will shape and transform the business further. The share 
of women in Biocon’s permanent workforce stands at  
17 percent. In absolute terms, the composition of the 
total number of women in the workforce increased to 
1,531 in FY22 from 1,354 in FY21.
Our concerted and focused efforts have been recognized 
by UN Women, as the winner in the ‘Transparency and 
Reporting’ category for exemplary practices in embracing 
Women’s Empowerment Principles, Asia Pacific. 
In line with our ambition of being an equal organization 
by 2030, we have undertaken several initiatives to 
promote inclusion and diversity. For example, we have an 
‘Equal Pay for Equal Work’ practice, where employees are 
compensated based on merit, rather than gender, race, 
or age. We also ensure that women are well-represented 
in every team, and therefore, we undertake distinct 
developmental programs to prepare them for managerial 
and leadership roles. 
In-Process Quality Assurance  
(IPQA Training) 
Recognizing the business need to strengthen the IPQA 
team’s existing skill sets, Biocon rolled out a targeted training 
program to build synergies between the quality and the 
production teams. To identify the key concerns and challenges 
faced by both teams, a stocktaking session was conducted. 
Following this, a roadmap for collaboration was built, which 
sought to address the identified bottlenecks and create new 
opportunities for effective teamwork.
Based on the collaboration roadmap, the IPQA training was 
rolled out in a workshop-based format for capacity building 
data-backed decision making. Phase one of the training 
has been completed and phase two will be concluded in 
FY23.
•	 Customer Centricity workshops: These have been 
conducted for employees across IT and Compliance teams. 
We conducted a refresher program for our Manufacturing 
& Quality team to build a quality mindset and be audit-ready 
throughout the year. Moreover, at Biocon Limited and 
Biocon Biologics Limited, our employees have undertaken 
mandatory trainings on the prevention of sexual 
Harassment (POSH), Information Security Management, 
Code of Conduct, Zero Tolerance, and Employee Health 
and Safety, amongst other function-based training.  
The total hours of training in FY22 stood at 178,264. 
The average training hours per full-time employee for 
FY22 stood at 19.9. Furthermore, the average amount 
spent per full-time employee on training and development 
stood at ` 3,033 in FY22. 
and dissemination. The training focused on enhancing the 
teams’ soft skills and creating awareness of the importance 
of knowledge acquisition and application in day-to-day 
processes and work. A post-training assessment was also 
conducted which indicated visible improvement in the IPQA 
team’s motivation levels and communication skills. 
| ESG Report 2022
50

To ensure that our employees can manage and perform 
their roles effectively, BioWin has been operationalized 
to promote healthy work life balance. A key pillar of 
BioWin is the maternity leave benefit programs. In FY22, 
1,299 employees were entitled to maternity leave11 out 
of which, 53 employees availed the same during the 
reporting year. The rate of return for employees who took 
maternity leave stood at 84 percent, and 86 percent for 
Biocon Limited, and Biocon Biologics India, respectively.
Creating an Inclusive Workplace 
An inclusive workplace is key to driving growth in the 
organization. This enables higher employee engagement, 
better innovation, and higher employee recognition. 
To bolster and action our commitment, we have focused on 
building and expanding our diversity and inclusion networks. 
At Biocon Biologics, we have institutionalized the diversity, 
equity, and inclusion (DE&I) Council and launched a three-
structured employee resource group. This includes creation of 
6 Biocon Women Network chapters and programs such as Back 
to Work and Old-Timers Network. We also support women 
in science through various activities, including mentoring. 
Moreover, in FY22, we launched the Biocon Women Mentors 
& Coaches Network for 300+ gender diverse students across 
STEM colleges and universities in India. 
11 Parental leave is understood as maternity leave for Biocon Limited, India. 
“Motherhood brings with it a tangle of responsibilities, 
but I was allowed the space to explore the scope of my 
work, helping me achieve a good balance between work 
and home”, says Vineela A, who made the shift to a new 
role that allowed her to develop new skills and challenge 
herself. 
“When you have a strong support system to not only 
guide you through your work but also provide a sense 
of assurance, it helps you rebuild your confidence”, says 
Lakshmi Bhavani, who will soon transitioning back to work 
after maternity leave, adding, “I had the full support of 
my team, especially during the challenging weeks before 
I went on leave.” 
Biocon Limited
TransformAction | 51

Employee initiatives
We pride ourselves on our people-centric approach. 
This is reflected in our practices for the health and 
well-being of our employees. We deployed an app-based 
wellness initiative–BioPulse, which includes different 
programs that focus on maximizing the physical, 
social, environmental, and emotional well-being of our 
employees. In FY22, we conducted various webinars 
for health awareness through BioPulse. This included 
webinars on eye care & vision, coping with stress and 
anxiety during the pandemic, breast cancer awareness 
sessions, and awareness sessions on mothers returning to 
work after a maternity break, among others. In FY22, a 
few notable programs included the celebration of World 
Health Day, #IBeatCOVID, yoga and meditation, cancer 
awareness sessions, pregnancy care, and sessions on 
women’s health concerns and preventive measures.
Empowering our employees
Awards12
Great Place to Work has certified Biocon 
Limited & Biocon Biologics Limited 
among the top 10 companies in India 
for best workplaces in Diversity, Equity, 
and Inclusion
Jobs4her recognized Biocon Limited & 
Biocon Biologics Limited as the  
“Top 20 Companies in DivHERsity (Large 
Enterprises)” and “Top 20 Most Innovative 
Practices — DivHERsity Policies
Working MOTHER & AVTAR  has awarded 
Biocon Limited as one of the Best 
Companies for Women and was featured 
among the 100 Best Hall of Fame for 
winning consistently for the 5 years
Employee Benefits including Annual 
Health Check-Up, Employee Engagement, 
RT-PCR Testing for Biocon Limited
 12.8 (Million in `)
12 https://www.jobsforher.com/accelherate/DivHERsity-Showcase
| ESG Report 2022
52

•	 Annual health check ups
•	 Medical benefits and 
insurance
•	 Occupation health centre
•	 Access to doctors and 
specialist
•	 Gym facility
•	 Yoga camps
•	 Zumba camps
•	 Aerobics and cardio
•	 lnterventions on occupational 
hazards
•	 Health and Safety guidelines
•	 Healthy work environment
•	 Awareness and training 
sessions
•	 Safety awareness session
•	 ‘National Safety Week’
•	 Preventive awareness session 
on a monthly basis
•	 Access to dieticians for a 
healthy lifestyle
•	 CSR wing - Employee’s 
participation in actvities
•	 Unlimited access to counsellor 
via chat, email & call
•	 Emotional wellbeing 
awareness session
•	 Health & Iifestyle
•	 Guided sessions burn out
•	 The wellness corner, wellness 
portal and mobile app to 
build a healthy lifestyle
Physical
Wellbeing
Environmental
Wellbeing
Emotional
Wellbeing
Social
Wellbeing
Biocon Limited
TransformAction | 53

At Biocon, we have created an environment where our 
employees are supported and cared for beyond their 
professional aspirations. With this resolve, we launched 
VEngage to interact with and holistically celebrate our 
people. In FY22, we undertook various webinars for health 
awareness through VEngage. This included webinars on 
eye care & vision, coping with stress and anxiety during 
the pandemic, breast cancer awareness sessions, and 
awareness sessions on mothers returning to work after a 
maternity break, among others. 
Furthermore, as part of our commitment to bring  
affordable healthcare to all, we introduced Biocare, 
a 
special 
access 
program 
for 
our 
employees. 
Through a digital platform, our people can request for  
Biocon’s critical, life-saving medicines for themselves and 
their immediate family members. 
Our progress for our employee initiatives work work 
in parallel with accelerating social transformation. 
In FY22, our employees represented an extraordinary 
drive for transformation. As an example, Biocon Limited 
in association with Narayana Health organized a blood 
donation camp at Biocon Park and Campus. This received 
a resounding response from 200+ donors at the drive. 
Along with wellbeing initiatives, capturing employee 
feedback is critical for enabling a positive work culture. 
In view of this, we rolled out the BioPulse Survey, to 
capture employee feedback and sentiment. This was 
launched across operations, including, R&D, quality, 
supply chain management, IT. The outcome/insights from 
the focus-group-discussion assisted us to understand 
employee concerns, suggestions for improvement and 
action planning.
We have enhanced our employees’ skills, specifically in 
professional behavior and growth that has enabled them 
to achieve their aspirations and shaped rewarding careers. 
In our transformative journey, we achieved a significant 
milestone three years ago when we shifted gears to 
design our ‘Good to Great’ or g2G initiative. The aim of 
the initiative is to establish a culture that embodies our 
values while fostering excellence. The initiative includes a 
set of five GREAT behavioral traits that is weaved into the 
DNA of our organization.
BioPulse
Fun@ 
Biocon
Photography
Club
Creche
Biocon
Day
Biocon 
Gym
Knowledge – 
driven forum
Biocon 
CSR Wing
Induction
Service
Awards
Annual 
Health 
Checkup
Health 
Awareness 
sessions
Biocon Adventure 
and Sports Club 
(BASC)
Pre-Employment 
Medical Check 
(PEMC)
Bio  
Contribute
HEALTH & WELLNESS
VALUE ADDED SESSIONS
EMPLOYEE INTEREST GROUP
EMPLOYEE ONBOARDING & SUPPORT
AWARDS & EVENTS
PILLARS OF EMPLOYEE ENGAGEMENT
GO-GETTER 
Have a Bias for Action
EMPATHY
Fosters Collaboration
TRUTHFULNESS
Demonstrate Integrity
RESPECT every idea
Think Out of the Box
APPROPRIATE
Walk the Talk
| ESG Report 2022
54

Employee health and safety
At Biocon, we foster an environment where our 
employees feel safe, healthy, and inspired. That is only 
possible by ensuring the highest degree of compliance 
with applicable laws and regulations while enhancing the 
mental, financial, and physical well-being of our people. 
Creating an environment that prevents accidents and 
incidents has positive impact on our business productivity.
Our efforts to create a safe work environment is evidenced 
by the facilities that are designed in accordance with 
the highest safety standards and state-of the-art safety 
controls. We regularly assess risks through audits of 
our equipment, systems, and processes across various 
parameters to detect and mitigate potential hazards. 
Process safety improvement programs are regularly carried 
out across all sites as part of the safety enhancement 
initiative.
All manufacturing areas are continuously monitored in 
line with stringent industrial hygiene protocols. For any 
new and existing process, periodic safety risk assessment 
is done to ensure safety interlocks and controls are 
functioning as per the required standards. A ‘Zero 
Tolerance’ program is present to strengthen discipline 
around workplace safety and make it an integral part of 
the organizational culture. 
To identify the ground level safety issues, the department 
heads periodically conduct GEMBA walks at the 
manufacturing site. To undertake any maintenance 
activity at the facility, a work permit system has been 
established to ascertain that equipment is isolated and 
maintenance work can be carried out. Further, Electrical 
safety programs such as lock out and tag out (LOTO), Arc 
flash assessment & Hazardous area classification are also 
implemented. Fire safety measures include maintaining a 
fire hydrant system, dry sprinkler powder aerosol (DSPA) 
fire protection system, fire extinguishers and an auto 
modular fire extinguishing system at the facilities.
All operations undergo periodic third-party audits to 
assess safety risks, identify gaps and define improvement 
measures. Walk through surveys, measurement of noise 
levels, illumination, indoor air quality and volatile organic 
compounds (VOC) monitoring are carried out as a part 
of assessment in order to locate various hazards of the 
workplace. Process safety improvement programs are 
A key event during the reporting period was ‘Red Tag’, 
an event where employees had to highlight potential 
workplace hazards. This event was conducted as a part of 
the larger event of EHS Culture Building. Furthermore, the 
Dynamic Emergency Response Team (ERT) displays safety 
performance boards across key manufacturing blocks to 
foster and increase emergency preparedness and safety 
performance awareness. At Biocon, we observed the 
regularly carried out across all sites as part of the safety 
enhancement initiative. Process risk register is maintained 
to manage and mitigate the residual risks, identified 
during safety assessments and those emerging during 
operations.
Our aim is to inculcate an efficient environment, where 
managers and employees can collaborate and drive 
the health and safety of our people. To this effect, we 
also organize internal and external training sessions on 
a periodic basis, aimed at spreading awareness on the 
health and safety aspects and guiding our employees on 
prevention and mitigation measures. During the year, 
several safety-related initiatives, awareness campaigns 
and drives like ‘National Safety Week’ and ‘Fire Services 
Week’ were conducted to advocate a “zero incidents” 
culture amongst employees. In alliance with the 
Karnataka State Fire and Emergency Services (KSFES), 
we organized mock fire drills to assess the coordination 
between the internal teams and external agencies and 
accordingly developed corrective action plans to modify 
our emergency response mechanism. Further, we 
organized ‘Advanced Firefighting’ sessions conducted by 
KSFES for our employees, which focused on preventing 
fire emergencies and acting responsibly in a contingency, 
in a manner that mitigates the risk of loss and injuries.
*A Japanese term, which means a workplace walkthrough aimed at observing 
employees, ask about their tasks, and identify productivity gains.
Biocon Limited
TransformAction | 55

‘Chemical Disaster Prevention Day’ in December 2021 
and conducted awareness programs to emphasize 
the importance of chemical safety. The main aim of 
these programs was to commemorate the Bhopal Gas 
Tragedy and disseminate information regarding safe 
manufacturing, transportation, storage, and use of 
chemicals to prevent accidents, injuries, and loss of 
property. We also observed the National Safety Week 
in March 2022 and undertook activities such as a safety 
poster-making competition and firefighting training.
We also provide our employees, including workers, with 
non-occupational medical and healthcare services at our 
occupational health centers, equipped with a competent 
team of paramedics and doctors. Our workers are also 
provided with non-occupational medical and healthcare 
services facilitated through various initiatives driven by the 
HR and EHS teams. The Company carries out a full annual 
health check-up for all employees and contract workers, 
aimed at identifying potential health problems and raising 
awareness about potential occupational illnesses.
Actioning Compliance
At Biocon, we have reinforced our commitment to 
adhere to our policies on Code of Conduct, Prevention 
of Sexual Harassment (PoSH), among others. We foster 
an ethical, fair, equitable and responsible environment 
that enables a culture of trust and transparency. This year 
we have developed and released our Human Rights 
Policy*, which is applicable to all employees of Biocon 
Limited and its subsidiaries, including business partners, 
contractual employees, trainees, volunteers, consultants, 
and members of the Board of Directors. At Biocon, we 
have zero tolerance for any kind of discrimination or 
Over 124 companies, from both public and 
private sectors, were in contention for this 
national level award.
harassment and have instituted robust mechanisms for 
escalation and redressal. 
Actions to protect our employees during the 
pandemic
Amid confusion and chaos caused by the pandemic 
during the past two years, the world had its hopes pinned 
on the pharmaceutical industry for recourse. While our 
employees were up to the challenge of providing for our 
customers, we were equally cognizant of the importance 
of protecting our employees. During the first wave of the 
pandemic, even as the nation went into a lockdown, our 
facilities remained operational.  However, we ensured 
that the necessary protocols were implemented to ensure 
the safety of our employees. We arranged transportation 
for employees who were required to come to work. 
Our facilities were completely sanitized, and the employees 
underwent thermal screening while entering the premises. 
Within the facilities, the employees were required to 
always wear their masks, maintain physical distance, and 
stay within their allocated zones while working. We also 
conducted RT-PCR tests for our employees and undertook 
contract tracing, where required. For our employees who 
lived in shared residences, we provided additional support 
and alternative accommodation, in case anyone on the 
premises was detected with COVID-19.  
In FY22, Biocon Biologics was 
conferred the ’20th Annual Greentech 
Safety Award 2021’ for outstanding 
achievements in the ‘Safety Excellence’ 
category.
“As a scientist, I felt the urge to help those patients 
who are dependent on Biocon’s therapies daily. At a 
time when COVID-19 cases were surging in India, my 
family and friends were concerned about my safety. 
I explained to them the situation and my reasons for 
reporting to work despite the challenges posed by the 
lockdown. I was anxious too, but I believe my expertise 
helped patients, which was the key motivation for me. 
I’m very humbled to be able to do my part. I encourage 
everyone to embrace that passion, because we’re in a 
unique position to help fight this pandemic, especially as 
a biotech company. I felt proud to be able to do my part.”  
– R&D team personnel, Biocon Limited 
*Similar principles applicable to Biocon Biologics, currently embedded in its Code 
of Conduct, is being developed as an independent global policy document.
| ESG Report 2022
56

To boost the morale of our frontline workers, we launched 
several 
campaigns 
like 
#SmashCOVID-19Stigma, 
#BreakTheChain, 
#YouAreImportant, 
and 
#UnitedAgainstCOVID on our social media channels to 
appreciate the efforts and contributions of our healthcare 
warriors. Additionally, we launched a dedicated microsite, 
‘UNITED AGAINST COVID-19’, as a one-stop resource 
for employees to receive all updates on government 
guidelines and health advisories. We have also initiated 
several online programs to provide counseling, healthcare 
tips, and yoga to our employees.
We have also launched a company-wide campaign called 
‘Your Safety, Our Priority’ with the intent of reinforcing 
the importance of vaccination against the virus by sharing 
relevant details on approved vaccines, registration 
process, and side effects as well as telling the facts from 
myths. We also launched a vaccination drive for all our 
employees and their dependents. 
We also ensured that there was continued interaction 
between our leadership team and the employees through 
shared videos, messages, town halls and focus groups to 
foster a sense of oneness at a time when teams were 
working virtually.
Tribute to colleagues lost to COVID-19
The last two years were extremely difficult for us, as 
we lost a few members of our family. We recognize the 
value of human life and take responsibility to support the 
families of our employees who have contributed to the 
company immensely. In addition to the Group Term Life 
Insurance and other applicable benefits, we undertook 
additional actions to assist and support the families. 
Our approach to human resource management can be 
described as holistic and forward-looking. The families 
were provided 50 percent of the employee’s gross salary 
for two years, up to a maximum payout of ` 5 Million. 
We also facilitated a special education allowance that 
supports two children up to 18 years of age. In addition, 
we provided support for the recruitment of either the 
spouse or the child in any of our group companies or in 
another suitable field depending on their qualifications 
and eligibility.
Biocon Limited
TransformAction | 57

Responsible 
Action Towards 
the Environment
As part of our commitment towards long-term sustainability 
and climate change mitigation, we aim to reduce our 
environmental footprint through the implementation of 
strategic initiatives that will bring about a transformative 
change in how we interact with the environment. They include 
identifying opportunities to increase the share of renewable 
energy mix in our operations, improving energy efficiency, 
innovating to drive productivity across our value chain, 
implementing the principles of circular economy and adopting 
digital solutions which minimize inefficiencies.
| ESG Report 2022
58

As part of our responsibility towards the environment, 
we also focus on collaborating with stakeholders to 
promote environmental stewardship in communities, 
thereby ensuring responsible long-term action towards 
sustainability and climate change mitigation.
Environmental stewardship has been a key focus for 
Biocon since our inception and we actively promote the 
same through judiciously optimizing resources to enhance 
healthcare outcomes and improve lives.
Most of our manufacturing processes have a relatively 
lower 
environmental 
footprint 
as 
compared 
to 
conventional pharmaceuticals. This helps in ensuring 
we stand out as a biopharma company that is more 
sustainable and less resource intensive.
In order to limit our environmental impact, we have taken 
progressive steps to accelerate our transition towards 
renewable energy, implemented efficient recycling of 
water and waste and adopted responsible procurement 
practices. Furthermore, as an environmentally responsible 
company, we go beyond statutory compliances and 
embrace responsible business practices that focus on the 
judicious use of natural resources.
We believe that creating a better business and creating 
a better world are not conflicting goals. They are 
both essential ingredients for long-term growth and 
sustainability.
Our approach to managing the environmental impact 
is holistic, transformative and inspired by our desire to 
promote and strengthen environmental stewardship. 
This starts by managing the environmental impact of our 
business including close collaboration and coordination 
with our stakeholders, thereby instilling environmental 
conscious decision making in our day-to-day practices.
Key highlights
•	 117,697 tCO2 reductions achieved in FY22*, a 12% 
increase from FY21
•	 ` 80 million invested in installing a new 600 kilo 
litres per day (KLD) capacity zero liquid discharge 
(ZLD) effluent treatment plant in Bengaluru enabling 
400,000 litres of incremental water savings per day 
and 680,000 additional savings achieved in FY22 due 
to water offset initiatives at BBL facilities
•	 Over 5,500 tonnes of fermentation waste sent for 
reuse as an auxiliary fuel to cement factories*
•	 100 percent of treated wastewater is recycled and 
reused in the process or in utilities
•	 58 percent of total purchased electricity for BL & BBL 
Indian operations in FY22 was green power
•	 60 percent of solid waste generated in our operations 
is sent for recycling 
•	 64,373 hours of EHS training
Awards
•	 We won the ‘Athyunnatha Suraksha Puraskara’ from 
National Safety Council, Karnataka in September 2021
•	 We were awarded the ‘Best Safe industry in the 
category of Mega industries’ by the Department of 
Factories, Karnataka in March 2022
•	 We won the prestigious ‘CII-SR EHS Excellence Awards 
2021’ for Bengaluru facilities for our commitment to 
EHS practices in March 2022
•	 In October 2021, we were awarded the ‘Greentech 
Environment Award 2021’ in the Environment 
Protection category for our Hyderabad facility 
* BL + BBL (excluding Malaysia)
Biocon Limited
TransformAction | 59

Biocon enters prestigious Dow 
Jones Sustainability Emerging 
Markets Index
Biocon was selected to be in the Dow Jones Sustainability 
Index (DJSI) in the Emerging Markets (EM) category for  
progressive ESG practices, which underlines our commitment 
to the larger goal of sustainable development. We made a 
formal submission for Corporate Sustainability Assessment 
for its listing on the DJSI for the first time in 2021 and made 
it to the DJSI EM Index with a total sustainability score of 
45 as against an industry average of 18, achieving a 93rd 
percentile position. It is among the Top 15 companies from 
India and one of the 12 companies from the pharmaceuticals, 
biotechnology, and life sciences sectors to be featured in the 
index for 2021. A total of 360 Indian companies were invited 
to participate in DJSI in 2021. Biocon has been listed amongst 
the Top 10 Global Biotech Companies in 2021 and will strive 
to improve its position through future disclosures.
Sustainability has been among our topmost priorities 
since inception and both Biocon and Biocon Biologics are 
committed to provide insights into their ESG performance to 
their stakeholders.
The DJSI Index provides an important yardstick for Biocon 
and Biocon Biologics to measure sustainability performance 
and continuously improve reporting on ESG to address the 
growing interest of our global stakeholders.
Biocon’s mAbs facility  
receives ISPE Award 
We ensure that all new facilities constructed on our campuses 
are designed with energy-efficient green building features. 
Multiple elements of sustainability were considered during 
the design of our new 340,000-sq. ft. monoclonal antibodies 
(mAbs) manufacturing facility (B3) in Bengaluru to ensure 
minimal environmental impact, despite the large size of 
the facility. We earned the distinction of being the first 
biopharmaceutical company from India to get an honorable 
mention at the International Society for Pharmaceutical 
Engineering’s (ISPE) Facility of the Year Award (FOYA) for this 
facility.
EHS governance
During FY22, Biocon introduced new governance 
mechanisms with regards to EHS in the form of enhanced 
policies, procedures, and management systems. This new 
mechanism comprises the Environment, Occupational 
Health, Safety, Sustainability (EHSS) policy which is driven 
by the top management. The EHSS policy is the foundation 
on which EHS governance is built and is applicable to the 
entire Biocon Group. 
The Policy is enforced and acted upon by the EHS heads 
of BL and BBL, who in turn are further supported by 
dedicated teams of 178 EHS specialists who are involved 
in the execution of EHS management systems. The policy 
is extended to all our internal and external stakeholders 
Additionally, with regards to the EHS Management System, 
Biocon has extensively bolstered it over the last two years 
by implementing the PDCA Approach. This approach is 
centered around the pillars of 1) Plan; 2) Do; 3) Check; 
and 4) Act. The intention behind bolstering this system 
is to ensure we are effectively and rapidly addressing 
the climate emergency through strategic transformative 
actions. 
and requires them to adhere to it. The Policy’s primary aim 
is to ensure environmental stewardship, sustainability, 
and safety. Through this Policy we also aim to minimize 
all safety incidents to achieve our target of zero incidents 
and keep our people safe. Our EHSS Policy principally 
alludes to the precautionary principle. 
Furthermore, our aim is to identify and mitigate potential 
environmental impacts by ensuring that all Biocon 
facilities meet strict environmental standards and our 
systems, practices and processes are regularly upgraded 
to align with leading industry standards. 
| ESG Report 2022
60

Addressing the climate emergency
Climate emergency is perhaps the biggest challenge 
facing humanity in the 21st century and requires collective 
action and transformative change to mitigate the impacts. 
At Biocon, we are cognizant of our responsibilities 
towards sustainable development, and we are actively 
taking necessary steps by collaborating both internally 
and externally to ensure we are doing our bit to address 
the climate emergency. 
This begins by increasing investments to help decarbonize 
our operations and build climate resilience. As a part of 
our unceasing efforts to lower carbon emissions over 
the long term, we leverage opportunities to increase the 
share of renewable energy across our operations through 
onsite solar installations and procurement of wind energy. 
These efforts have led to an increase in the share of green 
power to 58 percent of our total power consumption for 
BL & BBL Indian operations. All new facilities constructed 
on our campuses integrate green building design features 
to optimize resource use. 
To monitor our climate change related initiatives, targets, 
objectives, priorities and performance, aspirational goals 
are set as part of our Environmental Management System 
(EMS). 
Grid power, diesel, and natural gas account for a 
significant share of our direct energy consumption and we 
are continuously evaluating options to switch to cleaner 
sources of energy. As a result, over the years we have 
gradually reduced our dependence on traditional sources 
of energy and are moving towards more renewable 
forms. In FY22 we increased total renewable energy by 
13.6 percent compared to FY21. We strive to continue 
increasing the share of clean energy in our operations in 
the coming years.  
Over the course of FY22, our total energy consumption 
(direct and indirect) has increased by 8.4 percent  
attributed to increased production on account of greater 
demand.
Bolstered EHS Management System
Plan
Do
Check
Act
Implementation of and alignment 
with EHSS policy
Carrying out EHS related 
trainings
Conducting audits 
biannually
Incident 
management
Development of EHS goals and 
strategic objectives
Integrating EHS procedures 
in our business processes
Carrying out compliance 
evaluation assessments
Creation of action plans
Undertaking risk planning and 
assessment
Ensuring operational control
Ensuring management 
reviews are conducted
Continual improvement
Ensuring leadership commitment
Developing emergency 
management systems
Biocon’s EHS Management System is ISO 14001:2015 and ISO 45001:2018 Certified
Fig: Total energy consumption - Indirect Energy and Direct Energy
Indirect energy or grid electricity purchased has increased 
by 4.2 percent over the course of FY22. However, we have 
aimed to ensure we reduce our electricity purchased from 
non-renewable sources, and increase total renewable 
energy purchased. 
Biocon Limited
TransformAction | 61

Total direct energy consumption has increased by 12.3 
percent over the course of the last year on account of 
increased production.
We have also adopted innovative technologies like 
energy efficient centrifugal air compressors, water chillers 
and motors to reduce energy consumption, thereby 
reducing GHG emissions from our own operations. 
Furthermore, the use of variable refrigerant volume 
systems and steam condensate recovery measures have 
also helped us reduce our total energy consumption. 
Lastly, installed energy efficient economizers in boilers for 
steam generation, motors for air compressors and ETP, 
and motors for chilled water and cooling water pumps are 
also actively being implemented across our operations.
Greenhouse gas emissions (GHG) have increased 
marginally in FY22 by 1.1 percent on account of an 
increase in production, compared to FY21. The increase, 
however, is minimal and our GHG intensity of production 
has reduced16 compared to last year. This indicates that 
in relative terms we are reducing GHG emissions across 
our operations, although our overall energy consumption 
is increasing, by implementing forward looking and 
transformative initiatives.
Furthermore, by increasing the efficiency of our 
production, coupled with incorporating renewable energy 
technologies, we have substantially decreased GHG 
emissions. Increasing energy efficiency and upgrading 
our energy mix has also helped us offset a significant 
amount of our total GHG emissions. In FY22 procurement 
of green power from the grid has enabled us to offset 
approximately 99,000 tCO2.
We also have switched to natural gas, instead of using 
furnace oil to produce steam. Natural gas, a cleaner fuel, 
has considerably lowered GHG emissions compared to 
Fig: Total indirect energy purchased - Renewable and Non-Renewable
Fig: Total direct energy generation - Across LPG, HSD, Woodchips, 
Coal, Furnace, Diesel, and Natural Gas 
Fig: Total Greenhouse Gas Emissions - Scope 1 and Scope 2
16 Please refer to the “GHG emissions” table in Biocon’s ESG Scorecard
| ESG Report 2022
62

Water management
As our offices and manufacturing units are in regions that 
are projected to face moderate to extreme water stress 
by the mid-21st century, it is imperative for us to take the 
necessary actions to mitigate the risks of water scarcity in 
the region through responsible consumption.  
We realize the impact our business has on the communities 
we operate in, and we must be cognizant of our duty 
furnace oil, and this initiative alone has helped us achieve 
a reduction of 17,045 tCO2. Through other technological 
upgradations, such as installation of energy efficient 
boiler economizers that reduce natural gas consumption, 
we achieved a cumulative reduction of 117,697 tCO2
17. 
In FY22, we were able to offset approximately 63 percent 
of our total GHG emissions through technology upgrades, 
green power procurement and fuel switchovers.
Accelerating the Clean Energy Transition
To further our commitment to a greener and sustainable 
future, we have commissioned the first captive solar 
power plant of 20 MW over 60 acres in North Karnataka 
in collaboration with a leading renewable energy partner. 
It reduces carbon emission by 25,000 tons annually. 
This addition of solar power complements our existing wind 
power and balances our renewable energy requirements to 
cater to manufacturing all 24 hours a day throughout the 
year. Biocon is one of the first pharmaceutical companies to 
operate on hybrid renewable energy sources that includes 
both wind and solar.
to optimally utilize and manage the scarce freshwater 
resources that are available to us, as these sources of 
water are essential for both domestic consumption and 
agricultural use. Therefore, we have deployed best-in-
class water management practices to appropriately treat 
and reuse wastewater within our operations and facilities, 
thereby eliminating discharges into local water bodies 
and reducing our demand for freshwater. 
Fig: Total greenhouse gas emissions offset through various initiatives at Biocon Limited and Biocon Biologics India Operations (tCO2)
This image represents the first captive solar power plant of 20 MW over 
60 acres in North Karnataka.
Biocon Limited
TransformAction | 63

Our efforts to conserve water involve process modifications 
and the adoption of new technologies which allow us to 
undertake 100 percent recycling of treated wastewater. 
As our manufacturing processes are water intensive we 
have implemented targeted interventions to minimize our 
water footprint.
One of our key initiatives is the introduction of Membrane 
Bioreactor (MBR) technology which improved our water 
quality in our wastewater stream. MBR technology was 
introduced in the newly installed 600 KLD capacity ZLD 
effluent treatment plant in Bengaluru. Based on advanced 
membrane bioreactor technology, this ZLD effluent 
treatment plant facilitates the recycling of an incremental 
680,000 liters of water per day and allows us to reuse the 
treated permeate for boiler operations.
Furthermore, 
Multiple 
Effect 
Evaporator 
(MEE) 
and 
biological 
treatment 
has 
been 
expanded. 
Biological treatment is equipped with Membrane 
Bioreactors at one of the facilities to improve our 
treatment process as well as to improve the quality of the 
treated water.
Our transformative actions with regards to water 
management have enabled us to proudly state that 100 
percent of our treated wastewater is recycled and reused 
in different processes and utilities at Biocon Limited and 
Biocon Biologics India. We have made substantial capital 
investments to upgrade to the latest advancements in 
wastewater treatment. ZLD, an innovative engineering 
system designed to treat and reuse wastewater and 
effluents, is implemented across all our manufacturing 
units in India18.
Through water accounting, audits, demand management, 
efficiency initiatives and risk assessments, we ensure that 
we responsibly use the scarce freshwater resources. 
To further augment our water conservation efforts, we 
have also installed rainwater harvesting systems at our 
manufacturing units to reduce our reliance upon external 
sources of freshwater. We have also implemented several 
catchment-based interventions in local communities to 
promote aquifer recharge in the communities around our 
locations of operation.
Waste reduction
We strive to identify opportunities which promote the 
circular use of our resources and reduce waste disposal 
in the communities we operate in. This is guided by our 
approach to waste management and governed by the 
principles of reduce, reuse, and recycle. We extend our 
philosophy of circular economy across our operations and 
within the business value chain by actively engaging with 
our stakeholders, to effectively articulate our desire to 
enhance environmental equity.
Our EHSS policy clearly articulates procedures to manage 
waste in an environmentally responsible manner. 
Monthly reports track and categorize the waste generated, 
and our policies ensure that the waste is appropriately 
segregated, securely stored and safely disposed through 
authorized waste handlers and recyclers, in compliance 
with applicable central and state regulations in India.
In FY22, we recycled 60 percent of the total waste generated 
at Biocon Limited and Biocon Biologics. Our approach to 
waste management involves chronological considerations 
of the principles of prevention, reduction, recycling, 
recovery, and disposal. We continue to implement the 
18 Only two manufacturing units are in Special Economic Zones (SEZ) where wastewater and 
effluents are treated at a Common Effluent Treatment Plant (CETP)
Reusable Insulin 
pens:
Innovative product 
which allows 
administration of 
upto 80 insulin 
shots from a 
single pen, versus 
using 80 single 
use pen.
Solvent 
Recycling:
Solvents used in 
manufacturing 
are recovered and 
reintroduced into 
the production 
process. This 
reduces the need 
for fresh solvents.
Digitalization:
We have reduced 
80% of our 
paper waste by 
migrating to a 
digital platform. 
We are also 
trying to reduce 
layers within 
our product 
packaging.
Plastic Free 
campuses: 
Various steps have 
been taken to 
phase out single 
use plastics on 
our campuses 
including adoption 
of reusable water 
bottles and 
recyclable stirrers.
Container 
Optimization: 
Process in which 
container size is 
determined based 
on the volume of 
product that need 
to be shipped. 
Has resulted in 
reduced plastic 
and chemical use.
Waste to energy:
Diversion of 
5500 tons of 
fermentation waste 
to cement factories, 
where they are 
used as fuel. Helps 
reduce waste going 
into landfills and 
offsets equivalent 
fossil fuel use.
WASTE MANAGEMENT INITIATIVES
Fig: Waste management initiatives at Biocon
| ESG Report 2022
64

following initiatives within our operations and in our 
business value chain to minimize our waste generation 
and maximize the recycling and recovery of wastes. It is 
our ongoing focus to continuously reduce the fraction 
of our waste diversion to landfills.  We have introduced 
electric waste pickup vehicles as part of the solid waste 
management initiative at our SEZ facility in Bengaluru.
Air emissions
The air emission levels from our operations are significantly 
lower than the limits prescribed by regional pollution 
control boards and we monitor the air quality at our 
manufacturing units every quarter to track nitrogen oxide 
(NOx) compliance. Our transition to cleaner fuels such as 
natural gas in our boilers at the two sites in Bengaluru 
ensures minimum sulfur oxide (SOx) and NOx emissions. 
The use of diesel generators to generate power (which 
emits significant amounts of air pollutants) is restricted to 
times when grid power is interrupted. At our Bengaluru 
facilities, we have installed state-of-the-art continuous 
ambient air quality monitoring stations (CAAQMS) to 
improve the management of air quality parameters 
through real time monitoring. Lastly, the partial 
replacement of coal to biomass has also helped reduce 
the air pollution.
Green Chemistry
Another key area of focus in our R&D organization 
is ‘Green Chemistry’ that uses sustainable or green 
chemical development processes which, in turn, reduces 
or eliminates the use of polluting substances. 
We have initiated several measures in this regard, 
including switching from solvent based reactions to 
water-based reactions, replacing hazardous solvents 
with harmless, greener solvents, enhancing our solvent 
recovery capabilities and improving our processes to 
maximize the incorporation
of all materials used. These efforts extend to our existing 
as well as new product molecules. Green chemistry plays 
a key role in reducing our overall carbon footprint, by 
designing products that are not harmful to human or 
environmental health.’
Environmental awareness and engagement
We engage our employees in all aspects of sustainability. 
From 
design 
and 
manufacturing 
to 
community 
outreach, we aim to embed a culture of environmental 
care. EHS Learning Series, a knowledge platform, was 
launched to share insights on various topics including 
environmental management. Sessions were conducted by 
eminent speakers and subject matter experts. In FY22, our 
employees also attended specialized EHS training sessions 
conducted by reputed external agencies. 35 employees 
were certified as ISO Internal auditors and 17 employees 
as ISO lead auditors from Biocon Biologics by TUV Nord 
on ISO 14001 and 45001 standards. 
Our employees clocked over 64,373 hours of EHS training 
in FY22. 
As we have in the past, this year too we celebrated 
the World Environment Day to spread environmental 
awareness amongst our employees. To encourage 
environmental action amongst employees, we have 
instituted a program to recognize and reward innovative 
projects that have demonstrated an impact on emission 
reduction, energy efficiency and environmental excellence. 
Biocon Biologics has been conferred with the ‘20th Annual 
Greentech Safety India Award 2021’ for outstanding 
achievements in the ‘Safety Excellence’ category. Over 124 
companies from both public and private sectors were in 
contention for this national level award.
Environmental stewardship in our communities
As 
we 
work 
towards 
long-term 
environmental 
sustainability, we are determined to create a positive 
impact on the environment and safeguard ecological 
diversity. As a result, we have taken proactive steps to 
conserve biodiversity around our manufacturing units and 
other regions through our corporate social responsibility 
(CSR) initiatives. 
The ‘Namma Biocommunity’ initiative, which was started 
in 2017 by Biocon employees, allows us to implement 
change in local communities by making the environment 
cleaner, greener, and safer. Volunteers of the initiative 
engage with the local communities through activities 
like tree plantation drives, garbage cleanups and 
environmental awareness programs. In the past, we have 
also promoted conservation through celebration of the 
‘World Environment Day’, where Biocon employees, along 
with school children, planted 1,000 saplings to emphasize 
the importance of safeguarding the environment and 
biodiversity.
Biocon Limited
TransformAction | 65

Transforming  
our Communities
We believe that social transformation is only possible by making 
a tangible difference in the lives of our community members. 
Actions that promote inclusive growth, such as equal access 
to healthcare, education, and sustainable livelihoods, enable 
a metamorphosis in the lives of our beneficiaries. It is our 
firm belief that investing in the growth of people is the best 
utilization of financial resources. 
| ESG Report 2022
66

We aim to make a positive impact on our communities 
through our Corporate Social Responsibility (CSR) arm, 
the Biocon Foundation. We are acting by designing 
our programs to serve the needs of the disadvantaged, 
vulnerable and marginalized sections of society. 
The community-centered approach of our actions is 
reflected in the projects and partnerships we have 
initiated with like-minded, credible organizations. This has 
been undertaken through signing of memorandum of 
understandings and by providing grants to NGOs, trusts, 
and academic institutions under the Grant-in-Aid initiative 
for innovative and impactful social projects. The Foundation 
works across the following focus CSR areas: 
In FY22, our overall contribution stood at ` 113 million. 
We are focusing our resources on critical projects where 
our engagement has made a significant difference in 
the lives of our larger communities. The beneficiaries 
of these projects are primarily determined based on 
their socioeconomic status, gender, age, information 
OUR 
STRATEGIC 
OBJECTIVES
Vitalise preventive 
and primary 
healthcare
Empower 
communities 
through equitable 
employment 
opportunities
Reduce inequality 
and empower the 
marginalised
Contribute to 
welfare funds 
with statutory 
approvals 
Mitigate hunger, 
poverty and 
malnutrition
Ensure 
protection of the 
environment and 
natural resources
Conserve 
traditional art, 
culture and 
sites of national 
importance
Facilitate the 
development of 
sports
Provide safe 
drinking water, 
sanitation and 
hygiene
Augment essential 
rural resources 
Support projects 
that create and 
nurture science 
and technology
asymmetry, 
infrastructure 
constraints, 
geographical 
challenges, and cultural barriers. Armed with the 
knowledge that transformation begins from the ground 
up, our initiatives are currently carried out in and around 
our facilities, a few remote rural areas with low-resource 
settings and in one aspirational district as well. Focus areas 
for our CSR activities 
•	 Primary healthcare 
•	 Environmental sustainability
•	 Rural development
•	 COVID-19 relief
Our efforts have been recognized at several national as 
well as global platforms. We were awarded the ‘Mahatma 
Awards 2021‘ on the eve of Gandhi Jayanti, under 
the ‘Good health and well-being’ category. We won 
the ‘Best Corporate Foundation Award’ at the World 
CSR Congress, 2021 and were bestowed with the Jury 
Commendation Certificate for our oral cancer screening 
program at the 18th FICCI CSR Awards in the ‘Exemplary 
Innovation’ category. In addition to these awards, the 
‘Bengaluru Women Achievers’ award was conferred upon 
Dr. Anupama Shetty, Mission Director, Biocon Foundation 
by the Bangalore Political Action Committee. She also 
received the ‘South India’s best CSR Leaders’ award at the 
National CSR Leadership Congress & Awards.
Primary healthcare
eLAJ Smart Clinic services: 
The Government of India formally launched the 
Pradhan Mantri Digital Health Mission (PM-DHM) on 
27th September 2021, to enable unique health ID for 
every citizen and build an integrated digital health 
infrastructure in the country. The Biocon Foundation has 
continually invested in Information and Communications 
Technology (ICT), enabled process innovations by 
developing technology-enabled access to healthcare. 
Developed in-house, eLAJ Smart Clinic is a one-stop 
solution that addresses the issue of healthcare delivery 
in remote areas of the country. Through these clinics, 
we provide free lab investigations, doctor consultation 
and counseling for lifestyle changes and medication 
adherence. 
Biocon Limited
TransformAction | 67

This platform captures and securely stores electronic 
patient records to enable the practice of evidence-based 
precision medicine and ensure quality improvement in 
dispensing targeted, need-based care to the patient. 
A total of 20 government-run Primary Health Centers 
(PHCs) and three Biocon Foundation-operated health 
centers across seven districts of Karnataka, transformed 
into eLAJ Smart Clinics, remained operational in FY22. 
More than 711,000 patient visits have been recorded 
at eLAJ Smart Clinics since inception and approximately 
71,000 patient visits were recorded in FY22 alone.
Outpatients exit survey: Six key performance indicators 
(KPIs) were identified, and a five-point Likert scale was 
used to gauge the patient satisfaction. More than 1,100 
patients were asked to grade their experience on a 
scale of one to five, , with five signifying a very positive 
experience.
Oral cancer screening: Addressing the global burden 
of oral cancer, Biocon Foundation has formed an Oral 
Cancer Task Force composed of eminent national 
oncologists in 2018, with the objective of downstaging 
oral cancer through preventive and promotive efforts 
on ground leveraging on research, advocacy and use of 
28%
NCDs
5%
Gastrointestinal
4%
Anaemia
2%
ENT
2%
Skin
10%
Others
23% 
Infectious
19%
Pregnancy
7%
Musculoskeletal
NCDs and 
infectious diseases 
account for 51% 
of all conditions
Conditions (eLAJ Dashboard)
Breakup by Category
appropriate technologies. This Task Force has developed 
clear guidelines for the management of head and neck 
cancer. It aims to develop a strategy to downstage oral 
cancer in India over the next decade.  
As part of our oral cancer-screening program, the 
Foundation organized screening camps in partnership 
with KLE Society’s Institute of Dental Sciences (KLESIDS) in 
and around Bengaluru and Homi Bhabha Cancer Hospital 
in Varanasi.
Our mobile phone-based health technology platform 
captures data and intra-oral images of patients for 
recognizing the symptoms and signs of oral cancer in 
high-risk groups. The Foundation has built extensive field 
experience in early oral cancer screening, strengthening 
the initiative through a mobile health-based (mHealth) 
approach that equips the staff with smartphones to 
examine people in low-resource settings.
Our mHealth platform innovation supports early 
detection and management of oral precancerous lesions. 
The asymptomatic attribute of oral cancer in the early 
stages results in delayed presentation and late-stage 
diagnosis, and therefore, high morbidity and mortality. 
In a secure network, the mobile application creates a 
robust electronic health record, which includes intra-oral 
image-based data for active treatment and surveillance. 
The frontline health workers are trained for oral cancer 
prevention, early detection; and subsequent referral with 
the help of remote specialists, even in settings, where 
health resources are generally scarce. Our efforts through 
the platform were recognized by the CSR Journal as one 
of the ‘Top CSR initiatives for cancer prevention and early 
detection on National Cancer Awareness Day 2021.
| ESG Report 2022
68

Health clinics: 
Biocon Foundation also operates clinics that provide 
specialist diagnostic, management, and counseling on 
a range of issues including women and child health, 
nutrition, NCDs and comorbidities. 
•	 NCD Clinics to diagnose and manage type 2 diabetes 
and hypertension
•	 Geriatric Clinics for elderly health issues, including 
chronic health conditions
•	 The Well Woman Clinics provide services to deal 
with issues related to sexual and reproductive 
health, nutrition, diet related NCDs (diabetes and 
hypertension), common cancers and others
A cancer treatment beneficiary 
from Varanasi
Cancer was a scary word for me. I never thought that even 
consuming paan (betel leaves) with areca nuts could cause 
oral cancer, until I attended a screening organized by the 
Biocon Foundation and Homi Bhabha Cancer Hospital.
I was initially hesitant to undergo screening, but a counseling 
session helped me realize the significance of screening. 
The doctors identified white patches in my mouth, which 
were symptoms of oral cancer. I was explained that it was 
a precancerous lesion, which could turn into cancer if not 
treated.
I panicked and couldn’t come to terms with the fact that I had 
been diagnosed with cancer. Since I was struggling to repay 
the auto loan, I couldn’t think of ways to afford the treatment. 
It was so comforting to know that it was curable because the 
cancer was detected at an early stage and treatment would 
be provided free of cost. The screening, which I was hesitant 
to attend earlier, changed my perception about health and 
life. The cessation counseling helped me overcome my habit. I 
am extremely grateful to the organizations for taking up such 
a noble initiative to save the lives of people like me. I want to 
thank the entire team for being so compassionate and patient 
with me.
•	 The Well Baby Clinics to improve local access to 
cures for common childhood illnesses and to address 
malnutrition
•	 Support in augmenting the COVID-19 care infrastructure 
at the Anekal General Hospital in Bangalore. 
In FY22, our outreach has expanded to 14,000 patients 
who have benefited from the services of these clinics. 
Mazumdar-Shaw Advanced Research Center 
The former Vice-Chairman of Biocon, John Shaw, along 
with Kiran Mazumdar -Shaw, our Executive Chairperson, 
have been honored by University of Glasgow by having 
the University’s new research center named after them. 
The Mazumdar-Shaw Research Centre will be home to 
over 500 researchers, spanning across various disciplines 
with far reaching impacts. Their contribution of ` 580 
million in 2019 has been used to set up a new research 
hub within the University campus and create a Professor 
Chair, the Mazumdar-Shaw Chief of Molecular Pathology.
Environmental sustainability
Reviving Hebbagodi lake
In 2018, we executed a three-step bioremediation process 
using advanced technologies and implementing innovative 
solutions to revive the Hebbagodi lake. We installed trash 
barriers and bar screens to stop floating matter from 
entering the water body. In addition, we placed floating 
wetlands and also installed energy efficient cascading 
aerators and submersible mixers to increase dissolved 
oxygen and reduce sludge in the water. We have been 
regularly carrying out bioremediation to treat the organic 
pollutants. As a result of these concerted efforts, we 
successfully restored the ecosystem of the dying 35-acre 
Hebbagodi lake. 
Regular water quality audits are carried out by NABL 
accredited laboratories, through sample collection and 
analysis from various points around the lake. In the 
year 2017, pre-intervention assessment of water quality 
suggested that several parameters indicative of chemical, 
physical, and biological properties were abysmally poor. 
The higher COD, BOD & TDS represented the greater levels 
of water pollution and the environmental concern. Nil DO 
concentration was indicative of lack of aerobic aquatic 
life. Water quality was calculated as per the National 
Biocon Limited
TransformAction | 69

Sanitation Foundation Water Quality Index. A comparison 
between the pre-and post-intervention levels of COD, 
BOD, TDS, Nitrates and DO after our intervention 
showed a significant improvement in the water quality. 
Between 2017 to 2022, we have spent over ` 82 million 
towards the Hebbagodi lake rejuvenation project.
Despite the challenges presented by the pandemic, our 
efforts towards lake revival and maintenance continued 
unabated to prevent the waterbody from any degradation. 
We also undertook a series of activities along with the local 
community, to augment awareness towards protection of 
the lake.
Hebbagodi Metro project:
In 2020, the Biocon Foundation partnered with the 
Bengaluru Metro Rail Corporation Limited (BMRCL) to 
finance the construction of a metro station at Hebbagodi in 
Anekal Taluk, Bengaluru. We pledged to contribute ` 650 
million to fund the construction of the Hebbagodi Metro 
Station on Hosur Road and in FY22, over ` 32 Million  
was invested in this project by both Biocon Biologics and 
Biocon respectively.
The Hebbagodi Metro Station is part of the new 
18.82 km line from R V Road to Bommasandra, being 
constructed under Phase II of the Bengaluru Metro Rail 
Project. In recognition of our efforts, the Government of 
Karnataka issued an order in December 2020, renaming 
Hebbagodi Metro Station to ‘Biocon Hebbagodi Metro 
Station’ for a period of 30 years. Once operational, the 
metro line is expected to see an average daily ridership 
of over millions of passengers, thereby reducing traffic 
congestion and helping in lowering the environmental 
impact from vehicular pollution.  
Minsk Square landscaping: 
To restore a historically important site at Minsk Square, 
we initiated a project to create an urban green space at 
the heart of Bengaluru. The landscape design comprises 
hard-scape and soft-scape features. Phase I of the 
project, covering an area of 460 square meter, has been 
completed. The project will aim to plant 4,500 square feet 
with 20 varieties of more than 4,000 shrubs, deploying 
drip irrigation techniques.
Rural development
We work with partners in rural India and join hands with 
like-minded organizations to help improve the quality of 
learning outcomes. In FY21, we invested to build new 
buildings at the government higher primary schools in 
Huskuru, Bengaluru and Sira, Tumkuru. The improved 
infrastructure will provide an enabling environment to 
the students and is expected to positively influence the 
learning outcomes. Additionally, the school infrastructure 
project enabled 500 students to avail access to quality 
infrastructure. 
Regular engagements and interactions among the local 
communities has created a support network across various 
geographies in Karnataka. We also undertake Baseline 
studies and Focus Group discussions to understand the 
needs and challenges of the communities.
Covid-19 relief 
During the reporting period, we undertook the  
responsibility of augmenting the COVID-19 care 
infrastructure at the Anekal General hospital and 
supported the Government in its pandemic response 
efforts across other Primary Health Centres. With resources 
being diverted towards pandemic management, our 
health interventions addressed the need for prevention, 
screening, and control of common NCDs such as 
hypertension, diabetes, and common cancer. Our support 
in setting up the infrastructure stands to benefit over 
60,000 patients who annually use the hospital facilities. 
“We 
were 
conducting 
classes 
in 
an 
old 
and  
dilapidated school building, where walls and ceilings 
had developed cracks, posing a risk to the lives of the 
students. Our teachers and students thank the Biocon 
Foundation for reconstructing our school despite the 
challenges posed by COVID-19. The infrastructure 
has created a safe and fearless learning environment. 
As the students return to school, they are going to 
experience a friendly and conducive ambience.” 
- Srinivasamurthy R, Headmaster, Government Higher 
Primary School, Huskuru
| ESG Report 2022
70

Biocon Academy
The Biocon Academy is committed to building an 
ecosystem for biotech related skills in India. We help 
create an enabling environment that molds everyone into 
highly capable, forward-looking self-starters, equipped 
with the skills, experience and knowledge to move 
India forward. Since November 2013, over 700 people 
have received rigorous academic learning and world 
class industrial training on applied aspects of various 
life sciences disciplines at the Biocon Academy, and all 
of them have earned placements in some of the top 
biotech companies in India. The programs we offer aim 
to empower biotechnology and engineering graduates. 
Through the Biocon Academy, we partner with esteemed 
international education institutions such as Keck Graduate 
Institute, California, to deliver industry-oriented training 
programs for biotech students.
To enrich student experience and learning outcomes, 
we continue to implement innovative learning methods 
such as industry-oriented case study discussions and 
comprehensive project-based learning programs. We have 
now launched a unique program in Global Regulatory 
Affairs (GRA) in partnership with the JSS Academy of 
Higher Education and Research (JSS AHER), Mysuru. 
This program is exclusively structured for students to 
develop knowledge on various regulatory practices, 
clinical development processes, submission of filings, 
regulation for drugs, biologics, and medical devices. 
In addition to partly funding the course fees, we sponsor 
facilities such as meals and transportation, which enable 
students to retain their focus on their training. 
During FY22, 120+ students successfully graduated 
from the Academy and found jobs with leading biotech 
and biopharma companies in India including the Biocon 
Group-Bangalore, Chennai, Vizag and Hyderabad, 
Dr. Reddy’s Labs, Hetero Drugs-Hyderabad; Intas 
Biopharma-Ahmedabad and Baxter- Gurugaun. We are 
proud to have maintained a 100 percent placement 
record in leading biotech and biopharma companies, 
including Biocon. 
In addition to developing a talent pool for the industry, 
we are empowering many faculty members of the 
universities and colleges by imparting industry training in 
biopharmaceutical technologies. We are working closely 
with the Karnataka Science and Technology Academy 
(KSTA), Association of Biotechnology Led Enterprises 
(ABLE) and Biotecnika to organize joint webinars and 
seminars, promoting biotechnology initiatives across the 
country. Over 20 faculty members from more than 10 
universities and colleges across India and Malaysia also 
received training under the Biocon Academy Certificate 
Program in Faculty Development. For our efforts, 
we were awarded the ‘Smart Bio Award’ in 2021 by 
the Government of Karnataka under the ‘Best Social 
Enterprise/Institute’ category.
Biocon Limited
TransformAction | 71

ESG Scorecard
Economic Performance: 
Biocon Total refers to Biocon and Biocon Biologics (India and Malaysia).
*Syngene is not included
Economic Value Generated
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Total Revenue
₹ Million 
51,114
56,849
Economic Value Distributed and Retained
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Total Operating cost
₹ Million
29,518
34,648
Total employee related expenses (salaries + benefits)
₹ Million
10,808
11,620
Payments to providers of capital
₹ Million
0
0
Payment to government
₹ Million
1,220
1,367
Community investments
₹ Million
97
114
Economic Value Retained
₹ Million 
9,471
9,100
Data includes consolidated value excluding Syngene
Philanthropic Contributions
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
CSR expense
₹ Million
98.6
113
Charitable donations
% of total CSR spend
12
0
Community Investments
% of total CSR spend
88
100
Political contributions
₹ Million 
0
0
Research and Development
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Research & Development spending
$ Million
75.56
78.37
Research & Development spending
₹ Million
5,531
5,950
R&D spending as percentage of Sales
% 
11.23
11
No. of R&D positions
No. 
721
1,057
| ESG Report 2022
72

Fines/Settlements/Complaints
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Fines or settlements related to Anti-competitive practices
₹ 
0
0
Ongoing investigations related to anti-competitive practices
No.
None
None
Confirmed cases of Corruption & Bribery
No.
1
0
Current involvement in any ongoing corruption 
and bribery cases
No.
None
None
Contributions to and spending for political campaigns, 
political organizations, lobbying, trade associations, 
tax-exempt entities
₹
0
0
No. of incidents of discrimination and harassment
No.
1
5
No. of complaints related to Child labour/Forced labour/
Involuntary labour
No.
0
0
Class I product recalls
No.
0
1
Class II product recalls
No.
0
0
Regulatory agency inspections
No.
4
6 
Complaints concerning breaches of customer privacy and 
losses of customer data
No. 
0
0
Material Consumption
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Raw materials
tonnes/annum 
23,445
21,859
Associated materials
tonnes/annum
6,536
6,164
Semi-manufactured materials
tonnes/annum
187
-
Packaging materials
tonnes/annum
84
132
Environmental Performance* 
Biocon Limited
TransformAction | 73

Energy Consumption
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Natural Gas
MWh
201,198
226,790
Diesel 
MWh
16,492
22,755
Furnace oil 
MWh
233
0
Coal
MWh
9,782
11,192
Wood Chips*
MWh
1,581
1,665
HSD*
MWh
212
206
LPG*
MWh
2,083
1,546
Total Direct Energy
MWh
231,581
264,154
Electricity purchased (from non-renewable sources)
MWh
141,700
137,200
Electricity purchased (renewable sources)
MWh
95,000
110,000
Total Indirect Energy
MWh
236,700
247,200
Electricity purchased (renewable sources)
MWh
95,000
110,000
Biomass based Energy*
MWh
1,581
1,665
Total Renewable Energy
MWh
96,581
111,665
*Only BBL Malaysia
GHG Saving Initiatives^
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Green power (purchased)
tCO2
85,500
99,000
Furnace oil offset due to natural gas use in steam in boiler
tCO2
15,730
17,045
Boiler economiser induced natural gas savings
tCO2
1,362
1,652
Total carbon footprint reduction
tCO2
102,592
117,697
GHG emissions
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Scope 1: Direct emissions
tCO2
55,997
62,253
Scope 2: Indirect emissions
tCO2 
127,530
123,480
Total GHG emissions
tCO2 
183,527
185,733
GHG emission intensity
tCO2 eq/Revenue in 
Million ₹*
3.59
3.27
* Exchange rate used: INR 77.77 to USD 1 
^ BL+BBL India Operations’
| ESG Report 2022
74

Emissions of ozone-depleting substances (ODS)
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
HCFC-22 or R-22
tonnes
0.15
0.7
Air Pollutant Management
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Particulate matter (PM)
tonnes/annum
19.20
31.2**
Nitrogen Oxide (NOx)
tonnes/annum
0.60
0.76**
Sulfur Oxide
tonnes/annum
13.58
9.4**
*Excludes BBL Malaysia 
**BBL Malaysia: PM, NOx and SOx levels are monitored and are within the regulatory limit
Water Sourcing and discharge
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Municipal water supplies (or from other water utilities)
million m3
1.74
1.71
Fresh surface water (lakes, rivers, etc.)
million m3
0.00
0
Fresh groundwater
million m3
0.00
0
Total Withdrawal
million m3
1.74
1.71
Discharge post treatment
million m3
0
0
Treated wastewater recycled
%
100
100
*2 Sites in India (Hyd and Vizag) and Biocon Malaysia send wastewater to Common Effluent treatment plant (CETP) for further treatment
Waste generation and disposal and method*
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Hazardous 
MT
17,147
24,748
Authorised BMW waste handler
MT
30
160
Authorised disposal agency
MT
1,059
8,548
Authorised e-waste recycler
MT
3
10
Authorised recycler
MT
10,109
10,463
Authorised reprocessor
MT
23
157
Authorised TSDF
MT
4,868
4,774
incineration/co-processing
MT
1,056
628
*BL and BBL (India+Malaysia)
Biocon Limited
TransformAction | 75

Social Performance
Employee Information
Category
Employees
Unit Biocon Total (FY21) Biocon Total (FY22)
Senior management (L12+)
Male
No.
124
137
Female
No.
19
20
<30
No.
0
0
30-50
No.
88
103
>50
No.
55
54
Middle management (L5-11)
Male
No.
2,910
3,107
Female
No.
466
525
<30
No.
143
218
30-50
No.
3,105
3,322
>50
No.
128
92
Junior management (L1-L4)
Male
No.
3,784
4,014
Female
No.
869
986
<30
No.
2,518
3,034
30-50
No.
2,114
1,955
>50
No.
21
11
Contractual employees
Male
No.
1,611
1,687
Female
No.
460
469
<30
No.
1,001
948
30-50
No.
1,087
1,131
>50
No.
69
77
Waste generation and disposal and method*
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Non-Hazardous
MT
9,735
11,154
Authorised disposal agency
MT
1,351
-
Authorised recycler
MT
220
1,843
Composting
MT
88
0
Co Processing
MT
5,929
7,153
Recycling or reuse
MT
2,147
2,158
*BL and BBL (India+Malaysia)
| ESG Report 2022
76

New Employee Hires
Category
Employees
Unit Biocon Total (FY21) Biocon Total (FY22)
Senior management (L12+)+)
Male
No.
52
34
Female
No.
12
4
<30
No.
0
0
30-50
No.
50
26
>50
No.
14
12
Middle management (L5-11)
Male
No.
571
713
Female
No.
97
168
<30
No.
58
135
30-50
No.
607
739
>50
No.
3
7
Junior management (L1-L4)
Male
No.
287
1,465
Female
No.
52
422
<30
No.
228
1586
30-50
No.
105
301
>50
No.
6
0
Employee Turnover
Category
Employees
Unit Biocon Total (FY21) Biocon Total (FY22)
Senior management (L12+)
Male
No.
17
34
Female
No.
3
5
<30
No.
0
0
30-50
No.
12
28
>50
No.
8
11
Middle management (L5-11)
Male
No.
302
709
Female
No.
66
149
<30
No.
15
80
30-50
No.
342
761
>50
No.
11
17
Junior management (L1-L4)
Male
No.
522
1,028
Female
No.
120
265
<30
No.
373
799
30-50
No.
268
491
>50
No.
1
3
Biocon Limited
TransformAction | 77

Trainings Man Hours
Total Training Hours by Grade
Average Training Hours by Grade
Category
FY21
FY22
FY21
FY22
Senior management (L12+)
1,375
1,557
9.62
10.52
Middle management (L5-11)
91,861
67,366
27.21
18.64
Junior management (L1-L4)
159,957
109,341
34.38
21.95
Total
253,193
178,264
31
20.40
Workforce Breakdown: Gender
Category
Unit Biocon Total (FY21) Biocon Total (FY22)
No. of women in total permanent workforce
No.
1,354
1,531
Percentage of women in total permanent workforce (as % of 
total permanent workforce)
%
17%
17%
No. of women in top management positions, i.e. maximum 
two levels away from the CEO or comparable positions
No.
2
4
Percentage of women in top management positions, i.e. 
maximum two levels away from the CEO or comparable 
positions (as % of total top management positions)
%
0.02%
0.05%
Total Training Hours by Gender
Average Training Hours by Gender
Gender
Unit
FY21
FY22
FY21
FY22
Male
Hours
219,108
131,223
32
17
Female
Hours
34,538
47,559
26
26
Parental Leave*
FY 2020-21 
FY 2021-22
Category
Unit
Biocon, 
India 
Biocon 
Biologics, 
India
Biocon, 
India
Biocon 
Biologics, 
India
Employees entitled for maternity leave
No.
351
702
486
813
Employees that took maternity leave
No.
18
30
25
28
Employees that returned to work in the reporting 
period after maternity leave ended
No.
16
13
21
24
Employees that returned to work after maternity  
leave ended that were still employed 12 months after 
their return to work
No.
14
13
21
24
Rate of Return to work that took maternity leave
%
89%
100%
84%
86%
Retention rates of employees that took maternity  
leave
%
0
0
0
0
*Parental leave includes maternity leaves only
| ESG Report 2022
78

Suppliers and Procurement spend
Category
Unit
Biocon Total (FY21) Biocon Total (FY22)
Total Suppliers
No.
1,308
1,194
Critical suppliers
No.
304
296
Non-Critical Suppliers
No.
1,004
898
Total Procurement spend
Million ₹ 
17,870
20,700
Procurement spend on Critical Suppliers
Million ₹
16,250
18,120
Procurement spend on Non-Critical Suppliers
Million ₹
1,620
2,580
Procurement spend on locally based suppliers
Million ₹
4,210
5,520
Procurement spend on locally based suppliers(%)
%
24%
27%
No of Tier 1 suppliers identified for sustainability high-risk
No.
0
0
No of Non-Tier 1 suppliers identified for sustainability high-risk
No.
0
0
Health and Safety
Biocon Total (FY21)
Biocon Total (FY22)
Category
Unit
Biocon Total
Biocon Total
Fatalities
No.
0
0
Near miss incidents
No.
47
96
Occupational disease cases
No.
0
0
Man hours worked
No.
24,627,456
24,454,656
Total working days scheduled to be worked by the 
workforce
No.
288
288
Injuries (Total)  
Note: Only lost time injuries will be considered here. 
As per internal classification
No.
53
37
Lost time injury frequency rate (LTIFR)
Rate
2.15
1.51
Biocon Limited
TransformAction | 79

Benefits provided to Permanent employees and Temporary 
employees*
Biocon Total (FY22)
Category/Types of benefits provided
Permanent Employees
Contractors 
Life insurance
Yes
No
Health insurance
Yes
Yes (for those who are not 
covered under ESIC)
Accident insurance
Yes
Yes (covered under ESIC)
Parental Medical Insurance (including paternity leave option 
from Biocon Biologics, Malaysia)
Yes
Yes (covered under ESIC)
Disability
Yes
Yes (covered under ESIC)
Parental leave (**maternity leave or paternity leave)
Yes
Yes 
Marriage leave (additional to Normal leaves allotted)
No
No
Bereavement leave (additional to Normal leaves allotted)
Yes
No
Leave for Haj (additional to Normal leaves allotted)
No
No
Leave for Baptism (additional to Normal leaves allotted)
No
No
Leave for Circumcision Ceremony (additional to Normal leaves 
allotted)
No
No
Retirement provision
No
No
Stock ownership
*Yes
No
Transportation
Yes
Yes
Housing
No
No
Food allowance
Yes
Yes
Extra paid holidays
Yes
Yes
Citizenship leave
No
No
Children Education Reimbursement
Yes
No
Higher Education Policy
Yes
No
Day care facilities
Yes
Yes
Employee Car Scheme policies
Yes
No
*For select cadres of employees 
**Maternity, surrogacy and adoption
| ESG Report 2022
80

GRI Standards Index
GRI Classification References
Classification
GRI Standards
Disclosures
Report Section/ 
Chapters
GRI index 
(reference pages)
Organizational 
Profile
102-1
Name of the organization
About the Report
4
102-2
Activities, brands, 
products & services
Our Transformative story
6-9
102-3
Location of headquarters
Our Transformative story
6-8
102-4
Location of operations
Our Transformative story
6-8
102-5 Ownership and legal form
About the Report
4
102-6
Markets served
Our Transformative story
6-9
102-7
Scale of the organization
Our Transformative story
6-9
102-8 Information on employees 
and other workers
Transforming  
the workplace
46-49
102-9
Supply chain
Partnership in Action,  
ESG Scorecard
40-44, 79
102-10
Significant changes to 
the organization and its 
supply chain
Partnership in Action
40-44
102-11
Precautionary Principle  
or approach
Governance in action
30-37
102-12
External Initiatives
Transformation progress 
in action
20-23
102-13
Membership of 
associations
Partnership in action
40-43
Strategy
102-14
Statement from Senior 
decision maker
Statements from  
the Leadership
10-18
102-15
Key impacts, risks, and 
opportunities
Transformational progress 
in Action
20-23
Ethics and 
Integrity
102-16
Values, principles, 
standards, and norms  
of behaviour
Governance in Action
31-37
102-17
Mechanisms for advice 
and concerns about ethics
Governance in Action
31-37
Governance
102-18
Governance structure
Governance in Action
31-37
102-19
Delegating authority
Governance in Action
31-37
102-20
Executive-level 
responsibility for 
economic, environmental, 
and social topics
Our Transformative story
6-8
Biocon Limited
TransformAction | 81

GRI Classification References
Classification
GRI Standards
Disclosures
Report Section/ 
Chapters
GRI index 
(reference pages)
Governance
102-21
Consulting stakeholders 
on economic, 
environmental, and social 
topics
Materiality assessment 
and stakeholder 
engagement
37
102-22
Composition of the 
highest governance body 
and its committees
Governance in Action
31-37
102-23
Chair of the highest 
governance body
Governance in Action
31-37
102-24
Nominating and selecting 
the highest governance 
body
Governance in Action
31-37
102-25
Conflicts of interest
Governance in Action
31-37
102-26
Role of highest 
governance body in 
setting purpose, values, 
and strategy
Governance in Action
31-37
102-27
Collective knowledge of 
highest governance body
Governance in Action
31-37
102-28
Evaluating the highest 
governance body’s 
performance
Governance in Action
31-37
102-29
Identifying and managing 
economic, environmental, 
and social impacts
Governance in Action
31-37
102-30
Effectiveness of risk 
management processes
Governance in Action
31-37
102-31
Review of economic, 
environmental, and social 
topics
Governance in Action
31-37
102-32
Highest governance 
body’s role in 
sustainability reporting
Governance in Action
31-37
102-33
Communicating critical 
concerns
Governance in Action
31-37
102-35
Remuneration policies
Governance in action
31-35
102-36
Process for determining 
remuneration
Governance in action
31-35
102-37
Stakeholders Involvement 
in remuneration
Governance in action
31-35
| ESG Report 2022
82

GRI Classification References
Classification
GRI Standards
Disclosures
Report Section/ 
Chapters
GRI index 
(reference pages)
Stakeholder 
Engagement
102-40
List of stakeholder groups
Materiality assessment 
and stakeholder 
engagement
37
102-42
Identifying and selecting 
stakeholders
Materiality assessment 
and stakeholder 
engagement
37
102-43
Approach to stakeholder 
engagement
Materiality assessment 
and stakeholder 
engagement
37
102-44
Key topics and concerns 
raised
Materiality assessment 
and stakeholder 
engagement
37
Reporting 
Practice
102-45
Entities included in the 
Total financial statements
About the Report
4
102-46
Defining report content 
and topic boundaries
About the Report
4
102-47
List of material topics
Materiality assessment 
and stakeholder 
engagement
37
102-48
Restatements of 
information
NA
-
102-49
Changes in reporting
About the Report
4
102-50
Reporting period
About the Report
4
102-51
Date of most recent 
report
About the Report
4
102-52
Reporting cycle
About the Report
4
102-53
Contact point for 
questions regarding the 
report
About the Report
4
102-54
Claims of reporting in 
accordance with the GRI 
Standards
About the Report
4
102-55
GRI content index
GRI Index
81
102-56
External assurance
NA
-
Management 
Approach
103-1
Explanation of the 
material topic and its 
boundary
About the Report
4
103-2
The management 
approach and its 
components
About the Report
4
Biocon Limited
TransformAction | 83

GRI Classification References
Classification
GRI Standards
Disclosures
Report Section/ 
Chapters
GRI index 
(reference pages)
GRI 200 Economic Standard Series
Economic Performance
Indirect Economic Impact
GRI 201: 
Economic 
Performance
201-1
Direct economic value 
generated and distributed
ESG Scorecard
72
201-3
Defined benefit plan 
obligations and other 
retirement plans
ESG Scorecard
80
Procurement Practices
GRI 204: 
Procurement 
Practices
204-1
Proportion of spending 
on local suppliers
ESG Scorecard
79
Anti-corruption
GRI 205: Anti-
corruption
205-1
Operations assessed for 
risks related to corruption
Governance in Action
35
205-2
Communication and 
training about anti-
corruption policies and 
procedures
Governance in Action
35
205-3
Confirmed incidents of 
corruption and actions 
taken
ESG Scorecard
73
Anti-competitive Behavior
GRI 206: Anti-
competitive 
Behavior
206-1
Legal actions for anti-
competitive behavior, 
antitrust, and monopoly 
practices
Governance in action,ESG 
Scorecard
35, 73
GRI 300 Environmental Standards Series
Materials
GRI 301: 
Materials
301-1
Materials used by weight 
or volume
ESG Scorecard
73
Energy
GRI 302: Energy
302-1
Energy consumption 
within the organization
ESG Scorecard
73
302-3
Energy intensity
ESG Scorecard
73
Water
GRI 303: Water
303-1
Water withdrawal by 
source
ESG Scorecard
75
303-2
Water sources 
significantly affected by 
the withdrawal of water
ESG Scorecard
75
303-3
Water recycled
ESG Scorecard
75
| ESG Report 2022
84

GRI Classification References
Classification
GRI Standards
Disclosures
Report Section/ 
Chapters
GRI index 
(reference pages)
Emissions
GRI 305: 
Emissions
305-1
Direct (Scope 1) GHG 
emissions
ESG Scorecard
74
305-2
Energy indirect (Scope 2) 
GHG emissions
ESG Scorecard
74
305-4
GHG emissions intensity
ESG Scorecard
74
305-5
Reduction of GHG 
emissions
Responsible action 
towards environment
63
305-7
Nitrogen oxides (NOX), 
sulfur oxides (SOX), 
and other significant air 
emissions
ESG Scorecard
75
Effluents and Waste
GRI 306: 
Effluents and 
Waste
306-1
Water discharge by 
quality and destination
Responsible action 
towards environment, 
ESG Scorecard
58-64, 75
306-2
Waste by type and 
disposal method
ESG Scorecard
75-76
305-5
Water bodies affected by 
water discharges and/or 
runoff
Responsible action 
towards environment
58-64
Environmental Compliance
GRI 307: 
Environmental 
Compliance
307-1
Non-compliance with 
environmental laws and 
regulations
Responsible action 
towards environment
58-64
Supplier Environmental Assessment
GRI 308: 
Supplier 
Environmental 
Assessment
308-1
New suppliers that 
were screened using 
environmental criteria
Responsible action 
towards environment, 
ESG Scorecard
58-64, 79
GRI 400 Social Standards Series
Employment
GRI 401: 
Employment
401-1
New employee hires and 
employee turnover
ESG Scorecard
76-77
401-2
Benefits provided to 
full-time employees 
that are not provided to 
temporary or part-time 
employees
ESG Scorecard
80
401-3
Parental leave
ESG Scorecard
78
Biocon Limited
TransformAction | 85

GRI Classification References
Classification
GRI Standards
Disclosures
Report Section/ 
Chapters
GRI index 
(reference pages)
Occupational Health and Safety
GRI 403: 
Occupational 
Health and 
Safety
403-1
Workers representation 
in formal joint 
management–worker 
health and safety 
committees
Transforming our 
workplace
55-56
403-2
Types of injury and rates 
of injury, occupational 
diseases, lost days, and 
absenteeism, and number 
of work-related fatalities
Transforming our 
workplace, ESG Scorecard
55-56, 79
403-3
Workers with high 
incidence or high risk of 
diseases related to their 
occupation
Transforming our 
workplace, ESG Scorecard
55-56, 79
Training and Education
GRI 404: 
Training and 
Education
404-1
Average hours of training 
per year per employee
ESG Scorecard
78
404-2
Programs for upgrading 
employee skills and 
transition assistance 
programs
Transforming our 
workplace
46-56
404-3
Percentage of employees 
receiving regular 
performance and career 
development reviews
Transforming our 
workplace
48-49
Diversity and Equal Opportunity
GRI 405: 
Diversity 
and Equal 
Opportunity
405-1
Diversity of governance 
bodies and employees
Governance in Action
31-35
Non-Discrimination
GRI 406: Non- 
Discrimination
406-1 Incidents of discrimination 
and corrective actions 
taken
ESG Scorecard
73
Child Labor
GRI 408: Child 
Labor
408-1
Operations and suppliers 
at significant risk for 
incidents of child labor
Partnership in Action, ESG 
Scorecard
40-44, 79
| ESG Report 2022
86

GRI Classification References
Classification
GRI Standards
Disclosures
Report Section/ 
Chapters
GRI index 
(reference pages)
Forced or Compulsory Labor
GRI 409: Forced 
or Compulsory 
Labor
409-1
Operations and suppliers 
at significant risk for 
incidents of forced or 
compulsory labor
Partnership in Action, ESG 
Scorecard
40-44, 79
Human Rights Assessment
GRI 412: 
Human Rights 
Assessment
412-1
Operations that have 
been subject to human 
rights reviews or impact 
assessments
Governance in action ESG 
Scorecard
30-35, 73
412-2
Employee training on 
human rights policies or 
procedures
Governance in action
34
Local Communities
GRI 413: Local 
Communities
413-1
Operations with local 
community engagement, 
impact assessments, and 
development programs
Transforming our 
communities
66-71
413-2
Operations with 
significant actual and 
potential negative impacts 
on local communities
Transforming our 
communities
66-71
Supplier Social Assessment
GRI 413: 
Supplier Social 
Assessment
414-1
New suppliers that were 
screened using social 
criteria
Partnership in Action, ESG 
Scorecard
40-44, 79
Public Policy
GRI 415: Public 
Policy
415-1
Political contributions
ESG Scorecard
72
Customer Health and Safety
GRI 416: 
Customer Health 
and Safety
416-1
Assessment of the health 
and safety impacts of 
product and service 
categories
Transforming the 
workplace
73
416-2
Incidents of non-
compliance concerning 
the health and safety 
impacts of products and 
services
Transforming the 
workplace, ESG Scorecard
 73
Biocon Limited
TransformAction | 87

GRI Classification References
Classification
GRI Standards
Disclosures
Report Section/ 
Chapters
GRI index 
(reference pages)
Marketing and Labeling
GRI 417: 
Marketing and 
Labeling
417-1
Requirements for product 
and service information 
and labeling
Our Transformative story
6-7
417-2
Incidents of non-
compliance concerning 
product and service 
information and labeling
ESG Scorecard
73
417-3
Incidents of non-
compliance 
concerning marketing 
communications
ESG Scorecard
73
Customer Privacy
GRI 418: 
Customer 
Privacy
418-1
Substantiated complaints 
concerning breaches of 
customer privacy and 
losses of customer data
ESG Scorecard
73
| ESG Report 2022
88

BRSR Index
Corporate Identity Number (CIN) of the Listed Entity
L24234KA1978PLC003417
Name of the Listed Entity 
Biocon Limited
Year of incorporation 
1978
Registered office address 
20th KM Hosur Road, Electronic City, Bengaluru – 560 100, 
India
Corporate address
20th KM Hosur Road, Electronic City, Bengaluru – 560 100, 
India
E-mail 
co.secretary@biocon.com
Telephone
+91 80 2808 2808 /
+91 80 4014 4014
Website
www.biocon.com
Financial year for which reporting is being done
FY 2021-22
Name of the Stock Exchange(s) where shares are listed
BSE Limited
National Stock Exchange of India Limited
Paid-up Capital
INR 600,30,00,000 
Name and contact details (telephone, email address) of the 
person who may be contacted in case of any queries on the 
BRSR report
Mr. Mayank Verma
Email: co.secretary@biocon.com
Reporting boundary 
Are the disclosures under this report made on a standalone basis 
(i.e. only for the entity) or on a consolidated basis (i.e. for the 
entity and all the entities which form a part of its consolidated 
financial statements, taken together).
The reporting boundary for this BRSR Report includes Biocon 
Limited (BL) and Biocon Biologics Limited (India and Malaysia) 
(BBL), excluding Syngene International, for the period 
from 1st April, 2021 to 31st March, 2022. The entities will 
collectively be referred to as the ‘Company’ for the length of 
this report, unless specified otherwise.
Section A: General Disclosures 
1. Details of the listed entity 
Biocon Limited
TransformAction | 89

Over 54% of the Company’s total revenue can be attributed to its earnings from exports.
(b) A brief on types of customers 
The Company is invested in cutting-edge science, key research partnerships and global manufacturing scale to expand its reach and 
develop products that address unmet patient needs. Its customers fall under two broad categories:
Healthcare providers 
The Company is focused on delivering high-quality therapies to partners and healthcare systems across the globe. 
It has leveraged its unique strength in fermentation technology to develop a differentiated portfolio of generic Active Pharmaceutical 
Ingredients (API) which are used in a variety of therapy areas, including cardiology, immunosuppressants, anti-diabetics, multiple 
sclerosis and cancer. The APIs developed by the Company have found application in high quality drugs that treat oncology, 
3. Operations 
3.1 Number of locations where plants and/or operations/offices of the entity are situated: 
Location 
Number of plants/offices 
Number of offices  
Total
National
3 Manufacturing Locations (1 plant - 
Bengaluru, 2 plants - Hyderabad, Vizag)
18
21
International 
United States of America, Switzerland, 
United Kingdom, United Arab Emirates, 
Brazil, Malta and Singapore
11
12
3.3 What is the contribution of exports as a percentage of the total turnover of the entity?
3.2. Markets served by the entity:
(a) Number of locations 
Please refer to page numbers 6 - 9 for information on the number of national and international locations the Company has offices/
operations.
*As per National Industrial Classification – Ministry of Statistics and Programme Implementationmedicinal chemical and botanical products
2.2. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover):
S. No. 
Product/Service 
NIC Code* 
% of total turnover contributed
1
Manufacture of pharmaceuticals, 
medicinal chemical and botanical products
021
100
*Research services of the Company are undertaken by subsidiary Syngene International Limited. Syngene is excluded from the remainder of this report.
2.1. Details of business activities (accounting for 90% of the turnover):
2. Products/services 
Please refer to page numbers 6 - 9 for an overview of the Company’s services which constitute over 90% of the turnover.*
| ESG Report 2022
90

cardiology, CNS and neurology, orthopedic, pulmonology, gastroenterology, nephrology  ophthalmology, and endocrinology 
conditions. The Company supplies statins, immunosuppressants, cardiovascular drugs and other APIs to over 100 countries and has 
accomplished 33 filings and received 14 approvals for APIs globally. 
Biocon operates its biosimilar business through its subsidiary Biocon Biologics Limited (BBL). We develop high-quality, affordable 
biosimilars that can expand access to cutting-edge therapeutics for patients globally at our R&D sites in Bengaluru and Chennai 
(India). These are manufactured at scale for both developed and emerging markets in Bengaluru (India) and Johor (Malaysia). 
Our products are marketed globally through a hybrid commercial model, wherein we have direct commercial presence in a few 
countries and in others, we leverage partners such as Viatris to expand patient reach.
Patients 
We discover, develop, and deliver affordable medicines that help transform patient lives. Patients’ health and wellbeing are our top 
priority. Our products are helping enhance the healthcare process in both developed and developing countries, furthering our goal 
of achieving health equity for all.
Our commitment is to deliver medicines to a vast proportion of people and ensure better patient outcomes.   Over the past 20 years, 
Biocon has leveraged India’s value advantage of scientific talent and advanced manufacturing to deliver scale, speed and quality 
that enabled affordable access to complex therapies for chronic conditions. Through our generics, biosimilars and novel biologics 
we have strengthened our value proposition to reflect our four strategic pillars: accessibility, affordability, availability, and assurance.
Our global portfolio of APIs has catered to over 700 pharma companies, with an impeccable track record of quality, safety, and 
reliability, for the past 20 years.
The Company’s biosimilar portfolio has benefitted over 5.3 million Patients worldwide in FY22. 
Biocon’s subsidiary Biocon Biologics has launched a special program, ‘Mission 10 cents,’ to offer governments of Low- and 
Middle-Income Countries (LMIC) (specifically in the Philippines and Tanzania) its products for less than 10 U.S. cents a day.
4.2. Differently abled Employees and workers
S. No
Particulars
Total 
(A)
Male
Female
No. (B)
% (B / A)
No. (C)
% (C / A)
Differently abled employees
1. 
Permanent (D)
2
2
100%
-
-
2. 
Other than 
Permanent (E) 
-
-
-
-
-
3. 
Total differently 
abled employees 
(D + E)
2
2
100%
-
-
4. Employees
For information on the employee force at the Company, please refer to page number 76 of this Report.
Note: The Company does not have any ‘Workers’ as defined in the guidance note on BRSR
Note: The Company does not have any ‘Workers’ as defined in the guidance note on BRSR
4.1 Details as at the end of Financial Year: Employees and workers (including differently abled):
*Data excludes BBL Malaysia numbers
Biocon Limited
TransformAction | 91

4.3. Participation/Inclusion/Representation of women 
Total
(A)
No. and percentage of Females
No. (B)
% (B / A)
Board of Directors*
9
2
22%
Key Management Personnel
4
1
25%
*Note: Dr. Kiran Mazumdar Shaw, Executive Chairperson and Mr. Siddharth Mittal, Managing Director & CEO, are members of the Board of 
Directors and are also considered Key Managerial Personnel.
5.1. Names of holding / subsidiary / associate companies / joint ventures 
Name of the holding / 
subsidiary / associate 
companies / joint ventures (A)
Indicate whether holding/ 
Subsidiary/ Associate/ 
Joint Venture
% of shares held by  
listed entity
Does the entity 
indicated at column A, 
participate in the Business 
Responsibility initiatives 
of the listed entity?  
(Yes/No)
The company is associated with 
22 entities
Of the 22 entities, 20 are 
subsidiaries while Bicara is 
an associate and Neo Biocon 
is a joint venture
The % of shares held by 
the Company is present in 
the independent financial 
statements.
https://archive.biocon.
com/biocon_invrelation_
subsidiary.asp
Yes, Biocon Academy (Non-
Profit company), subsidiary 
of the Company, participates 
in the BR initiatives of the 
Company.
5. Holding, Subsidiary and Associate Companies (including joint ventures)
6. CSR Details
(i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) -Yes
(ii) Turnover (in Rs.) - 17,382 Mn
(iii) Net worth (in Rs.) - 80,929 Mn
*Data for turnover and Net worth are standalone figures
4.4. Turnover rate for permanent employees  
Please refer to page number 48 & 77 of the Report for details on the turnover rate of the Company’s employees.
| ESG Report 2022
92

Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on 
Responsible Business Conduct:
Stakeholder 
group from whom 
complaint is 
received
Grievance 
Redressal 
Mechanism in Place 
(Yes/No) (If Yes, 
then provide web-
link for grievance 
redress policy) *
FY 2021-22
FY 2020-21
Number of 
complaints filed
during the year
Number of 
complaints 
pending 
resolution at 
close of the year
Number of 
complaints filed 
during the year
Number of 
complaints 
pending 
resolution at 
close of the year
Communities
Yes
0
0
0
0
Investors/
Shareholders
Yes
119
1
184
0
Employees and 
Workers 
Yes
1
0
2
0
Customers
Yes
0
0
0
0
Value Chain Partners 
Yes
0
0
0
0
Others (Please 
specify)
Yes
*4
0
0
0
7. Transparency and Disclosures Compliances 
**Please note complaints that were material and substantial have been considered.
The Company’s grievance redressal mechanism has been detailed in its process for complaint/grievance redressal  
- https://www.biocon.com/whistle-blower-integrity-policy/ 
* Whistleblowing complaints
Biocon Limited
TransformAction | 93

7.1. Overview of the entity’s material responsible business conduct issues 
Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters 
that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk 
along-with its financial implications, as per the following format
S. No.
Material issue 
identified
Indicate 
whether 
risk or 
opportunity 
(R/O)
Rationale for 
identifying the risk 
/ opportunity
In case of risk,  
approach to adapt or mitigate
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
1
Product 
quality
Risk
All pharmaceutical 
companies are 
constantly being 
evaluated on possible 
recalls, product safety 
concerns. 
We have implemented a system 
to ensure  quality of products and 
continuous compliance to regulatory 
requirements.
Additionally, through the 
pharmacovigilance process, Biocon 
tracks responses to actively address 
product related risks and continuously 
improve the products. 
A dedicated pharmacovigilance team 
tracks and reports complaints received 
via a purpose-built web portal. 
We also have a toll-free number, 
publicly available on the web portal 
for patients or other stakeholders 
to report complaints. All reports are 
proactively investigated to ensure 
that timely action is taken where 
necessary. 
Further, all employees undergo 
mandatory pharmacovigilance 
training.
Negative: 
In the case of poor 
product quality, 
Biocon can face 
reputational as well as 
operational damage. 
This may also lead 
to a decrease in 
customer satisfaction 
and trust.
2
Research and 
Development
Opportunity
R&D investment has 
a positive impact on 
green innovation 
ie: technologies 
which are developed 
to reduce the 
environmental 
impact and ESG 
performance of an 
enterprise. Therefore, 
strategically 
investing in R&D and 
disclosing publicly 
on its investments 
allows internal and 
external stakeholders 
to understand 
the approach and 
scale taken by an 
organization.
At Biocon, a key area of focus is 
‘Green Chemistry’ and we have 
implemented several initiatives for 
the same. These include transitioning 
from solvent based reactions to water 
based reactions, using harmless, 
greener solvents instead of hazardous 
solvents, enhancing our solvent 
recovery capabilities and overall, 
improving our processes to maximize 
the incorporation of all materials 
used.
Positive: 
Cutting edge 
technological 
innovations can 
place Biocon at the 
forefront of industry-
leading discoveries 
and open new 
avenues for business 
growth. 
| ESG Report 2022
94

S. No.
Material issue 
identified
Indicate 
whether 
risk or 
opportunity 
(R/O)
Rationale for 
identifying the risk 
/ opportunity
In case of risk,  
approach to adapt or mitigate
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
3
Access & 
affordability
Opportunity
Responsible pricing 
for innovative and 
generic medicines 
which take 
affordable access, 
positive cost-benefit 
ratio, and overall 
healthcare costs into 
consideration, have 
a high chance of  
impacting Biocon’s 
reach and favor 
amongst patients, 
as compared to 
competitors. 
At Biocon, our aim is to achieve 
health equity and believe that 
everyone, across the globe, has 
the right to access affordable and 
quality medicines. Through our 
generics, biosimilars and novel 
biologics businesses, we consistently 
work towards enhancing our value 
proposition and deliver best-in-class 
solutions to our patients.
Positive: 
Enabling access to 
affordable drugs 
and other services 
can support the 
reach and growth of 
Biocon, providing a 
competitive edge
4
Environmental 
performance
Risk
Biocon’s commitment 
towards protecting 
the natural 
environment and 
conserving resources 
has been embedded 
in our value system.
Upholding these 
principles and 
complying with 
applicable regulatory 
requirements can 
affect the overall 
performance and 
enhance Biocon’s 
image with the 
stakeholders. 
To limit the environmental impact of 
the operations, Biocon continuously 
strives to reduce the carbon footprint, 
recycle resources, transition to 
renewable energy, adopt responsible 
sourcing practices, drive productivity 
across the value chain and adopt 
digital solutions that reduce 
inefficiencies
For more details on the initiatives 
undertaken, please refer to: please 
refer to the chapter -  “Responsible 
Action towards Environment”
Negative: 
In the case of non-
compliance with 
environmental norms 
and regulations, 
Biocon can face 
reputational damage 
as well as well as 
adverse financial 
repercussions
Biocon Limited
TransformAction | 95

5
Safe & 
empowering 
workplace
Risk
As a responsible 
employer, it is our 
duty to create a 
safe and healthy 
workplace that is free 
of injuries, fatalities 
and illness. 
In addition to this, 
it is imperative to 
foster a conducive 
workplace that 
attracts and retains 
talent by enabling 
empowerment, 
growth, flexibility, 
remuneration and 
purpose.
Biocon implements robust procedures 
and continuous process safety 
improvements at all the sites to show 
commitment towards a zero-incident 
safety culture. There are employee 
training and protocols for preventing, 
reporting and addressing behavior 
that is not in line with the Business 
Principles and standards, including 
sexual, discriminatory or other 
misconduct. 
For more details on the initiatives 
undertaken, please refer to ‘Employee 
Health and Safety’.
To inculcate an empowering 
workplace, we have developed 
stringent processes which focus on 
enabling our employees to achieve 
their personal aspirations as well as 
their professional goals. 
For more information please refer 
to the chapter - Transforming our 
workplace
Negative: 
The absence of a safe 
and empowering 
workplace 
could result in 
adverse financial 
consequences such as 
fines and penalties. 
Additionally, it could 
lead to operational 
and reputational 
damage
6
Digitization
Opportunity
Utilization of digital 
technology to 
improve efficiency 
in operations and 
quality management 
in the Pharmaceutical 
Industry is a clear 
opportunity for 
Biocon. 
This includes 
deploying digital 
initiatives to fully 
integrate supply 
chains and improve 
operational processes, 
making them 
more adaptive and 
responsive.
Biocon is investing in building a 
robust digital architecture that will 
support data platforms networks 
across all functions. 
ESG is at the core of Biocon’s digital 
transformation where the aim is to 
enhance quality and compliance, 
augment productivity through 
enhanced operational excellence 
and enable data integrity through 
technology-led data transparency. 
More information on the initiatives 
can be found across the ESG Report 
for FY21-22
Positive: 
Digitization can lead 
to improved sale 
and efficiency across 
operations which 
can impact Biocon’s 
performance as 
compared to  peers. 
S. No.
Material issue 
identified
Indicate 
whether 
risk or 
opportunity 
(R/O)
Rationale for 
identifying the risk 
/ opportunity
In case of risk,  
approach to adapt or mitigate
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
| ESG Report 2022
96

S. No.
Material issue 
identified
Indicate 
whether 
risk or 
opportunity 
(R/O)
Rationale for 
identifying the risk 
/ opportunity
In case of risk,  
approach to adapt or mitigate
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
7
Supply chain 
sustainability
Risk
In the Pharmaceutical 
Industry, it is 
extremely imperative 
to ensure a stable 
supply chain to 
ensure business 
continuity.
Initiatives must 
be undertaken to 
anticipate, prevent 
and mitigate any 
concerns that cause 
disruptions. 
The integrated supply chain ensures 
uninterrupted medicine availability to 
the customers, patients, partners and 
healthcare systems globally. 
Biocon relies on cost-effective and 
sustainable logistics and supply chain 
rationalisation to increase access, 
right from the stage of procurement 
of raw materials to the last-mile 
delivery of products to patients. 
Biocon enforces a mandatory 
minimum level of adherence towards 
environmental compliance for our 
critical vendors through periodic  
site audits. 
Additionally, a Supplier Code 
of Conduct to guide the value 
chain partners on applicable laws, 
regulations, policies and procedures, 
as well as, the behavioral and ethical 
standards has been developed.
For more information, please refer to 
the chapter – ‘Partnerships in Action’ 
Negative: 
Disruption across 
Biocon’s value chain 
can adversely impact 
the operations, thus 
hampering the supply 
of products and 
increasing costs
8
Community 
engagement
Opportunity
It is crucial that 
Biocon engages with 
the communities we 
operate in to increase 
trust and foster 
harmony.
The Biocon Foundation is the 
principal channel for the corporate 
philanthropy undertaken by the 
Company.
The aim of this Foundation is to 
build resilient solutions that enable 
underserved communities to live 
better, every day.
The core areas of intervention are:
•	 Primary Healthcare
•	 Environmental Sustainability 
•	 Rural Development 
•	 COVID-19 Relief
For more details on the initiatives 
undertaken, please refer to the 
chapter – Transforming our 
Communities 
Positive: 
By empowering 
and uplifting 
our surrounding 
communities, 
we can mitigate 
future grievances 
or concerns, thus 
safeguarding the 
business from any 
adverse events
Biocon Limited
TransformAction | 97

9
Inclusion and 
diversity
Opportunity
This aspect addresses 
a company’s ability 
to ensure that 
its culture, hiring 
and promotion 
practices embrace 
representation 
from a diverse and 
inclusive workforce 
across all levels of the 
organization (board, 
senior, mid and junior 
levels).
Numerous steps have been 
undertaken to build a gender-inclusive 
workplace, which includes an 
extended maternity leave, part-time 
opportunities for returnees, gender 
sensitization sessions and women’s 
health initiatives. The Company also 
has several distinct developmental 
programs in place, focused on the 
Company’s female employees, 
geared towards preparing them for 
managerial and leadership roles.
The Company has an ‘Equal Pay for 
Equal Work’ practice in place, where 
employees are compensated based on 
their merit, irrespective of the gender 
they identify with.
More information can be found 
in the chapter – Transforming the 
Workplace 
Positive: 
A pool of diverse 
workforce from 
different genders, 
ages and ethnic 
diversity, will enable 
Biocon to develop, 
expand and mitigate 
operational risks. 
10
Ethical 
governance
Risk
To ensure the smooth 
functioning of the 
company, Biocon 
has implemented 
clear systems and 
defined roles and 
responsibilities of 
concerned personnel 
for managing topics 
related to ethics 
and integrity (e.g. 
anti-bribery and 
corruption, anti-
money laundering, 
code of conduct, 
whistle blowing etc.). 
At Biocon, the principles of integrity, 
transparency, accountability and 
ethics resonate throughout the 
organization.
Professional management teams 
and independent Boards for Biocon 
Limited, Biocon Biologics Limited and 
Syngene International Limited have 
been built to allow better governance 
across the Biocon Group. 
By implementing global best practices 
in corporate governance and risk 
management, we ensure that the 
Group consistently preserves and 
enhances value.
For more details, please refer to the 
chapter – Governance in Action  
Negative: 
Absence of 
adherence with 
the policies of the 
Company on business 
conduct and ethical 
governance can lead 
to reputational as 
well as operational 
damage.
S. No.
Material issue 
identified
Indicate 
whether 
risk or 
opportunity 
(R/O)
Rationale for 
identifying the risk 
/ opportunity
In case of risk,  
approach to adapt or mitigate
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
| ESG Report 2022
98

Section B: Management and Process Disclosures
S. No.
Principle Description
P1
Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and 
Accountable
P2
Businesses should provide goods and services in a manner that is sustainable and safe
P3
Businesses should respect and promote the well-being of all employees, including those in their value chains
P4
Businesses should respect the interests of and be responsive to all its stakeholders
P5
Businesses should respect and promote human rights
P6
Businesses should respect and make efforts to protect and restore the environment
P7
Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible 
and transparent
P8
Businesses should promote inclusive growth and equitable development
P9
Businesses should engage with and provide value to their consumers in a responsible manner
This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the 
NGRBC Principles and Core Elements.
Biocon Limited
TransformAction | 99

1. Policy and management processes
1. 1. Whether your entity’s policy/policies cover each 
principle and its core elements of the NGRBCs. (Yes/No)
Y
Y
Y
Y
Y
Y
N
Y
Y
1.2 Has the policy been approved by the Board? 
(Yes/No)
Y
Y
Y
Y
Y
Y
N
Y
Y
1.3. Web Link of the Policies, if available
Y
Y
Y
Y
Y
Y
N
Y
Y
1.4. Whether the entity has translated the policy into 
procedures. (Yes / No)
Y
Y
Y
Y
Y
Y
N
Y
Y
1.5. Do the enlisted policies extend to your value chain 
partners? (Yes/No)
Yes, the Company’s Supplier Code of Conduct largely includes the 
above-mentioned principles, and the value chain partners are expected 
to adhere to the requirements outlined.
1.6. Name of the national and international codes/
certifications/labels/standards (e.g. Forest Stewardship 
Council, Fairtrade, Rainforest Alliance, Trustea) 
standards (e.g. SA 8000, OHSAS, ISO, BIS) mapped to 
each principle. **
-	
Environmental Management System (ISO 14001)
-	
Occupational Health & Safety Management System 
(ISO 45001)
-	
Good Manufacturing Practice (GMP) compliance certification 
for the Company’s facilities across Bengaluru, Hyderabad and 
Visakhapatnam in India, and Malaysia 
1.7. Specific commitments, goals and targets set by the 
entity with defined timelines, if any.
Please refer to Chapters - ‘Transforming patient lives’, ‘Partnership in 
action’, ‘Transforming the workplace’, ‘Responsible action towards 
environment’ & ‘Transforming our communities’ for an in-depth 
description of our actions and commitments towards fulfilling the 
NGBRC principles.
1.8. Performance of the entity against the specific 
commitments, goals and targets along-with reasons in 
case the same are not met.
Please refer to chapters  ‘Transforming patient lives’, ‘Partnership in 
action’, ‘Transforming the workplace’, ‘Responsible action towards 
environment’ & ‘Transforming our communities’ to get an overview 
of our performance against our efforts towards fulfilling the NGBRC 
principles. 
*The Company plays a strong role in public policy advocacy through regular engagement with specific external stakeholders including industry 
associations, government bodies and regulatory departments. However, the Company does not have a formal advocacy policy
**Link to the Company’s ISO 14001 & ISO 45001 certifications: http://www.biocon.com/biocon_aboutus_ehspolicy.asp 
2.Governance, leadership and oversight
2.1. Management’s statement 
Please refer to page numbers 10 - 19 for statements from our leadership.
2.2. Details of the highest authority responsible 
for implementation and oversight of the Business 
Responsibility policy/policies
The Business Responsibility (BR) policies are broadly managed by 
the Board of Directors, Chief Executive Officer and the concerned 
departmental head(s).
2.3. Does the entity have a specified Committee of 
the Board/ Director responsible for decision making on 
sustainability related issues? (Yes / No). If yes, provide 
details.
Please refer to page number 14 of the Report for information on Board 
Committees on ESG
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7*
P8
P9
| ESG Report 2022
100

2.4. Details of Review of NGRBCs by the Company:
Subject for Review
Indicate whether review was 
undertaken by Director / 
Committee of the Board/ Any 
other Committee
Frequency 
(Annually/ Half yearly/ 
Quarterly/ Any other – 
please specify) 
Performance against above policies
and follow up action
The Corporate Social Responsibility Committee of the Board 
assesses the Business Responsibility (BR) performance of the 
Company on a half yearly basis and reports to the Board. The 
Board assesses the report on BR on an annual basis.
Compliance with statutory requirements of 
relevance to the principles, and rectification of 
any non-compliances
The Business Responsibility report is being published annually 
as part of the Company’s annual report in compliance with the 
provisions of SEBI Listing Regulations, which can be accessed at 
www.biocon.com.
Has the entity carried out independent assessment/ 
evaluation of the working of its policies by an external 
agency? (Yes/No). If yes, provide the name of the agency.
No, the Company does not conduct an independent assessment 
by external agencies. But all Company policies are regularly 
monitored and reviewed by respective policy owners
2.5. If answer to question (1.1) above is “No” i.e. not all Principles are covered by a policy, reasons to be stated: 
The entity does not consider the Principles material to its 
business (Yes/No)
The Company considers all the principles material to the 
business. It does not currently conduct independent third-party 
assessments of its policies.
The entity is not at a stage where it is in a position to 
formulate and implement the policies on specified principles 
(Yes/No)
No
The entity does not have the financial or/human and 
technical resources available for the task (Yes/No)
No
It is planned to be done in the next financial year (Yes/No)
No
Any other reason (please specify)
Note on P7: While the Corporation may share its expertise to 
help in the formulation of public policy, it does not directly 
engage in lobbying or advocacy activities and hence, does not 
have a specific policy for this purpose.
Biocon Limited
TransformAction | 101

Section C: Principle Wise Performance Disclosure 
Segment
Total number of training 
and awareness programmes 
held
Topics / principles covered 
under the training and its 
impact
Percent of persons in 
respective category 
covered by the awareness 
programmes
Board of Directors
13
Business model and overview 
of business units, Technical 
specification, building strategy 
and Regulatory policies and 
updates
100%
Key Managerial Personnel
1 (BL)
1 (BBL)
Talent Assessment for 
customized development 
journey (BL)
Trainings cover topics including 
BBL values, vision and 
Company culture.
82% (BL)
90% (BBL)
Employees other than BoD and 
KMPs*
29 (BL)
135 (BBL)
The topics covered under 
training include Talent 
Assessment, mandatory & 
Functional SOP Training, 
Interpersonal skills & 
Leadership development and 
Business specific functional 
training (such as Lean 6 Sigma, 
Quality Refresher, 
CRE, etc.) (BL)
93% (BL)
90% (BBL)
Workers
The company does not categorize any employee under the worker category.
Principle 1: Businesses should conduct and govern themselves with integrity, and in a manner 
that is Ethical, Transparent and Accountable 
Essential Indicators
1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year:
*Data for employees excludes BBL Malaysia numbers
| ESG Report 2022
102

Monetary
NGRBC 
Principle
Name of the 
regulatory/ 
Enforcement 
agencies/ judicial 
institutions
Amount (In INR)
Brief of the Case
Has an appeal 
been preferred? 
(Yes/No)
Penalty/ Fine
Nil
Settlement
Compounding fee 
Non-Monetary
NGRBC 
Principle
Name of the 
regulatory/ 
enforcement 
agencies/ judicial 
institutions
Brief of the Case
Has an appeal been  
preferred? (Yes/No)
Imprisonment
Nil
Punishment
FY 2021-22
FY 2020-21
Directors
Nil
Nil
KMPs
Employees 
Workers
3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary 
or non-monetary action has been appealed. 
Nil.
4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, 
provide a web-link to the policy. 
The Company has a Code of Conduct which further highlights the Company’s commitment to do business with integrity and its 
zero-tolerance approach towards bribery and corruption. It is applicable to all operations, regardless of local business practices 
(https://www.biocon.com/code-of-conduct/)
5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law 
enforcement agency for the charges of bribery/ corruption.
2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by 
the entity or by directors / KMPs) with regulators/ law enforcement agencies/judicial institutions, in the financial 
year, in the following format:
Biocon Limited
TransformAction | 103

FY 2021-22
FY 2020-21
Number of complaints received in relation to issues of Conflict of 
Interest of the Directors
Nil
Nil
Number of complaints received in relation to issues of Conflict of 
Interest of the KMPs
2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? 
(Yes/No) If Yes, provide details of the same.
Please refer to page numbers 30 - 36 of the report for details on the processes set in place for conflicting management.
7. Provide details of any corrective action taken or underway on issues related to fines / penalties /action taken by 
regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.
Not applicable.
6. Details of complaints with regard to conflict of interest:
Total number of awareness 
programmes held
Topics / principles covered under the 
training
%age of value chain partners covered 
under the awareness programmes
The Company has a ‘Supplier Code 
of Conduct’ (SCoC) that provides 
guidance to value chain partners. The 
SCoC contains critical information on 
applicable laws, regulations, policies and 
procedures. It also provides direction on 
the behavioral and ethical standards to 
be met. 
The SCoC provides necessary guidance 
on topics of training to be undertaken.
The Biocon’s Good practices covers 
information related to Sustainability, 
management of Greenhouse gas, natural 
resources and waste management. 
The Biocon’s good practices document 
has been shared with all key KSM/
intermediate vendors.
1. Awareness programmes conducted for value chain partners on any of the Principles during the financial year: 
Leadership Indicators
| ESG Report 2022
104

Principle 2: Businesses should provide goods and services in a manner that is sustainable and 
safe 
Essential Indicators
Biocon Limited (Amount in Mn INR)
Details of improvements in environmental and social impacts
FY 2021-22
FY 2020-21
R&D
906 
1,223
For details on environmental and social benefits driven by 
the Company, please refer to Chapters - (‘Responsible action 
towards the environment’) and – (‘Transforming patient lives’).
Capex
2,852
1,312
Biocon Biologics (Amount in Mn INR)
R&D
5,863
4,383
Capex
8,183
10,399
2. Does the entity have procedures in place for sustainable sourcing? (Yes/No) If yes, what percentage of inputs were 
sourced sustainably? 
Please refer to page numbers 40 - 44 and 79 for overview of our procedures in place for ensuring responsible and local sourcing. 
We also have set systems in place to periodically evaluate our suppliers, which are mentioned in these pages.
3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of 
life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.
Please refer to page number 58-65 and 73-76 of the Report for details on the Company’s waste management processes.
4. Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No). If yes, whether 
the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution 
Control Boards? If not, provide steps taken to address the same.
Our waste collection and management plan in our manufacturing facilities is in line with applicable central and state regulations. 
The Company does not have a formal EPR system in place. Steps taken to responsibly collect and dispose of the various types of 
waste generated via its operations have been detailed in response to Q.3 above. 
1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the 
environmental and social impacts of product and processes to total R&D and capex investments made by the entity, 
respectively.
Biocon Limited
TransformAction | 105

Name of Product/Service
Boundary for which the 
Life Cycle Perspective / 
Assessment was conducted
Whether conducted by 
independent external 
agency (Yes/No)
Results communicated in 
public domain (Yes/No) If 
yes, provide the web-link.
Vlidagliptin
Cradle to gate
No
No
Mycophenolate mofetil
Cradle to gate
No
No
Lenalidomide
Cradle to gate
No
No
Rosuvastatin
Cradle to gate
No
No
Leadership Indicators
4. Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, 
and safely disposed. 
Please refer to page numbers 58-65 for details on waste management through reuse, recycle and other forms of disposal 
undertaken by the Company. 
5. Reclaimed products and their packaging materials (as percentage of products sold) for each product category.
The Company’s waste collection and management plan in its manufacturing facilities is in line with the applicable central and 
state regulations. The Company is also currently evaluating EPR applicability in its business value chain.
1. Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing 
industry) or for its services (for service industry)? If yes, provide details in the following format?
The Company has a Life Cycle Assessment concept in place for our key products considering consecutive and interlinked stages 
of a product (or service) system, from raw material acquisition or generation from natural resources to final disposal.
Name of Product / Service
Description of the risk / concern
Action Taken
Vlidagliptin
Nil
NA
Mycophenolate mofetil
Nil
NA
Lenalidomide
Nil
NA
Rosuvastatin
Nil
NA
2. If there are any significant social or environmental concerns and/or risks arising from production or disposal of 
your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, 
briefly describe the same along-with action taken to mitigate the same. 
Indicate input material
Recycled or reused input material to total material*
FY 2021-22
FY 2020-21
Process Solvents
70%
52.5%
*Use of recycled/reused material to total material is not tracked at Biocon Biologics.
3. Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing 
industry) or providing services (for service industry). 
| ESG Report 2022
106

Principle 3: Businesses should respect and promote the well-being of all employees, including 
those in their value chains 
Essential Indicators
3. Accessibility of workplaces  
Are the premises / offices of the entity accessible to differently abled employees and workers, as per the 
requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the 
entity in this regard. 
Yes
4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, 
provide a web-link to the policy. 
The Company has a Code of Conduct which covers equal opportunity for all employees  https://www.biocon.com/docs/Code-
of-conduct-2021.pdf
5. Return to work and Retention rates of permanent employees and workers that took parental leave:   
Please refer to page number 78 of the Report for details on the Company’s Return to work and Retention rate.
6. Is there a mechanism available to receive and redress grievances for the following categories of employees and 
workers? 
Yes, the Company has a mechanism to receive and redress grievances.
1. Employees 
a. Details of measures for the well-being of employees. 
Please refer to page numbers 46-53 of the Report for details on employee benefits provided by the Company
b. Details of measures for the well-being of workers: 
The Company does not have any ‘Workers’ as defined in the guidance note on BRSR.
FY 2021-22
FY 2020-21
Benefits
No. of employees 
covered as 
a % of total 
employees
No. of workers 
covered as a % 
of total workers
Deducted and 
deposited 
with the 
authority 
(Y/N/N.A.)
No. of 
employees 
covered as 
a % of total 
employees
No. of 
workers 
covered as 
a % of total 
workers
Deducted and 
deposited 
with the 
authority 
(Y/N/N.A.)
PF
100%
100%
Y
100%
100%
Y
Gratuity
100%
100%
Y
100%
100%
Y
ESI
100% for 
applicable 
employees (whose 
gross is less than 
21k per month
100%
Y
100% for 
applicable 
employees 
(whose gross is 
less than 21k 
per month
100%
Y
Others- please 
specify
-
-
-
-
-
-
*Please note the data coverage includes India employees.
2. Details of retirement benefits*:
Biocon Limited
TransformAction | 107

FY 2021-22
FY 2020-21
Category
Total 
(A)
On Health 
and 
safety 
measures
On Skill 
upgradation
Total 
(D)
On 
Health 
and 
safety 
measures
On Skill 
upgradation
No. (B)
% (B / 
A)
No. (C)
% (C / A)
No. (E)
% (E / 
D) 
No.(F) % (F / 
D)
Employees
Male
7,250
6,281
87%
5,565
77%
6,782
5,222
77%
3,377
50%
Female
1,541
1,260
82%
953
62%
1,359
1,036
76%
489
36%
Total
8,791
7,541
86%
6,518
74%
8,141
6,258
77%
3,866
47%
Category of employees 
and workers
Mechanism for grievance redressal
Permanent Workers
The mechanism comprises of the following steps:
•	
The Integrity Committee determines whether the concern or complaint actually pertains to 
an unethical/non-compliant activity. 
•	
If the enquiry indicates further action, it is carried out by the Investigation Committee 
nominated by the Integrity Committee. 
•	
The investigation would be conducted in a fair manner, as a neutral fact-finding process 
and without presumption of guilt.
•	
Depending on the seriousness of the matter, the Integrity Committee may refer the matter 
to the Audit Committee with the proposed disciplinary action/counter measure. 
•	
The Audit Committee may decide the matter as it deems fit. In such cases, Integrity 
Committee shall ensure direct access for Whistleblower to the Chairperson of the Audit 
Committee. 
•	
In case of dissatisfying solution by the Integrity Committee, employee may reach out to the 
Chairman of the Audit Committee.  
Other than Permanent 
Workers
Permanent Employees
Other than Permanent 
Employees
7. Membership of employees and worker in association(s) or Unions recognised by the listed entity:
The Company is not associated with any associations or Unions.
8. Details of training given to employees and workers: 
If yes, give details of the mechanism in brief. 
*Data excludes BBL Malaysia figures
| ESG Report 2022
108

FY 2021-22
FY 2020-21
Category
Total (A)
No. (B) 
% (B / A) 
Total (C)
No. (D) 
% (D / C)
Employees
Male
7,100
5,748
81%
6,673
5,375 
81%
Female
1,499
1,138
76%
1,288
990 
77%
Total
8,599
6,886
80%
7,961
6,365 
80%
*The company does not categorize any employee under the worker category.
For more details on our Talent and Organization Development Strategy, please refer to page nos 46-56 of the Report.
10. Health and safety management system
a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). 
Yes, the Company has a well-established occupational health and safety management system in place, detailed on pages 55-57 
of the Report.
If yes, what is the coverage of such a system?
The system has 100% coverage. All internal and external stakeholders of the Company Group, including personnel associated 
with its Joint Ventures, suppliers, contractors and other stakeholders like NGO, are covered as part of the Company health and 
safety system.
b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis 
by the entity?
For details on the Company’s risk management identification and control process, please refer to page numbers 55-57 of the 
Report.
For all workplace hazards, the Company conducts routine process safety risk assessments. It has the requisite permits in place for 
undertaking non-routine work-related hazards. Integrated process safety management systems ensure all existing processes and 
new developments are assessed for risk. Process safety studies such as Process Hazard Analysis, Equipment Safety Study through 
techniques including HAZOP, What-if and Risk Matrix are conducted by cross functional teams. Detailed risk-based assessments 
are conducted regularly along with extensive audits to evaluate our health and safety performance at the site level.
c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such 
risks? 
Several channels are in place for the Company’s workers to report concerns related to health and safety at the workplace. These 
include:
•	
Making use of the Whistleblower policy to report any kind of harmful condition in the workplace.
•	
Raising concerns during the periodic departmental level safety meetings. Based on the concern/s raised an action plan, with 
a strict timeline and a dedicated responsible person, is identified to ensure timely resolution.
•	
Following the Standard Operating Procedure on ‘Incident reporting and investigation’ 
•	
In the event of an incident at the site, the workers are required to immediately make a report to the plant head. The event 
is analysed by the Investigating team, consisting of cross functional departments, which is responsible for taking appropriate 
action
9. Details of performance and career development reviews of employees and worker*
Biocon Limited
TransformAction | 109

The Company has also implemented the Hazard Identification and Risk Assessment (HIRA) system to identify work-related hazards 
followed by routine risk assessment. We organize regular safety committee meetings to provide a forum for management, 
employees and contract workmen to come together to identify and resolve health and safety problems. The committee meets 
once every three months and consists of members who represent employees from all units and departments. 
d. Do the employees/ workers of the entity have access to non-occupational medical and healthcare services? 
Yes, the Company’s employees have access to non-occupational medical and healthcare services. Additionally, the company 
has well established occupational health centers in its facilities with a competent team of paramedics and doctors. Periodical 
examinations of employees are conducted to detect the initial stage of any occupational disease. Workers’ access to non-
occupational medical and healthcare services are facilitated through various initiatives driven by the HR and EHS team. 
11. Details of safety related incidents, in the following format: 
For details on the Company’s health and safety track record over the past year, please refer to page number 79 of the Report.
12. Describe the measures taken by the entity to ensure a safe and healthy workplace. 
Please refer to page numbers 55-57 of the Report for details on the measures set in place by the Company to ensure a safe 
working environment for all its employees.
15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on 
significant risks / concerns arising from assessments of health & safety practices and working conditions.
Hazard identification and risk assessment (HIRA) is employed to identify work-related hazards and assess risks on a routine and 
non-routine basis. These processes are periodically subject to internal and external audits as part of EHS Management systems. 
As part of the audit, competency of persons is also checked to see if he/she is aware of the standard operating procedure and 
trained in HIRA. As an outcome of HIRA, for unacceptable risks, remediation actions are defined by proposing implementation of 
controls as per hierarchy of controls. 
FY 2021-22
FY 2020-21
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Filed during the 
year
Pending 
resolution  
at the end 
of year 
Remarks
Working Conditions
0
0
-
0
0
-
Health & Safety
0
0
-
0
0
-
13. Number of complaints on the following made by employees and workers
% of your plants and offices that were assessed (by entity 
or statutory authorities or third parties)
Health and safety practices
100%
Working Conditions
100%
14. Assessments for the year
| ESG Report 2022
110

Leadership Indicators
1. Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees 
(Y/N) (B) Workers (Y/N). 
Yes, the Company provides Group Term Life Insurance and other applicable benefits to their employees.
2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited 
by the value chain partners. 
All statutory compliances related to MSME vendors have been instituted. The Company procures raw materials from approved 
vendors, both national and international. Additionally, a periodical audit is also conducted of all critical suppliers on business 
sustainability parameters. The company has also instituted a checks and balances system that ensures that the company’s 
business partners adhere to national codes on EHS and labor practices. 
3. Provide the number of employees / workers having suffered high consequence work related injury / ill-health 
/ fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable 
employment or whose family members have been placed in suitable employment: 
No employee or worker has suffered high consequence work related injury/ill-health or fatality during the reporting period.
4. Details on assessment of value chain partners:
% of value chain partners (by value of business done with 
such partners) that were assessed
Health and safety conditions
100%: All business partners of the Company are trained to 
adhere and comply with EHS norms and labor practices.
Working conditions
Biocon Limited
TransformAction | 111

Stakeholder Group
Whether identified 
as Vulnerable & 
Marginalized Group 
(Yes/No)
Channels of 
communication
Frequency of 
engagement
Purpose and scope 
of engagement 
including key 
topics and concerns 
raised during such 
engagement
Government and 
regulatory authorities
No
By Email, through 
phone, In person, 
through meetings 
(visual and/or face to 
face)
Event driven and as 
need basis
Regarding ANDA/
DMF/Query response 
submissions, GDUFA 
& BLA compliance 
activities, clarification on 
guidelines and advice 
on technical/regulatory 
points, controlled 
correspondence, 
Pre-ANDA meeting, 
CARES ACT, 
Marketing Application 
submissions, Follow 
ups, Discussions, Query 
response submissions 
for regulatory 
approvals/ permissions, 
Post approval 
variation submissions/ 
Fee payment 
correspondence, 
Scientific advice 
NGOs
No
Direct Engagement at 
the project site, CSR 
activities and project 
team engagement, visit 
to NGO facilities and 
offices
Event driven and as 
need basis
Provide support to NGOs 
for social upliftment
Ensure communities we 
operate in are supported 
through a network  
of NGOs
Creating shared value
Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders
Essential Indicators
1.Describe the processes for identifying key stakeholder groups of the entity. 
Please refer to page number 36 of the Report for the process followed by the Company to identify and interact with its key 
stakeholders.
2.List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder 
group:
| ESG Report 2022
112

Stakeholder Group
Whether identified 
as Vulnerable & 
Marginalized Group 
(Yes/No)
Channels of 
communication
Frequency of 
engagement
Purpose and scope 
of engagement 
including key 
topics and concerns 
raised during such 
engagement
Academia
No
Meetings, thought 
leadership events, 
campus events
Event driven and as 
need basis
Transfer of knowledge 
through engagement 
with students and 
universities
Recruitment and hiring 
of freshers
Employees
No
Townhalls, emails, 
employee engagement 
surveys, grievance 
mechanisms, training 
activities, and appraisals
Regular and on a 
continuous basis
Providing employees 
with adequate training 
and development for 
career progression
Ensuring employees 
are aligned with 
organizational values 
and code of conduct
Addressing employee 
grievances
Instilling health and 
safety practices in the 
organization
Customers
Yes, based on 
predefined criteria such 
as income, gender, etc.
Customer feedback 
forms, emails, 
telephone calls
Regular and on a 
continuous basis
Ensuring customer 
satisfaction and needs 
are met
Resolving customer 
grievances 
Providing affordable 
and accessible 
healthcare
Suppliers
No
Audits, meetings, 
emails, initial screening
Regular and on a 
continuous basis
Ensuring business ethics 
and alignment with 
organizational values
Ensure quality of 
material is met
Integration of ESG 
aspects into supplier 
operations
Biocon Limited
TransformAction | 113

Stakeholder Group
Whether identified 
as Vulnerable & 
Marginalized Group 
(Yes/No)
Channels of 
communication
Frequency of 
engagement
Purpose and scope 
of engagement 
including key 
topics and concerns 
raised during such 
engagement
1.	Local community
2.	Local NGOs
3.	Panchayat
4.	City Municipal Council
5.	Local Education officials
6.	Local Health officials
7.	Front-line Healthcare 
workers
8.	Civil Society Institutions
9.	Local environmentalists
10.Residents Welfare 
Associations
Not all stakeholder 
groups are considered 
vulnerable.
(In the local community, 
the company work 
with the lower socio-
economic section of 
society)
Pamphlets / Community 
Meetings
Fortnightly/ Monthly 
meetings
Topics of engagement:
1.	Building awareness 
towards health 
services
2.	Sensitization 
workshops on 
preventive health
3.	Lake management 
updates
4.	Civic issues
5.	Capacity Building 
on relevant topics in 
health / education
Local community
Yes, based on 
predefined criteria such 
as income, gender, etc.
CSR activities, local 
community visits
Regular and on a 
continuous basis
Ensuring community 
growth and 
development with 
regards to employment, 
education, healthcare, 
etc.
Enhancing reputation. 
Investors
No
	- Calls/In Person 
Meetings (one on 
one/group)
	- Annual General 
Meeting
	- Through Press 
Releases and website
	- Publishing Annual 
Report
	- Investor Presentations
Quarterly/Annually, 
Event based and need 
based
To discuss about 
business performance 
and outlook, details of 
the announced events 
and to discuss about 
concerns/issues (if any)
Shareholders
No
Shareholder 
meets, annual and 
sustainability reports, 
communication of 
financial results through 
emails, media and news
Annual, Quarterly, Need 
Basis
To discuss about 
business performance 
and outlook, details of 
the announced events 
and to discuss about 
concerns/issues (if any)
Ensure transparency and 
accountability
| ESG Report 2022
114

Principle 5: Businesses should respect and promote human rights
Essential Indicators
Category
FY 2021-22
FY 2020-21
Employees*
Total (A)
No. of 
employees 
covered (B)
% (B / A) 
Total (C)
No. of employees  
covered (D)
% (D / C)
Permanent
6,839
6,298
92%
6,731
6,417
95%
Other than 
permanent 
1,846
1,785
97%
1,741
1,660
95%
Total employees
8,685
8,083
93%
 8,472
8,077
95%
*Data excludes BBL Malaysia numbers
*Data excludes BBL Malaysia numbers.
1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in 
the following format:
2. Details of minimum wages paid to employees and workers, in the following format:
Category
FY 2021-22
FY 2020-21
Employees*
Total (A)
Equal to 
minimum wage
More than 
minimum wage
Total (D)
Equal to 
minimum wage
More than 
minimum wage
No. (B)
% (B / 
A)
No. (C)
% (C / 
A)
No. (E)
% (E / 
D)
No. (F)
% (F / 
D)
Permanent
7,503
3,560
47%
3,943
53%
6,406
3,394
53%
3,012
47%
Male
6,340
2,948
47%
3,392
53%
5,644
3,018
53%
2,626
47%
Female
1,163
  612
53%
551
47%
762
376
49%
386
51%
Other than 
permanent 
1,846
990
54%
856
46%
1,741
606
35%
1,135
65%
Male
1,433
814
57%
619
43%
1,329
450
34%
879
66%
Female
413
176
43%
237
57%
412
156
38%
256
62%
Biocon Limited
TransformAction | 115

Biocon Limited:
Male
Female
Number 
Median remuneration/ salary/wages of 
respective category
Number 
Median 
remuneration/ 
salary/wages of 
respective category
Board of Directors 
(BoD):
Executive Directors
1
42.20
1
24.60
Non-Executive, 
Non-Independent 
Directors
1
4.20
-
-
Non-Executive, 
Independent 
Directors
4
4.87
1
4.68
Key Managerial 
Personnel
2
7.10
0
NA
Employees other 
than BoD and KMP
2,819
0.59
380 
0.61
Biocon Biologics Limited
Male
Female
Number 
Median remuneration/ salary/wages of 
respective category
Number 
Median 
remuneration/ 
salary/wages of 
respective category
Board of Directors 
(BoD):
Executive Directors
1
47.50
1
25
Non-Executive, 
Non-Independent 
Directors
*1
2.70
-
-
Non-Executive, 
Independent 
Directors
4
6.07
1
5.54
Key Managerial 
Personnel
2
27.5
-
-
Employees other 
than BoD and KMP
3,516
0.73
782
0.6
 
3. Details of remuneration/salary/wages (Amount in Mn INR), in the following format:
 *Mr. John Shaw stepped down effective from July 22, 2021 and Mr. Eric Mazumdar was appointed effective from November 1, 2021, hence 
the details for both of them are not covered.
*Mr. Thomas Jason Roberts was appointed effective from November 15, 2021
| ESG Report 2022
116

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues 
caused or contributed to by the business? (Yes/No) 
Yes, there is a Compliance Officer who looks after all human right related grievances.
5. Describe the internal mechanisms in place to redress grievances related to human rights issues. 
Integrity committee is made available to address such issues consisting of CEO, CFO and Head HR who delegate the investigation 
to relevant stakeholders.
The Company has a set procedure to address all complaints and grievances received: 
•	 The Company’s Integrity Committee determines whether the concern or complaint received pertains to an unethical/non-
compliant activity. 
•	 If the enquiry indicates further action, it is carried out by the Investigation Committee nominated by the Integrity Committee, 
which consist of the CEO, CFO and Head HR. 
•	 The investigation is conducted in a fair manner, as a neutral fact-finding process and without presumption of guilt.
•	 Depending on the seriousness of the matter, the Integrity Committee may refer the matter to the Audit Committee with the 
proposed disciplinary action/counter measure. 
•	 The Audit Committee may decide the matter as it deems fit. In such cases, the Integrity Committee shall ensure direct access 
for Whistleblower to the Chairperson of the Audit Committee. 
•	 In case of dissatisfying solutions by the Integrity Committee, employees may reach out to the Chairman of the Audit 
Committee. 
6. Number of Complaints on the following made by employees and workers: 
Please refer to page number 73 of the Report for information related to Human Rights related cases/complaints.
Biocon Limited
TransformAction | 117

7. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases. 
The company have Whistle Blower policy & Code of Conduct elaborating formation of committee to address cases related to 
discrimination. Additionally, a POSH committee to address harassment related cases. Apart from this, the code of conduct details 
the process to be followed in case any such instance happens.
The company has an Integrity and Whistleblower policy which covers measures to protect the complainant:
•	 If any Whistleblower feels that he/she is experiencing any kind of retaliation, victimization or discrimination in nature 
of intimidation, pressure to withdraw the complaint or threats for reporting, testifying or otherwise participating in the 
investigation proceedings, he/she should report the matter to the Integrity Committee.
•	 As with complaints of unethical/non-compliant activities, such actions of retaliation, victimization or discrimination too will be 
treated as misconduct and upon notification and the Integrity Committee will immediately take appropriate action to prevent/
rectify the retaliation, including. For more details, please refer to the Company’s policy - https://www.biocon.com/docs/Biocon-
Integrity-and-Whistle-Blower-Policy_2020.pdf)
•	 The Company also has a POSH committee which addresses harassment related cases. 
•	 Apart from this, the Company’s Code of Conduct details the process to be followed in case of any discrimination or 
harassment cases.
8. Do human rights requirements form part of your business agreements and contracts? (Yes/No)
Yes.
9. Assessments of the year
% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour
Assessment has been done atleast once in all entities by the independent internal auditor.
All the compliances are tracked on an ongoing basis using a workflow, which covers all the sites/entities.
Forced/
involuntary 
labour 
Sexual 
harassment 
Discrimination at 
workplace 
Wages 
Others – please 
specify
10. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the 
assessments at Question 9 above. 
No significant gaps identified as part of the reviews carried out. The company has a process to track the closure of non-critical 
observations (If any) identified as a part of such reviews.
| ESG Report 2022
118

Leadership Indicators
1. Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of 
Persons with Disabilities Act, 2016?
Yes.
2. Details on assessment of value chain partners.
100%: All business partners of the company are trained to adhere and comply with EHS norms and labor practices.
Principle 6: Businesses should respect and make efforts to protect and restore the environment 
Essential Indicators
1. Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format: 
Please refer to page number 74 of the Report for details on the Company’s energy consumption.
2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve 
and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme 
have been achieved. In case targets have not been achieved, provide the remedial action taken, if any. 
Not Applicable
3. Provide details of the following disclosures related to water, in the following format:
Please refer to page number 75 of the Report for details on the Company’s water consumption.
4. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and 
implementation.
Yes, the Company has a zero liquid discharge system consisting of Multiple Effect Evaporation (MEE) and Vertical Thin Film Dryer 
(VTDF). Water is treated in a biological treatment system, followed by a three-stage reverse osmosis system. All water is then 
recycled for non-process purposes. The system has 100% coverage (only within the Indian operations of the Company).
5. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format: 
Please refer to page number 75 of the Report for details on the Company’s air emissions.
6. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following 
format: 
Please refer to page number 74 of the Report for details on the Company’s GHG emissions.
7. Does the entity have any project related to reducing Greenhouse Gas emission? If Yes, then provide details. 
Yes, the Company has several initiatives in place to reduce its GHG emissions. It has switched to natural gas, instead of using 
furnace oil, to produce steam. The Company is also committed to increasing its share of renewable energy in its energy mix, via 
purchase of green energy from the grid as well as installing onsite solar technologies and procurement of wind energy. 
Biocon Limited
TransformAction | 119

Additionally, implementation of energy-efficient boilers have led to a reduction in fuel consumption. Some examples for energy 
efficient measures adopted by the Company include:
•	 Installation of energy efficient centrifugal air compressors;
•	 Installation of LED lighting to replace fluorescent lamps;
•	 Power Trading through Indian Energy Exchange;
•	 Installation of energy efficient air blower motors;
•	 Installation of solar powered lighting;
•	 Installation of waste steam recovery system;
•	 Partial usage of Biomass briquettes as an alternative to coal
For more information, please refer to the chapter “Responsible action towards environment”.
8. Provide details related to waste management by the entity:
Please refer to page number 75, 76 of the Report for details on the Company’s waste generation and management processes.
9.  Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted 
by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices 
adopted to manage such wastes.
Please refer to page numbers 62-65 of the Report for details on the Company’s waste management practices.
10. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife 
sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where 
environmental approvals / clearances are required, please specify details in the following format.
No Company offices are located in/around ecologically sensitive areas.
11. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in 
the current financial year: 
Nil
12. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water 
(Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act 
and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format: 
The company is compliant with all national and state regulations.
| ESG Report 2022
120

Leadership Indicators
1. Provide break-up of the total energy consumed from renewable and non-renewable sources. 
Please refer to page number 74 of the Report for details on the Company’s break-up of total energy consumed
2. Provide the following details related to water discharged: 
Please refer to page number 75 of the Report for details on the water discharged.
3. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource 
efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the 
same as well as outcome of such initiatives, as per the following format:
Please refer to page numbers 58-65 of the Report for initiatives/interventions undertaken by the Company to improve resource 
efficiency, reduce emissions/effluent discharge/waste generated.
4. Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link. 
The Company’s Disaster Management system covers both natural disasters such as earthquakes and floods as well as manmade 
disasters such as bomb attacks among others with key mitigation measures in place. The authority to implement mitigation 
manners lies with the Site Controller, Incident Controller, Central Utility In charge and Shift Engineer in a structured manner. In 
case of a bomb threat, control measures as per the On Site Emergency Plan will be initiated by the Site Controller. 
The Company’s Information Technology (IT) team has implemented a Disaster Recovery capability which helps the organization 
to regain use of critical systems and IT infrastructure instantly in emergency situations and minimize the impact on business 
operations.
5. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What 
mitigation or adaptation measures have been taken by the entity in this regard? 
We identify and evaluate the actual or potential aspects and impacts to the environment and climate change related, whether 
adverse or beneficial, from its activities, services and facilities through aspect impact assessment which is a part of our EHS 
Management Systems. During the evaluation process, significant impacts to the environment are determined which inturn 
addresses climate change impacts as well. We constantly check on existing or future regulations, among others on climate-related 
issues (e.g. emission trading schemes, energy efficiency requirements, reporting requirements, climate-related taxes etc.). Based 
on this, the businesses are informed on new developments and possible risks.
Biocon Limited
TransformAction | 121

S. No.
Name of the trade and industry chambers/ 
associations
Reach of trade and industry chambers/ 
associations (State/National)
1
Federation of Indian Export Organisation (FIEO)
-
2
Service Export Promotion Council (SEPC)
-
3
Export Promotion Council EOU’S and SEZ’s (EPCES)
-
4
Bangalore Commerce & Industry Chambers (BCIC)
State
5
Confederation of Indian Industry (CII)
-
6
Hyderabad Management Association (HMA)
State
7
The Federation of Telangana Chambers of Commerce and 
Industry (FTCCI)
-
8
Bulk Drug Manufacturers Association (BDMA)
-
9
FICCI (Federation of Indian Chamber of Commerce and 
Industry)
-
10
USIBC Global Board of Directors
-
11
Association of Biotechnology Led Enterprises (ABLE)
-
Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so 
in a manner that is responsible and transparent 
Essential Indicators
1. a. Number of affiliations with trade and industry chambers/ associations. - 11
b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such a body) the entity is 
a member of/ affiliated to.
2. Provide details of corrective action taken or underway on any issues related to anti-competitive conduct 
by the entity, based on adverse orders from regulatory authorities. 
Nil
| ESG Report 2022
122

FY 2021-22
FY 2020-21
Directly sourced from MSMEs/ small 
producers 
25%
15%
Sourced directly from within the district 
and neighboring districts
25%
15%
Principle 8: Businesses Should Promote Inclusive Growth and Equitable Development 
Essential Indicators
Leadership Indicators
1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the 
current financial year. 
While the Company does not have a mandatory requirement of conducting SIA of its projects, it conducts internal assessments 
and identifies the impacts achieved. The details of the assessments are further shared during the CSR meetings.
2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by 
your entity, in the following format.    
Not Applicable.
3. Describe the mechanisms to receive and redress grievances of the community. Sources of Adverse event 
information/ Complaints/ Medical Information queries:
The Company has set up mechanisms to address the grievances, contextualized for specific community programs. The strategy to 
address this is through structured monitoring and evaluation of all programs, with assessment of stakeholder perceptions, either 
through regular surveys by the Company’s Foundation team or third-party impact assessment. 
The main grievance of the life sciences student community is the lack of adequate practical skills that is required in the industry. 
Biocon Academy plays an active role in reducing the existing skill deficit and is working on transforming students into industry-
ready professionals.
4. Percentage of input material (inputs to total inputs by value) sourced from suppliers*:
1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments 
(Reference: Question 1 of Essential Indicators above)
The Company is not mandated to conduct SIA through a third-party. However, internal assessments are done for the projects 
implemented. During recent assessments, the Company has identified potential areas where negative impact could occur (e,g, 
Lake management, staff concerns in eLaj clinics, etc,) and necessary steps have been taken to rectify the impact. In the year under 
consideration, no negative has been identified.
2. (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers 
comprising marginalized /vulnerable groups? (Yes/No)
The Company has always strived to work alongside and develop the small and medium enterprises around its area of operation. 
The Company procures a considerable part of its goods and avails services from local and small vendors, particularly those located 
around its manufacturing locations. 15-20% of its total supplier base are small and medium enterprises. There is also a strong 
corporate directive to develop sourcing capabilities locally. This enables the Company to achieve multiple benefits like: 
*Data is not captured within BL. Above information is only for BBL.
Biocon Limited
TransformAction | 123

As a percentage to total turnover
Environmental and social parameters relevant to the product
100%
Safe and responsible usage
Recycling and/or safe disposal
Principle 9: Businesses should engage with and provide value to their consumers in a 
responsible manner 
Essential Indicators
a)	 Shorter turn-around times for delivery. 
b)	Promoting Vendor-Managed Inventory, closer to our facilities. 
c)	 Quicker resolution of issues pertaining to material quality. 
d)	Contribute to the local economy, thereby enhancing sustainability of our operations. Additionally, we aid the long-term 
capacity planning for such vendors by sharing forecasts for up to 12 months.
3. Details of beneficiaries of CSR Projects: 
Please refer to page number 66-71 of the Report for details on the Company’s CSR projects.
1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback. 
Sources of Adverse event information/ Complaints/ Medical Information queries:
•	 We receive queries via various methods like telephone calls received on Biocon’s toll free no., emails received at Drug Safety 
mailbox (drugsafety.smv@biocon.com), Fax, any postal mails received at Biocon offices e.g. MedWatch forms received from US 
FDA etc.
•	 All AE/ PQC/ MI collection modalities are periodically tested. Further required reconciliation is performed on a periodic basis.
•	 MICC call handlers managing the toll free numbers send the information to Drugsafety Mailbox or to the PQC department 
depending on their assessment of the type of report.
•	 All MedWatch forms received as postal mail at 485 US HIGHWAY 1 S Suite B305 ISELIN NJ 08830 are managed by a 
designated employee at the US office and these are converted into a scanned pdf and sent to the Drugsafety mailbox.
•	 All kinds of information received via different methods in the Drugsafety mailbox are tracked & monitored on all business days.
2. Turnover of products and/ services as a percentage of turnover from all products/service that carry information 
about: 
| ESG Report 2022
124

3. Number of consumer complaints in respect of the following: 
4. Details of instances of product recalls on account of safety issues: 
FY 2021-22
Remarks
FY 2020-21
Remarks
Received 
during the year
Pending 
resolution at 
end of year
Received 
during the year
Pending 
resolution at 
end of year
Data privacy
0
0 
-
0 
0 
-
Advertising
0
0
-
0 
0 
-
Cyber-security
0
0 
-
0 
0 
-
Delivery of 
essential services
16
5
-
10
0
-
Restrictive Trade 
Practices
0
0 
-
0 
0 
-
Unfair Trade 
Practices
0 
0 
-
0 
0
-
Other 
0
0
-
0
0
-
Number
Reasons for Recall
Voluntary recalls
1
-
Forced recalls
Nil
-
5. Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, 
provide a web-link of the policy.
The Company respects the privacy of all individuals and confidentiality of the personal information it holds about them. Identified 
as a progressively critical risk, due to the increased adoption of the remote working model over the course of the COVID-19 
pandemic, key mitigation measures were put in place to support business continuity and ensure safety of operations.
The Company’s IT infrastructure and information security management system is certified to ISO 27001:2013 and has undergone 
external third-party audits. This is supplemented with third-party vulnerability analyses including stimulated hacker attacks. 
The manner in which the Company collects, uses, protects or otherwise has been provided in detail in the Company Privacy policy 
(Privacy policy). In collecting, using or storing personal data, each employee must comply with the following:
•	 Data is obtained from the individual with level of consent required by local laws or internal policies including where personal 
data is obtained from third parties
•	 Data collected is adequate, relevant and used solely for the purpose for which it is collected
•	 Personal data is used in accordance with relevant published Privacy laws
•	 Personal data is kept confidential and secure
Biocon Limited
TransformAction | 125

All employees of the Company undergo annual awareness training on information security/cyber security. Special sessions are 
also conducted over the course of the year on critical focus areas. A clear escalation matrix has been established for employees to 
report suspicious activities in a timely manner. Information security/ cyber security are also included as a parameter for employee 
performance evaluation. 
6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of 
essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty 
/ action taken by regulatory authorities on safety of products / services.
We take proactive steps in case any issue arises pertaining to any one of these categories. Corrective actions are also taken to 
prevent recurrences of similar instance.
Disclaimer
The contents of this report are intended to provide accurate and authoritative information in relation to the subject matter covered. 
Information regarding medical products or devices mentioned in the report is not intended to endorse, advertise, recommend or even act as 
an alternative to consulting qualified doctors or healthcare professionals. Nothing contained herein should be construed as an endorsement 
or be relied upon as the basis for making a decision without consulting a healthcare professional.
| ESG Report 2022
126

Biocon Limited
20th KM Hosur Road, Electronic City, Bengaluru – 560 100, India
Telephone: +91 80 2808 2808
Email: corporate.communications@biocon.com
Website: www.biocon.com
Scan this QR code  
to download the  
ESG Report.
Scan this QR code 
to download the 
Annual Report.